

CURRICULUM VITAE

Alexandre Chan, PharmD, MPH, FCCP, FISOPP, BCPS, BCOP, APH

Address: 802 W Peltason Dr, Berk Hall, Department of Clinical Pharmacy Practice,
University of California, Irvine School of Pharmacy & Pharmaceutical Sciences
CA 92697-4265, USA
Phone: Office: (949) 824-8896; Cell (949) 690-8230
Email: a.chan@uci.edu

PROFESSIONAL PROFILE

I am an international expert in cancer supportive care/survivorship and integrative oncology, with expertise and interests in translational science, implementation science, supportive oncology trials, population science and global oncology. I have >20 years of cancer care experience in North America and Asia, as well as administrative experience in academia and governmental agencies. To date, I have published >310 peer-reviewed manuscripts (h-index=53) and received ~10 million USD funding from agencies including NIH/NCI (USA), NMRC (Singapore), foundations, and the pharmaceutical industry.

Professionally, I am currently serving as the President-Elect for the Multinational Association of Supportive Care in Cancer (MASCC). I have also served as the Past President for the International Society of Oncology Pharmacy Practitioners (ISOPP). I currently serve as an Assistant Editor for the Dipro's Pharmacotherapy: A Pathophysiologic Approach, the most widely used Pharmacotherapy textbook worldwide. I have also led and served on clinical practice guidelines pertaining to cancer care within ASCO, ESMO, ISOPP, and MASCC.

CURRENT APPOINTMENTS

01/2020 - Now

**Founding Department Chair, Department of Clinical Pharmacy Practice,
School of Pharmacy & Pharmaceutical Sciences (SPPS)
University of California Irvine (UCI), USA**

Core responsibilities include coordinate/facilitate the shared activities of the core faculty of the department, including academic personnel reviews, teaching assignments, department committee assignments, mentoring, recruiting, retention, and award nominations while maintaining equity and increasing excellence, diversity, and inclusion. Major achievements include:

- *Hired and assembled a team of 22 full time professors and 42 volunteer clinical professor to buildout and teach the flagship Doctor of Pharmacy program (graduating in May 2025)*
- *Formed an administrative team in the Chair's office to provide support to faculty*
- *Created development programs and research support for faculty members*
- *Facilitated faculty's clinical practices and strategic planning with UCI Health Pharmacy*

01/2020 - Now

**Professor of Clinical Pharmacy, Department of Clinical Pharmacy Practice
Joint Faculty (WOS), Department of Pharmaceutical Sciences, SPPS
Joint Faculty (WOS), Division of Hematology/Oncology, School of Medicine**

Core responsibilities include research, teaching, and service activities. Created a NIH/NCI-funded supportive care research program with the following research focus:

- *Translational supportive care research in cancer survivorship, specifically on innovative biomarkers for survivorship symptoms.*

- *Implementation research on supportive care and survivorship care models through patient-reported outcome tools and navigation pathways*
- *Integrative oncology clinical trials involving oriental medicine modalities including herbal concoctions and electroacupuncture*
- *Population health research using big data to evaluate impact of anticancer treatment on symptoms, quality of life, toxicities, and clinical outcomes*

05/2020 - Now

Member & Clinical Pharmacist, UCI Chao Family Comprehensive Cancer Center (CFCCC)

Core responsibilities include weekly supportive care clinic which operates under a Pharmacy & Therapeutics committee approved collaborative practice agreement.

- *Provide direct patient care to patients receiving anticancer treatment at CFCCC*
- *Implement innovative supportive care models using patient reported outcome tools*
- *Provide preceptorship to oncology fellows, oncology residents, student pharmacists and medical students*

01/2020 - Now

Adjunct Faculty, Duke-NUS Medical School, Singapore

09/2022 -Now

Joint Research Professor, National Cancer Centre Singapore**EDUCATION**

09/1998 – 05/2004

Doctor of Pharmacy (Highest Honors), Ernest Mario School of Pharmacy, Rutgers University, New Jersey, USA

07/2004 – 06/2005

Pharmacy Practice Residency, Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA

08/2005 – 07/2006

Oncology Specialty Residency, Department of Pharmaceutical Services, University of California Davis Medical Center, Sacramento, California, USA

09/2009 – 05/2011

Master of Public Health (Specialization: Clinical Epidemiology), Department of Epidemiology and Public Health, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

In Progress

Doctor of Philosophy (Candidate), Flinders University, Australia. Expected Graduation Date: End of 2025. Supervisor: Dr. Gillian Harvey

LICENSES AND CERTIFICATES

2022

Health Equity and Diversity Certificate Program (UCI Susan & Henry Samueli College of Health Sciences)

2020 – Present

Advanced Practice Pharmacist, State of California, USA (APH 10838)

2005 – Present

*Recertified in 2019

Board Certified Pharmacotherapy Specialist (BCPS), USA (305007257)

2007 – Present

*Recertified in 2021

Board Certified Oncology Pharmacist (BCOP), USA (507007257)

2004 - Present

Registered Pharmacist, State of California, USA (56158)

2004 - Present

Registered Pharmacist, State of New Jersey, USA (29414)

2005 - Present	Registered Pharmacist, Macau Special Administrative Region, China (138)
2007 - Present	Registered Pharmacist and Specialist in Oncology Pharmacy, Republic of Singapore (01787f)

PREVIOUS APPOINTMENTS

01/2020 – 08/2022	Visiting Professor, Oncology Pharmacy, National Cancer Centre Singapore, Singapore
01/2016 – 12/2019	Deputy Head (Clinical), Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore
01/2012 – 12/2019	Associate Professor (with Tenure), Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore
10/2010 – 12/2019	Specialist Pharmacist, Department of Pharmacy, National Cancer Centre Singapore, Singapore
04/2015 – 12/2019	Associate Professor, Duke-NUS Medical School, Singapore
11/2015 – 12/2019	Academic Advisor, Office of Residency Training, Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore
07/2018 – 12/2019	National Oncology Pharmacy Residency Associate Program Director, Ministry of Health, Singapore
06/2013 – 12/2019	Adjunct Professor, Pharmacy Practice Department, Thomas J. Long School of Pharmacy & Health Sciences, University of the Pacific, Stockton, USA
05/2015 – 07/2018	National Oncology Pharmacy Residency Program Director, Ministry of Health, Singapore
04/2014 – 12/2015	Assistant Head, Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore
01/2011 – 11/2015	Senior Project Administrator, Chief Pharmacist Office, Ministry of Health, Singapore
08/2009 – 04/2015	Co-Director, Oncology Pharmacy Residency, Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore
04/2011 – 04/2013	Assistant Clinical Professor (Without Salary), Department of Clinical Pharmacy, University of California San Francisco, San Francisco, USA
06/2014	Visiting Fellow, School of Nursing, Faculty of Health, Queensland University of Technology, Australia
07/2007 – 12/2011	Assistant Professor, Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore
10/2006 – 09/2010	Clinical Pharmacist, Department of Pharmacy, National Cancer Centre Singapore, Singapore

08/2006 – 07/2007 Lecturer, Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore

HONORS AND AWARDS

- 2025 UCI 2025 Basic Science College of Health Sciences Team Research Award
- Partnering with Dr. Munjal Acharya - <https://assembly.cohs.uci.edu/2025-awardees/>
- 2025 Hematology Oncology Pharmacy Association (HOPA) 2025 Oncology Pharmacy Practice Literature Award
- Electronic Patient-Reported Outcome-Driven Symptom Management by Oncology Pharmacists in a Majority-Minority Population: An Implementation Study
- 2024 UCI Chancellor's Award for Distinguished Fostering of Undergraduate Research
- *UCI recognizes a faculty member for their distinguished fostering of undergraduate research*
- 2024 The International Society of Oncology Pharmacy Practitioner – The Helen McKinnon Award
- *ISOPP recognizes a member for their professional achievements, contributions to oncology pharmacy practice and to the society*
- 2024 Hematology Oncology Pharmacy Association (HOPA) 2024 Basic and Clinical Research Literature Award - Substance Use Among Young Adult Survivors of Childhood Cancer with Cognitive Impairment: An Analysis of the Project Forward Cohort
- 2023 Recipient of the 2023 MASCC Innovator Award –
- *MASCC recognizes an individual with novel, bold thinking, impactful, non-traditional, out-of-the-box idea(s) that have changed or enhanced direction, practices, and services in supportive care in cancer*
- 2020 American College of Clinical Pharmacy (ACCP) 2020 Adult Medicine PRN Outstanding Paper Award - Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy
- 2020 Hematology Oncology Pharmacy Association (HOPA) 2020 Oncology Pharmacy Practice Literature Award - Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy
- 2018 Fellow (Elected), International Society of Oncology Pharmacy Practitioners (ISOPP)
- 2017 Recipient of the Long Service Award, National University of Singapore
- 2017 Recipient of the SingHealth 10th Allied Health Innovative Practice Award
- *In recognition of innovative excellence in patient care*
- 2015 Recipient of the Steven M. Grunberg Memorial Award
- *In recognition of scientific excellence, leadership and mentoring in the field of supportive care, Multinational Association of Supportive Care in Cancer (MASCC)*

- 2014 Fellow (Elected), American College of Clinical Pharmacy (ACCP)
- *Fellowship in the American College of Clinical Pharmacy (FCCP) recognizes excellence in the practice and science of clinical pharmacy.*
- 2013 Recipient of the Young Scientist Award, Faculty of Science, National University of Singapore
- *In recognition of scientific achievements among faculty members at National University of Singapore*
- 2011 Recipient of the Best Oral Paper Award (Allied Health), 19th Annual Science Meeting, Singapore General Hospital
- 2011 Recipient of the Special Award, National Cancer Centre Singapore for contributions at the cancer center
- 2010 Recipient of the Supervisor Award, Undergraduate Research Opportunities Program –Center for Remote Imaging, Sensing and Processing (CRISP)
- 2009 Recipient of the Best Oral Paper Award (Allied Health), 18th Annual Science Meeting, Singapore General Hospital
- 2008 Recipient of the Best Poster Award (2nd Prize), The 2nd Asia-Pacific Oncology Pharmacy Congress
- 2004 The Ernest Little Award (Graduation Award)
- 2002 Member and Past President (02/03), Rho Chi Honors Society, Alpha Eta Chapter
- 2002 Member, Phi Lambda Sigma Leadership Honors Society, Lambda Chapter
- 2003 – 2004 Recipient of the NCPA Foundation Presidential Scholarship
- 2003 – 2004 Recipient of the Pathmark Academic Achievement Award
- 2003 – 2004 Recipient of the James Croucher Scholarship
- 2002 – 2003 Recipient of the Martin Daffner Scholarship
- 2001 – 2002 Recipient of the Pharmacy Alumni Award
- 2000 – 2001 Recipient of the Walgreen's Scholarship Award
- 1998 – 2004 Ernest Mario School of Pharmacy Dean's List
- 1998 – 2002 Recipient of the Rutgers University Outstanding Scholar
- 1998 – 2002 Recipient of the Edward J. Bloustein Distinguished Scholar
- 1998 Valedictorian, Dwight Morrow High School, Englewood, New Jersey

RESEARCH AND SCHOLARLY ACTIVITIES

A. RESEARCH SUPPORT (SUCCESSFULLY FUNDED PROJECTS ONLY)

2025 - 2027	Principal Investigator. Merck Sharp & Dohme. A randomized controlled, type 1 hybrid effectiveness-implementation trial study to compare the effectiveness of a Patient-Reported Outcomes (PRO)-driven culturally grounded supportive care navigation in reducing healthcare disparities among Hispanic/Latinx patients receiving anticancer therapies – USD \$250,000.00
2024 – 2025	Principal Investigator. UCI Anticancer Challenge. Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Breast Cancer Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial – USD \$50,000.00
2024 - 2026	Principal Investigator. COHS Pilot Award. Augmentation of Dynamin-1 levels using Catalpol to Prevent Cancer-related Cognitive Impairment (ADC Study) – USD \$75,000.00
2024 - 2025	Principal Investigator. UCI School of Medicine Bridging the Gap Funding. Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Breast Cancer Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial – USD \$50,000.00
2023 - 2024	Co-Investigator. National Institute of Health (NIH) / National Cancer Institute (NCI). R01 Supplement Subaward – Indicators of Accelerated Aging in Asian American Childhood Survivors – USD \$10,000.00, Miller (PI): \$100,000.00
2023 - 2028	Principal Investigator. National Institute of Health (NIH) / National Cancer Institute (NCI). R01 grant – R01CA276212. Neurotrophic strategy to mitigate chemotherapy-related brain injury – USD \$2,407,573.00
2023 - 2024	Co-Investigator – Electroacupuncture in Symptom Management after CRS/HIPEC: A Pilot Study. Samueli Integrative Health Institute Pilot Program – USD \$25,000
2023 – 2024	Co-Investigator/Mentor. SingHealth Regional Health System (RHS): Population-based, Unified, Learning System for Enhanced and Sustainable Health (PULSES) Grant Call. EmPowering Breast Cancer Survivors (EPiCS) – Decision Aids and Self Efficacy. USD \$37,500.00
2023 - 2025	Co-Investigator/Mentor. PhRMA Foundation 2023 Predoctoral Fellowship in Value Assessment-Health Outcomes Research. Value Assessment of ACUpuncture analGESia In Cancer: a Real-world Data Analysis (ACU-GESIC). USD \$50,000.00
2023 – 2028	Co-Investigator. National Institute of Health (NIH) / National Cancer Institute (NCI). R01 grant – R01CA262213. Stem cell-derived exosomes to ameliorate chemobrain, Acharya (PI). USD \$1,962,500.00
2022 – 2023	Principal Investigator. ICTS Planning Grant Awards in Translational Science. Interdisciplinary and translational research in cancer-related cognitive impairment. USD\$50,000.00
2022 – 2024	Principal Investigator. California Breast Cancer Research Program 2022 - Innovative, Developmental, and Exploratory Award (IDEA). Electroacupuncture for the management of cancer-related cognitive impairment in breast cancer (ECCO). USD\$200,000.00

2022 – 2024	Principal Investigator. Anti-Cancer Challenge Pilot Project Grant. Electroacupuncture for the management of cancer-related cognitive impairment in adolescent and young adults – a pilot clinical trial. USD \$40,000.00
2022 – 2024	Principal Investigator. 2021 Hematology/Oncology Pharmacy Association (HOPA) Research Award. Patient-Reported Outcomes (PRO)-driven pharmacy education In ethnic minOrity patients Receiving antlancer TherapIES (PRIORITIES). USD \$38,116.00
2021 – 2022	Principal Investigator. Institute for Clinical and Translational Science (ICTS). Augmentation of BDNF levels to Prevent Cancer-related Cognitive Impairment (ABC Study). USD \$25,000.00
2021 – 2022	Co-Investigator. Safer medication use for <i>All of Us</i> : developing a clinical prediction model for <u>a</u> dverse <u>d</u> rug <u>e</u> vents (SPADE). USD \$ 2500.00
2020 – 2021	Co-Investigator. All of Us Research Program. <u>D</u> escri <u>b</u> ing <u>V</u> accination Character <u>i</u> stics in All of U <u>s</u> (DIVERS). USD \$ 2500.00
2020 - 2022	Principal Investigator. An ISOPP Education Program on Global Oncology Pharmacotherapy and Applications of Biosimilars. Pfizer Education Grant to International Society of Oncology Pharmacy Practitioners. USD 242,000.00
2020 - 2022	Mentor and Co-Investigator. A Pharmacist-led Assessment of cancer Supportive Care in the sub-Saharan African region based on Locally adapted standards of care (PASCAL). CAD \$10,000.00 or USD\$ 7,328.83
2019 - 2022	Mentor and Investigator. ACCESS program for breast and gynecological cancer supportive care. Supported by Temasek Foundation. SGD \$ 2,200,000.
2019 - 2021	Principal Investigator. NUS Initiative to Improve Health in Asia. Impact of a Breast cAncer Survivorship Inter-professional Community care model (BASIC): A Randomized Controlled Trial. (SGD \$ 300,000.00 or USD \$ 221,067.27)
2019 - 2021	Principal Investigator. Ministry of Health. HEalth-Related quality of life-intervention in Breast Cancer Survivors experiencing cancer-related fatigue using TraditionAL Chinese Medicine: The HERBAL Trial. (SGD \$ 426,875.46 or USD \$ 314,560.64)
2017 -2020	Principal Investigator. Singapore Cancer Society. Economic Burden in Early-Stage Breast Cancer Survivors. (SGD\$ 29,500.00 or USD \$21,500.00)
2017 -2020	Principal Investigator. International Neighbour of Choice Grant. Community Breast Cancer Survivorship Program 2018 (USD \$32,500.00)
2017-2020	Principal Investigator. National Medical Research Council: Clinician -Scientist Individual Research Grant (CS-IRG). Adolescent and young adult cancer patients: Cognitive Toxicity on Survivorship (ACTS).(SGD \$1,292,074.50 or USD \$943,120.00)
2017-2018	Principal Investigator. Singapore Cancer Society. Early survivorship needs' assessment in adolescents and young adults with cancer – a preliminary study. (SGD\$ 24,000.00 or USD\$ 17,518.00)
2017-2019	Principal Investigator. NUS Faculty Research Council. Harnessing big data to personalize symptom management in cancer survivors. (SGD \$179,820.00 or USD\$ 131,255.47)

- 2016-2017 **Mentor.** Terry Fox Grant. Cryotherapy for management of chemotherapy-induced peripheral neuropathy in breast cancer patients. (SGD\$50,000.00 or USD \$36,496.35) Mentee: Dr. Kiley Loh
- 2016-2018 **Mentor.** SingHealth Foundation Research Grant. Hepatitis B virus reactivation (HBVr) in patients with resolved HBV infection receiving rituximab or rituximab-based chemo-immunotherapy for Non-Hodgkin lymphoma (NHL) in Singapore. (SGD \$150,000.00 or USD \$109,489.05) Mentee: Dr. Tiffany Tang
- 2016-2017 **Co-Principal Investigator.** National Cancer Centre Singapore Foundation Grant. Evaluating the Cost Burden of Cancer Care Among Adolescents and Young Adult (AYA) – A Cohort Study. (SGD \$50,000.00 or USD\$ 36,496.35)
- 2016-2017 **Co-Principal Investigator.** Cross Faculty Grant. Unravelling health problems and impact of medication on construction safety and productivity among migrant construction workers in Singapore. (SGD \$25,000.00 or USD\$ 18,248.18)
- 2015-2016 **Principal Investigator.** Community Cancer Fund. A psycho-educational group (PE) intervention on supportive care and survivorship issues in early-stage breast cancer survivors who have received chemotherapy: A Pilot Evaluation. (SGD \$49,500.00 or USD\$ 36,131.39)
- 2014-2015 **Co-Investigator.** Princess Alexandra Hospital Research Support Scheme 2015 ALH Breast Cancer Grant. Enhancing cognitive function after breast cancer treatment with the Younger Women's Wellness After Cancer Program. (AUD \$75,000.00 or USD\$ 54,744.53)
- 2014-2017 **Principal Investigator.** National Medical Research Council: Clinician-Scientist Individual Research Grant (CS-IRG). Prevalence, severity and determinants of cancer-related fatigue (CRF) in Asian breast cancer patients. (SGD \$783,166.00 or USD\$ 571,654.01)
- 2014-2017 **Co-Investigator.** NTU-NHG Ageing Research Grant. Controlled Release Polypharmacy System for Parkinson's Disease Management. (SGD \$341,500.00 or USD\$ 249,270.07)
- 2014-2015 **Co-Principal Investigator.** NUS Pharmacy Thematic Research Grant. Managing cardiotoxicity in chemotherapy: Improving monitoring and response. (SGD \$ 20000.00 or USD\$ 14,598.54)
- 2013-2015 **Co-Principal Investigator.** Terry Fox's Foundation Grant. Symptom Burden in Local Breast Cancer Survivors. (SGD\$ 44000.00 or USD\$ 32,116.79)
- 2012-2014 **Principal Investigator.** National Cancer Centre Singapore Foundation Grant. Clinical and Biological Determinants of Cognitive Changes in Asian Breast Cancer Patients. (SGD\$ 49,270.00 or USD\$ 35,963.50)
- 2012-2015 **Principal Investigator.** NUS Faculty Research Council. Clinical and Biological Determinants for Chemotherapy-Associated Cognitive Changes in Breast Cancer Patients. (SGD\$ 126,370.00 or USD\$ 92250.88)
- 2011-2014 **Principal Investigator.** SingHealth Foundation Grant. Quetiapine versus Aprepitant based regimens for the prevention of chemotherapy-induced nausea and vomiting. (SGD \$ 199,004.24 or USD \$145258.57)
- 2011-2013 **Principal Investigator.** Singapore Cancer Society. Optimization of a dosing regimen for sunitinib in metastatic renal cell carcinoma (mRCC) treatment through

pharmacokinetic monitoring to achieve better efficacy and safety profile. (SGD \$99,700.00 or USD \$ 72,773.72)

- 2011-2012 **Principal Investigator.** Virtual Institute for the Study of Ageing (VISA). National University of Singapore. Financial constraints in elderly to afford novel anticancer therapies - A prevalence evaluation. (SGD \$18,488.00 or USD\$ 13,494.89)
- 2011-2013 **Principal Investigator.** Merck Sharp & Dohme. Investigator-Initiated Studies Program Grant. Clinical Predictors for Chemotherapy Induced Nausea and Vomiting Among Head and Neck Cancer Patients Receiving Cisplatin. (SGD \$ 81,000.00 or USD 59,054.09)
- 2009-2011 **Co-Investigator.** National Medical Research Council. Prevalence and Clinical Impact of Adverse Drug-Drug Interactions in Cancer Patients. (SGD \$160,000.00 or USD \$116,778.32)
- 2008-2011 **Principal Investigator.** National University of Singapore Start up Grant. Application of Pharmainformatics in the Clinical Setting: Solving Drug-related Problems through the Innovative Use of Information Technology. (SGD \$179,990.00 or USD \$131,386.13)

B. PEER-REVIEWED PUBLICATIONS (Total: 313, h-index=53)

- 313 Wei Y, Xiao P, Deng W, Wong CL, Ngan CK, Tso WW, Leung AW, Loong HH, Li CK, **Chan A**, Cheung YT. Psychosocial challenges among Asian adolescents and young adults with cancer: a scoping review. *BMC Cancer*. 2025 Apr 24;25(1):770. doi: 10.1186/s12885-025-14169-x. PMID: 40275220; PMCID: PMC12020170.
- 312 Thamm C, Button E, Johal J, Knowles R, Paterson C, Halpern MT, Charalambous A, **Chan A**, Aranda S, Taylor C, Chan RJ. Describing the Core Attributes and Impact of Comprehensive Cancer Centers Internationally: A Chronological Scoping Review. *Cancers (Basel)*. 2025 Mar 18;17(6):1023. doi: 10.3390/cancers17061023. PMID: 40149356; PMCID: PMC11940407.
- 311 Maggadani BP, Junusmin KI, Aldila F, Audrienna J, Rabbani B, Maulana Y, Tanu SG, Gabriella G, Amelia M, Agatha FA, et al. CYP2D6 Genotyping for Optimization of Tamoxifen Therapy in Indonesian Women with ER+ Breast Cancer. *Journal of Personalized Medicine* 2025; 15(3):93.
- 310 Ng, F.F., Verma, R., Sani, L. *et al.* A feasibility study on implementing pre-emptive pharmacogenomics testing in outpatient clinics in Singapore (IMPT study). *Pharmacogenomics J* **25**, 7 (2025).
- 309 Haywood D, Chan A, Chan RJ, Dauer E, Dhillon HM, Henneghan AM, Lustberg MB, O'Connor M, Vardy JL, Rossell SL, Hart NH. Accounting for unmet needs resulting from cancer-related cognitive impairment. *J Cancer Surviv* 2025 Mar 11. doi: 10.1007/s11764-025-01769-6. Epub ahead of print. PMID: 40067418.
- 308 Chan RJ, Walker A, Vardy J, Chan A, Oppegaard K, Conley YP, Paul SM, Kober KM, Harris C, Shin J, Morse L, Roy R, Olshen A, Hammer MJ, Levine JD, Miaskowski C. Perturbations in the neuroactive ligand-receptor interaction and renin angiotensin system pathways are associated with cancer-related cognitive impairment. *Support Care Cancer* 2025 Mar 6;33(4):254. doi: 10.1007/s00520-025-09317-9. PMID: 40047999; PMCID: PMC11885406.
- 307 Chan A, Baker WL, Abazia D, Bauman J, Devane CL, Goodlet KJ, Hall N, Hicks JK, Jones E, Lu CH, Moore DC, Nelson NR, Putney K, Sosa A, Trujillo T, Zhou C. Impact

- of artificial intelligence on future clinical pharmacy research and scholarship. *J Am Coll Clin Pharm*. 2025; 1-6.
- 306 Chan RJ, Crawford-Williams F, Han CY, Jones L, **Chan A**, McKavanagh D, Ryan M, Carrington C, Packer RL, Crichton M, Hart NH, McKinnell E, Gosper M, Ryan J, Crowe B, Joseph R, Ee C, Lee J, McPhail SM, Cuff K, Teleni L, Emery J. Implementing a nurse-enabled, integrated, shared-care model involving specialists and general practitioners in early breast cancer post-treatment follow-up (EMINENT): a single-centre, open-label, phase 2, parallel-group, pilot, randomised, controlled trial. *EClinicalMedicine* 2025 Feb 5;81:103090. doi: 10.1016/j.eclinm.2025.103090. PMID: 39996124; PMCID: PMC11848094.
- 305 Di Meglio A, Catanuto G, Zambon M, **Chan A**, Kassianos AP, Cloconi C, Rohr S, Steele R, Coersmeyer M, Ujupan S, Peccatori F. Experiences and preferences about information on treatment-related side effects among patients with early breast cancer. *Breast*. 2025 Feb 6;80:104414. doi: 10.1016/j.breast.2025.104414. Epub ahead of print. PMID: 39947086.
- 304 Haywood D, Henneghan AM, **Chan A**, Chan RJ, Dhillon HM, Lustberg MB, Vardy JL, O'Connor M, Elvidge N, Dauer E, Franco-Rocha OY, Vasan S, Murray J, Crichton M, Wilding H, Rossell SL, Hart NH. The effect of non-pharmacological interventions on cognitive function in cancer: an overview of systematic reviews. *Support Care Cancer* 2025 Feb 4;33(2):151. doi: 10.1007/s00520-025-09212-3. PMID: 39904905; PMCID: PMC11794363.
- 303 Hertz DL, Tanay M, Tofthagen C, Rossi E, Bernasconi DP, Sheffield KE, Carlson M, Nekhlyudov L, Grech L, Von Ah D, Mayo SJ, Ruddy KJ, **Chan A**, Alberti P, Lustberg MB. Patient-reported strategies for prevention and treatment of chemotherapy-induced peripheral neuropathy. *Support Care Cancer* 2025 Feb 3;33(2):142. doi: 10.1007/s00520-025-09190-6. PMID: 39899120.
- 302 Haywood D, **Chan A**, Chan RJ, Baughman FD, Dauer E, Dhillon HM, Henneghan AM, Lawrence BJ, Lustberg MB, O'Connor M, Vardy JL, Rossell SL, Hart NH. The MASCC COG-IMPACT: An unmet needs assessment for cancer-related cognitive impairment impact developed by the Multinational Association of Supportive Care in Cancer. *Support Care Cancer* 2025 Jan 24;33(2):120. doi: 10.1007/s00520-025-09149-7. PMID: 39853439; PMCID: PMC11761510.
- 301 **Chan A**, Chan D, Ng DQ, Zheng HF, Tan QM, Tan CJ, Toh JHM, Yap NY, Toh YL, Ke Y, Wang ECA, Lim QPN, Ho HK, Chew L, Tan TJ. HEalth-Related Quality of Life-Intervention in Survivors of Breast and Other Cancers Experiencing Cancer-Related Fatigue and Associated Cognitive Symptoms Using TraditionAL Chinese Medicine: The 'HERBAL' Trial. *Integr Cancer Ther*. 2025 Jan-Dec;24:15347354251314514. doi: 10.1177/15347354251314514. PMID: 39840742.
- 300 Chan RJ, Ke Y, Carerra P, **Chan A**. Addressing Financial Toxicity From a Global Perspective: How to Advance Shared-Learning to Facilitate Change? *JCO Oncol Pract*. 2025 Jan;21(1):69-72. doi: 10.1200/OP.24.00073. Epub 2025 Jan 10. PMID: 39793556.
- 299 Cathcart-Rake EJ, **Chan A**, Menendez A, Markstrom D, Schnitzlein C, Chong YW, Dizon DS. Cancer care for transgender and gender-diverse people: Practical, literature-driven recommendations from the Multinational Association of Supportive Care in Cancer. *CA Cancer J Clin*. 2024 Dec 9. doi: 10.3322/caac.21872. Epub ahead of print. PMID: 39652385.
- 298 Heshmatipour M, Quan Ng D, Yi-Wen Truong E, Zheng J, **Chan A**, Wang Y. Impact of COVID-19 Pandemic on Emergency Department Visits for Opioid Use Disorder Across

- University of California Health Centers. *West J Emerg Med*. 2024 Nov;25(6):883-889. doi: 10.5811/westjem.18468. PMID: 39625758; PMCID: PMC11610740.
- 297 Arcos D, Dagsi M, Nasr R, Nguyen C, Ng DQ, **Chan A**. Perceptions of Implementing Real-Time Electronic Patient-Reported Outcomes and Digital Analytics in a Majority-Minority Cancer Center. *JCO Clin Cancer Inform*. 2024 Nov;8:e2400188. doi: 10.1200/CCI-24-00188. Epub 2024 Nov 21. PMID: 39571110; PMCID: PMC11594559.
- 296 Ng DQ, Hudson C, Nguyen T, Gupta SK, Koh YQ, Acharya MM, **Chan A**. Dynamin-1 is a potential mediator in cancer-related cognitive impairment. *Neurotherapeutics*. 2024 Nov 7:e00480. doi: 10.1016/j.neurot.2024.e00480. Epub ahead of print. PMID: 39516074.
- 295 Thamm C, Button E, Johal J, Knowles R, Gulyani A, Paterson C, Halpern MT, Charalambous A, **Chan A**, Aranda S, Taylor C, Chan RJ. A systematic review and meta-analysis of patient-relevant outcomes in comprehensive cancer centers versus noncomprehensive cancer centers. *Cancer*. 2024 Nov 20. doi: 10.1002/cncr.35646. Epub ahead of print. PMID: 39565056.
- 294 El-Khatib SM, Vagadia AR, Le ACD, Baulch JE, Ng DQ, Du M, Johnston KG, Tan Z, Xu X, **Chan A**, Acharya MM. BDNF augmentation reverses cranial radiation therapy-induced cognitive decline and neurodegenerative consequences. *Acta Neuropathol Commun*. 2024 Dec 18;12(1):190. doi: 10.1186/s40478-024-01906-9. PMID: 39696694; PMCID: PMC11654382.
- 293 Aldila F, Fj FN, Audrienna J, Sj LL, Tang S, Tanu SG, Fernandez EA, Agatha FA, Wijaya M, Sormin STB, Sani L, Irwanto A, Haryono SJ, Li J, **Chan A**, Hartman M. What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries. *J Community Genet*. 2024 Oct;15(5):517-528. doi: 10.1007/s12687-024-00735-6. Epub 2024 Sep 25. PMID: 39320562; PMCID: PMC11549266.
- 292 Lee JY, Nguyen J, Rodriguez V, Rodriguez A, Patel N, **Chan A**, McBane S, Mayorga J. Digital Innovation to Grow Quality Care Through an Interprofessional Care Team (DIG IT) Among Underserved Patients With Hypertension. *Ann Fam Med*. 2024 Sep-Oct;22(5):410-416. doi: 10.1370/afm.3151. PMID: 39313344; PMCID: PMC11419718.
- 291 Chan RJ, Knowles R, Ashbury FD, Bowen J, **Chan A**, Chin M, Olver I, Taylor C, Tinianov S, Alberti P, Bossi P, Brito-Dellán N, Cooksley T, Crawford GB, Dixit N, Fitch MI, Freedman JL, Ginex PK, Hart NH, Hertz DL, Jefford M, Koczwara B, Naito T, Orsey AD, Ruhlmann CH, Tsoukalas N, van den Hurk C, Van Sebille Y, Wardill HR, Scotte F, Lustberg M; Multinational Association of Supportive Care in Cancer (MASCC) Study Group Chairs. Supportive care 2030 movement: towards unifying ambitions for global excellence in supportive cancer care-an international Delphi study. *EClinicalMedicine*. 2024 Sep 11;76:102825. doi: 10.1016/j.eclinm.2024.102825. PMID: 39309723; PMCID: PMC11415959.
- 290 Ng DQ, Lee S, Lee RT, Wang Y, **Chan A**. Real-world impact of acupuncture on analgesics and healthcare resource utilization in breast cancer survivors with pain. *BMC Med*. 2024 Sep 16;22(1):394. doi: 10.1186/s12916-024-03626-2. PMID: 39285302; PMCID: PMC11406884.
- 289 **Chan A**, Eng L, Jiang C, Dagsi M, Ke Y, Tanay M, Bergerot C, Dixit N, Gutiérrez AC, Velazquez AI, Islami F, Soto-Perez-de-Celis E. Global disparities in cancer supportive care: An international survey. *Cancer Med*. 2024 Sep;13(17):e70234. doi: 10.1002/cam4.70234. PMID: 39268694; PMCID: PMC11393557.

- 288 Haywood D, O'Connor M, Baughman FD, **Chan A**, Chan RJ, Dauer E, Dhillon HM, Henneghan AM, Lawrence BJ, Lustberg M, Vardy JL, Rossell SL, Hart NH. Protocol for the Development and Initial Validation of the COG-IMPACT Tool: A Purpose-Built Unmet Needs Assessment for Cancer-Related Cognitive Impairment. *Methods Protoc.* 2024 Jul 10;7(4):54. doi: 10.3390/mps7040054. PMID: 39051268; PMCID: PMC11270296.
- 287 Abolarin O, Oladipo HJ, Chan D, Olarewaju ML, **Chan A**. Perception on hematology/oncology pharmacy practice and education needs in Nigeria: A national survey. *J Oncol Pharm Pract.* 2024 Jul 23:10781552241264553. doi: 10.1177/10781552241264553. Epub ahead of print. PMID: 39042932.
- 286 **Chan A**, Ng DQ, Arcos D, Heshmatipour M, Lee BJ, Chen A, Duong L, Van L, Nguyen T, Green V, Hoang D. Electronic Patient-Reported Outcome-Driven Symptom Management by Oncology Pharmacists in a Majority-Minority Population: An Implementation Study. *JCO Oncol Pract.* 2024 Jul 15:OP2400050. doi: 10.1200/OP.24.00050. Epub ahead of print. PMID: 39008806.
- 285 Sayer M, Ng DQ, Chan R, Kober K, **Chan A**. Current evidence supporting associations of DNA methylation measurements with survivorship burdens in cancer survivors: A scoping review. *Cancer Med.* 2024 Jul;13(13):e7470. doi: 10.1002/cam4.7470. PMID: 38963018; PMCID: PMC11222976.
- 284 **Chan A**, Ke Y, Tanay M, Dagsi M, Bergerot C, Dixit N, Eng L, Cardeña Gutiérrez A, Jiang C, Velázquez AI, Islami F, Soto-Perez-de-Celis E. Financial Toxicity in Cancer Supportive Care: An International Survey. *JCO Glob Oncol.* 2024 Jul;10:e2400043. doi: 10.1200/GO.24.00043. PMID: 38959449.
- 283 Orhan A, Nguyen C, **Chan A**, Herrstedt J. Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. *Expert Opin Drug Metab Toxicol.* 2024 Jun;20(6):473-489. doi: 10.1080/17425255.2024.2367593. Epub 2024 Jun 25. PMID: 38878283.
- 282 Siegel RD, LeFebvre KB, Temin S, Evers A, Barbarotta L, Bowman RM, **Chan A**, Dougherty DW, Ganio M, Mulvey TM, Ouzts A, Polovich M, Salazar-Abshire M, Stenstrup Z, Sydenstricker CM, Tsai S, Olsen M. Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards. *Oncol Nurs Forum.* 2024 Jun 14;51(4):297-320. doi: 10.1188/24.ONF.297-320. PMID: 38950089.
- 281 Ke Y, Neo PSH, Yang GM, Neo SH, Tan YY, Tan YP, Ramalingam MB, Loh KW, Quah DSC, Chew L, Si PEH, Chan RJ, Hwang WYK, **Chan A**. Impact of a Multidisciplinary Supportive Care Model Using Distress Screening at an Asian Ambulatory Cancer Center: A Cluster Randomized Controlled Trial. *JCO Oncol Pract.* 2024 Sep;20(9):1207-1218. doi: 10.1200/OP.23.00505. Epub 2024 Jun 5. PMID: 38838278; PMCID: PMC11398295.
- 280 Siegel RD, LeFebvre KB, Temin S, Evers A, Barbarotta L, Bowman RM, **Chan A**, Dougherty DW, Ganio M, Hunter B, Klein M, Miller TP, Mulvey TM, Ouzts A, Polovich M, Salazar-Abshire M, Stenstrup EZ, Sydenstricker CM, Tsai S, Olsen MM. Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards. *JCO Oncol Pract.* 2024 May 22:OP2400216. doi: 10.1200/OP.24.00216. Epub ahead of print. PMID: 38776491.
- 279 Yusuf R, Ng DQ, Torno L, **Chan A**. Current evidence of integrative oncology modalities for managing adverse effects and survivorship issues among adolescents and young adult (AYA) cancer patients and survivors. *Current Opinion in Oncology*

():10.1097/CCO.0000000000001033, February 27, 2024. | DOI: 10.1097/CCO.0000000000001033

- 278 **Chan A.** Implementing a cancer survivorship seminar course to non-healthcare professional undergraduate students. *Support Care Cancer* **32**, 227 (2024). <https://doi.org/10.1007/s00520-024-08426-1>
- 277 Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, Aapro M, Dennis K, Hesketh PJ, Navari RM, Schwartzberg L, Affronti ML, Garcia-Del-Barrio MA, **Chan A**, Celio L, Chow R, Fleury M, Gralla RJ, Giusti R, Jahn F, Iihara H, Maranzano E, Radhakrishnan V, Saito M, Sayegh P, Bosnjak S, Zhang L, Lee J, Ostwal V, Smit T, Zilic A, Jordan K, Scotté F; participants of the MASCC/ESMO Consensus Conference 2022. Electronic address: clinicalguidelines@esmo.org. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. *ESMO Open*. 2024 Feb;9(2):102195. doi: 10.1016/j.esmoop.2023.102195. Epub 2024 Jan 11. PMID: 38458657.
- 276 Eng L, Chan RJ, **Chan A**, Charalambous A, Darling HS, Grech L, van den Hurk CJG, Kirk D, Mitchell SA, Poprawski D, Rammant E, Ramsey I, Fitch MI, Cheung YT. Perceived Barriers Toward Patient-Reported Outcome Implementation in Cancer Care: An International Scoping Survey. *JCO Oncol Pract*. 2024 Mar 8:OP2300715. doi: 10.1200/OP.23.00715. Epub ahead of print. PMID: 38457755.
- 275 Soto-Perez-de-Celis E, Ke Y, Tanay M, Dagsi M, Bergerot C, Dixit N, Eng L, Cardeña-Gutiérrez A, Jiang C, Velazquez AI, Islami F, **Chan A**. Equity, diversity, and inclusion in the Multinational Association for Supportive Care in Cancer: a global membership survey. *Support Care Cancer*. 2024 Mar 4;32(3):205. doi: 10.1007/s00520-024-08416-3. PMID: 38433160.
- 274 Spooner AJ, Turner J, Button E, Yates P, Kennedy G, Butler J, Bradford N, **Chan A**, Hart NH, Chan RJ. Supporting Cancer Survivors Following Treatment for Non-Hodgkin's and Hodgkin's Lymphoma: A Pilot Study Assessing the Feasibility and Process Outcomes of a Nurse-Led Intervention. *Semin Oncol Nurs*. 2024 Feb 16:151592. doi: 10.1016/j.soncn.2024.151592. Epub ahead of print. PMID: 38368204.
- 273 Wang Y, **Chan A**, Beuttler R, Fleming ML, Schneberk T, Nichol M, Lu H. Real-World Dispensing of Buprenorphine in California during Prepandemic and Pandemic Periods. *Healthcare (Basel)*. 2024 Jan 18;12(2):241. doi: 10.3390/healthcare12020241. PMID: 38255128; PMCID: PMC10815450.
- 272 Sepassi A, Li M, Zell J, **Chan A**, Saunders IM, Mukamel DB. Rural-Urban Disparities in Colorectal Cancer Screening, Diagnosis, Treatment, and Survivorship Care: A Systematic Review and Meta-Analysis. *Oncologist*. 2024 Jan 19:oyad347. doi: 10.1093/oncolo/oyad347. Epub ahead of print. PMID: 38243853.
- 271 Herrstedt J, Celio L, Hesketh PJ, Zhang L, Navari R, **Chan A**, Saito M, Chow R, Aapro M. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. *Support Care Cancer*. 2023 Dec 21;32(1):47. doi: 10.1007/s00520-023-08221-4. PMID: 38127246; PMCID: PMC10739516.
- 270 Arcos D, Ng DQ, Ke Y, Toh YL, **Chan A**. Prediction of gastrointestinal symptoms trajectories using omega-3 and inflammatory biomarkers in early-stage breast cancer patients receiving chemotherapy. *Support Care Cancer*. 2024 Jan 3;32(1):76. doi: 10.1007/s00520-023-08274-5. PMID: 38170327; PMCID: PMC10764400.
- 269 Hertz DL, Tofthagen C, Rossi E, Bernasconi DP, Lim J, Carlson M, Sheffield KE, Nekhlyudov L, Grech L, Von Ah D, Mayo SJ, Ruddy KJ, **Chan A**, Alberti P, Lustberg

- MB, Tanay M. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy. *Support Care Cancer*. 2023 Dec 22;32(1):48. doi: 10.1007/s00520-023-08209-0. PMID: 38129602.
- 268 Jordan K, **Chan A**, Gralla RJ, Jahn F, Rapoport B, Ruhlmann CH, Sayegh P, Hesketh PJ. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation. *Support Care Cancer*. 2023 Dec 22;32(1):53. doi: 10.1007/s00520-023-08220-5. PMID: 38129530; PMCID: PMC10739277.
- 267 Lee BJ, Griffin SP, Doh J, **Chan A**, Ciurea SO, Jeyakumar D, Fleischman AG, Naqvi K, Pannunzio NR, O'Brien S, Kongtim P. HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia. *Eur J Haematol*. 2023 Nov 6. doi: 10.1111/ejh.14125. Epub ahead of print. PMID: 37933194.
- 266 Agapito I, Ng DQ, Milam J, Ziogas A, Anton-Culver H, **Chan A**. Neuropsychiatric complications and associated management in adolescent and young adult cancer survivors: An All of Us study. *Cancer Med*. 2023 Oct 30. doi: 10.1002/cam4.6641. Epub ahead of print. PMID: 37902258.
- 265 Ng DQ, Cheng I, Wang C, Tan CJ, Toh YL, Koh YQ, Ke Y, Foo KM, Chan RJ, Ho HK, Chew L, Bin Harunal Rashid MF, **Chan A**. Brain-derived neurotrophic factor as a biomarker in cancer-related cognitive impairment among adolescent and young adult cancer patients. *Sci Rep*. 2023 Sep 28;13(1):16298. doi: 10.1038/s41598-023-43581-1. PMID: 37770565; PMCID: PMC10539508.
- 264 Malhotra R, Suppiah SD, Tan YW, Sung P, Tay SSC, Tan NC, Koh GC, **Chan A**, Chew LST, Ozdemir S; PROMISE Study Group. Older adult patient preferences for the content and format of prescription medication labels - A best-worst scaling and discrete choice experiment study. *Res Social Adm Pharm*. 2023 Jul 20:S1551-7411(23)00327-3. doi: 10.1016/j.sapharm.2023.07.009. Epub ahead of print. PMID: 37507340.
- 263 Ng DQ, Chan D, Acharya MM, Grill JD, **Chan A**. Research Attitude and Interest among Cancer Survivors with or without Cognitive Impairment. *Cancers (Basel)*. 2023 Jun 29;15(13):3409. doi: 10.3390/cancers15133409. PMID: 37444519; PMCID: PMC10340755.
- 262 Wang Y, Zheng J, Schneberk T, Ke Y, **Chan A**, Hu T, Lam J, Gutierrez M, Portillo I, Wu D, Chang CH, Qu Y, Brown L, Nichol MB. What quantifies good primary care in the United States? A review of algorithms and metrics using real-world data. *BMC Prim Care*. 2023 Jun 24;24(1):130. doi: 10.1186/s12875-023-02080-y. PMID: 37355573; PMCID: PMC10290298.
- 261 Goyal J, Ng DQ, Zhang K, **Chan A**, Lee J, Zheng K, Hurley-Kim K, Nguyen L, He L, Nguyen M, McBane S, Li W, Cadiz CL. Using machine learning to develop a clinical prediction model for SSRI-associated bleeding: a feasibility study. *BMC Med Inform Decis Mak*. 2023 Jun 11;23(1):105. doi: 10.1186/s12911-023-02206-3. PMID: 37301967; PMCID: PMC10257821.
- 260 Koczwara B, **Chan A**, Jefford M, Lam WWT, Taylor C, Wakefield CE, Pathy NB, Gyawali B, Harvet G, Lou Y, Pramesh CS, Takahashi M, Yu K, Chan RJ. Reply to E.C. Dee et al. *JCO Glob Oncol*. 2023 Jun;9:e2300102. doi: 10.1200/GO.23.00102. PMID: 37290019.
- 259 Malhotra R, Tan YW, Suppiah SD, Tay SSC, Tan NC, Liu J, Koh GC, **Chan A**, Vaillancourt R; PROMISE Study Group. Pharmaceutical pictograms: User-centred

- redesign, selection and validation. *PEC Innov.* 2022 Dec 9;2:100116. doi: 10.1016/j.pecinn.2022.100116. PMID: 37214531; PMCID: PMC10194347.
- 258 Usmani MT, Krattli RP Jr, El-Khatib SM, Le ACD, Smith SM, Baulch JE, Ng DQ, Acharya MM, **Chan A**. Correction to: BDNF Augmentation Using Riluzole Reverses Doxorubicin-Induced Decline in Cognitive Function and Neurogenesis. *Neurotherapeutics.* 2023 Apr;20(3):909. doi: 10.1007/s13311-023-01381-5. Erratum for: *Neurotherapeutics.* 2023 Apr;20(3):838-852. PMID: 37138161; PMCID: PMC10275834.
- 257 Lee BJ, Kongtim P, Doh J, Griffin SP, **Chan A**, O'Brien S, Ciurea SO, Jeyakumar D. Impact of triple intrathecal prophylaxis in acute lymphoblastic leukemia adults receiving HyperCVAD: A COVID-19 practice change. *Eur J Haematol.* 2023 Apr 22. doi: 10.1111/ejh.13980. Epub ahead of print. PMID: 37086155.
- 256 Xie L, Ng DQ, Heshmatipour M, Acharya M, Coluzzi P, Guerrero N, Lee S, Malik S, Parajuli R, Stark C, Tain R, Zabokrtsky K, Torno L, **Chan A**. Electroacupuncture for the management of symptom clusters in cancer patients and survivors (EAST). *BMC Complement Med Ther.* 2023 Mar 27;23(1):92. doi: 10.1186/s12906-023-03926-9. PMID: 36973688; PMCID: PMC10041509.
- 255 Ke Y, Tan YY, Neo PSH, Yang GM, Loh KW-J, Ho S, Tan YP, Ramalingam MB, Quah DSC, Chew L, Si PEH, Tay BC, **Chan A**. Implementing an Inclusive, Multidisciplinary Supportive Care Model to Provide Integrated Care to Breast and Gynaecological Cancer Survivors: A Case Study at an Asian Ambulatory Cancer Centre. *International Journal of Integrated Care* 2023; 23(1): 14, 1–16. DOI: <https://doi.org/10.5334/ijic.6480>
- 254 Lee BJ, Griffin SP, Doh J, Kongtim P, **Chan A**, O'Brien S, Jeyakumar D, Ciurea SO. Timing of Intrathecal Chemotherapy and Blinatumomab Impacts Neurotoxicity in Acute Lymphoblastic Leukemia. *Am J Hematol.* 2023 Feb 16. doi: 10.1002/ajh.26880. Epub ahead of print. PMID: 36794446.
- 253 Suppiah SD, Tan YW, Tay SSC, Tan VSY, Tan NC, Tang WE, **Chan A**, Koh GC, Malhotra R; PROMISE Study Group. Challenges encountered by pharmacy staff in using prescription medication labels during medication counselling with older adults and solutions employed: A mixed-methods study. *Explor Res Clin Soc Pharm.* 2023 Jan 20;9:100226. doi: 10.1016/j.rcsop.2023.100226. PMID: 36785794; PMCID: PMC9918413.
- 252 Usmani MT, Krattli RP Jr, El-Khatib SM, Le ACD, Smith SM, Baulch JE, Ng DQ, Acharya MM, **Chan A**. BDNF Augmentation Using Riluzole Reverses Doxorubicin-Induced Decline in Cognitive Function and Neurogenesis. *Neurotherapeutics.* 2023 Jan 31. doi: 10.1007/s13311-022-01339-z. Epub ahead of print. PMID: 36720792.
- 251 **Chan A**, Ports K, Ng DQ, Nasr R, Hsu S, Armenian S, Baca N, Freyer DR, Kuo DJ, Lin C, Milam J, Valerin J, Yun C, Torno L. Unmet Needs, Barriers, and Facilitators for Conducting Adolescent and Young Adult Cancer Survivorship Research in Southern California: A Delphi Survey. *J Adolesc Young Adult Oncol.* 2023 Jan 25. doi: 10.1089/jayao.2022.0086. Epub ahead of print. PMID: 36695742.
- 250 Lim SY, Ke Y, Mok NK, Tan YY, Neo PSH, **Chan A**, Yang GM. Factors associated with distress and the impact of distress on acute health-care service utilization among patients diagnosed with breast and gynecological cancers. *Palliat Support Care.* 2023 Jan 9:1-8. doi: 10.1017/S1478951522001444. Epub ahead of print. PMID: 36622079.
- 249 Ng DQ, Jia S, Wisseh C, Cadiz C, Nguyen M, Lee J, McBane S, Nguyen L, **Chan A**, Hurley-Kim K. Sociodemographic characteristics differ across routine adult vaccine cohorts: An All of Us descriptive study. *J Am Pharm Assoc (2003).* 2022 Nov 13:S1544-

- 3191(22)00385-5. doi: 10.1016/j.japh.2022.11.005. Epub ahead of print. PMID: 36549934.
- 248 Anwar K, Nguyen L, Nagasaka M, Ou I, **Chan A**. Overview of Drug-Drug Interactions Between Ritonavir-boosted nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer. *JTO Clin Res Rep*. 2022 Dec 17:100452. doi: 10.1016/j.jtocrr.2022.100452. Epub ahead of print. PMID: 36568522; PMCID: PMC9759297.
- 247 Joseph R, Hart NH, Bradford N, Wallen MP, Han CY, Pinkham EP, Hanley B, Lock G, Wyld D, Wishart L, Koczwara B, **Chan A**, Agbejule OA, Crichton M, Teleni L, Holland JJ, Edmiston K, Naumann L, Brown T, Chan RJ. Essential elements of optimal dietary and exercise referral practices for cancer survivors: expert consensus for medical and nursing health professionals. *Support Care Cancer*. 2022 Dec 16;31(1):46. doi: 10.1007/s00520-022-07509-1. PMID: 36525094.
- 246 Ke Y, Cheng I, Tan GSH, Fok RWY, Chan JJ, Loh KW, **Chan A**. Development and pilot testing of a decision aid for navigating breast cancer survivorship care. *BMC Med Inform Decis Mak*. 2022 Dec 15;22(1):330. doi: 10.1186/s12911-022-02056-5. PMID: 36522635; PMCID: PMC9753367.
- 245 Ng DQ, Ritt-Olson A, Freyer DR, Miller KA, Thomas SM, Milam J, **Chan A**. Substance Use Among Young Adult Survivors of Childhood Cancer With Cognitive Impairment: An Analysis of the Project Forward Cohort. *JCO Oncol Pract*. 2022 Dec 12:OP2200458. doi: 10.1200/OP.22.00458. Epub ahead of print. PMID: 36508698.
- 244 Tio MC, Shafi T, Zhu X, Kalantar-Zadeh K, **Chan A**, Nguyen L. Traditions and innovations in assessment of glomerular filtration rate using creatinine to cystatin C. *Curr Opin Nephrol Hypertens* 2023;32(1):89-97. doi: 10.1097/MNH.0000000000000854.
- 243 **Chan A**, Cheng I, Wang C, Tan CJ, Toh YL, Ng DQ, Koh YQ, Zhou H, Foo KM, Chan RJ, Ho HK, Chew L, Farid M, Tannock I. Cognitive impairment in adolescent and young adult cancer patients: Pre-treatment findings of a longitudinal study. *Cancer Med*. 2022 Oct 11. doi: 10.1002/cam4.5295. PMID: 36221816.
- 242 **Chan A**, Elsayed A, Ng DQ, Ruddy K, Loprinzi C, Lustberg M. A global survey on the utilization of cryotherapy and compression therapy for the prevention of chemotherapy-induced peripheral neuropathy. *Support Care Cancer* 2022 Oct 10. doi: 10.1007/s00520-022-07383-x. Epub ahead of print. PMID: 36214880.
- 241 Toh YL, Tan CJ, Yap NY, Parajuli R, Lau AJ, **Chan A**. Longitudinal evaluation of dehydroepiandrosterone (DHEA), its sulfated form and estradiol with cancer-related cognitive impairment in early-stage breast cancer patients receiving chemotherapy. *Sci Rep* 2022 Oct 3;12(1):16552. doi: 10.1038/s41598-022-20420-3. PMID: 36192413; PMCID: PMC9529889.
- 240 Ramsey I, **Chan A**, Charalambous A, Cheung YT, Darling HS, Eng L, Grech L, Hart NH, Kirk D, Mitchell SA, Poprawski D, Rammant E, Fitch MI, Chan RJ. Exercise counselling and referral in cancer care: an international scoping survey of health care practitioners' knowledge, practices, barriers, and facilitators. *Support Care Cancer* 2022 Sep 29:1–13. doi: 10.1007/s00520-022-07342-6. Epub ahead of print. PMID: 36173560; PMCID: PMC9521001.
- 239 Tan CJ, Ng KYJ, Goh WL, Poon E, Chan RJ, Chew L, Farid M, **Chan A**. Work Outcomes and Medical Costs Among Singaporean Adolescent and Young Adult Cancer Survivors. *J Adolesc Young Adult Oncol* 2022 Sep 27. doi: 10.1089/jayao.2022.0036. Epub ahead of print. PMID: 36169562.

- 238 Lee BJ, Griffin SP, Doh J, **Chan A**, O'Brien S, Jeyakumar D, Ciurea SO, Becker PS, Kongtim P. CD19-Directed Immunotherapy Use in KMT2A-Rearranged Acute Leukemia: A Case Report and Literature Review of Increased Lymphoid to Myeloid Lineage Switch. *Am J Hematol* 2022 Sep 3. doi: 10.1002/ajh.26713.
- 237 Lee BJ, Doh J, **Chan A**, Jeyakumar D, O'Brien S. Increased incidence of Pegaspargase-induced hypertriglyceridemia and associated pancreatitis observed in the Hispanic adult patient population. *Leuk Lymphoma*. 2022 Jul 14:1-4. doi: 10.1080/10428194.2022.2098288.
- 236 Ke Y, Zhou H, Chan RJ, **Chan A**. Decision aids for cancer survivors' engagement with survivorship care services after primary treatment: a systematic review. *J Cancer Surviv* 2022; 7. doi: 10.1007/s11764-022-01230-y. Epub ahead of print. PMID: 35798994.
- 235 Ng DQ, Chan D, Agrawal P, Zhao W, Xu X, Acharya M, **Chan A**. Evidence of Brain-Derived Neurotrophic Factor in Ameliorating Cancer-Related Cognitive Impairment: A Systematic Review of Human Studies. *Critical Review in Hematology/Oncology* 2022; ONCH_103748.
- 234 Ozaki A, Cadiz CL, Hurley-Kim, K, Wisseh C, Knox ED, Lee J, Wang A, Patel SG, **Chan A**. Worldwide characteristics and trends of pharmacist interventions contributed to minimize health disparities. *JACCP* 2022; <https://doi.org/10.1002/jac5.1657>
- 233 Wang Y, Wu D, **Chan A**, Chang CH, Lee VWY, Nichol MB. Temporal trend of opioid and nonopioid pain medications: results from a national in-home survey, 2001 to 2018. *Pain Rep*. 2022 May 17;7(3):e1010. doi: 10.1097/PR9.0000000000001010
- 232 Tan YW, Suppiah SD, **Chan A**, Koh GC, Tang WE, Tay SSC, Malhotra R; PROMISE Study Group. Older adult and family caregiver experiences with prescription medication labels and their suggestions for label improvement. *Explor Res Clin Soc Pharm* 2021;4:100087.
- 231 Joseph R, Hart NH, Bradford N, Agbejule OA, Koczwara B, **Chan A**, Wallen MP, Chan RJ. Diet and exercise advice and referrals for cancer survivors: an integrative review of medical and nursing perspectives. *Support Care Cancer* 2022; doi: 10.1007/s00520-022-07152-w.
- 230 Ke Y, Fok RWY, Soong YL, Loh KW, Farid M, Low LL, Quah JHM, Vasanwala FF, Low SG, Soh LL, Tan NC, **Chan A**. Implementing a community-based shared care breast cancer survivorship model in Singapore: a qualitative study among primary care practitioners. *BMC Prim Care* 2022 Apr 8;23(1):73. doi: 10.1186/s12875-022-01673-3. PMID: 35395732; PMCID: PMC8991467.
- 229 Walker A, Chan A, Labra CC, de Lemos ML, Geirnaert M, Albert-Marí MA, Atik EA, Borlagdan J, Crespo A, Danilak M, Kandemir EA, Lim C, Alabelewe RM, Mutiara R, Tewthanom K, Yim B, Nakashima L. International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions. *J Oncol Pharm Pract*. 2023 Jul;29(5):1065-1074. doi: 10.1177/10781552221090199. Epub 2022 Apr 5. PMID: 35382638.
- 228 Ke Y, Tan CJ, Yeo HLA, **Chan A**. Adherence to Cancer Survivorship Care Guidelines and Health Care Utilization Patterns Among Nonmetastatic Breast Cancer Survivors in Singapore. *JCO Glob Oncol* 2022 Mar;8:e2100246. doi: 10.1200/GO.21.00246.

- 227 Hurley-Kim K, Unonu J, Wisseh C, Cadiz C, Knox E, Ozaki A, **Chan A**. Health Disparities in Pharmacy Practice Within the Community: Let's Brainstorm for Solutions. *Frontiers in Public Health* 2022; Accepted for publication.
- 226 Wardill HR, Chan RJ, **Chan A**, Keefe D, Costello SP, Hart NH. Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: supportive care implications and recommendations. *Support Care Cancer* 2022; doi: 10.1007/s00520-022-06948-0
- 225 **Chan A**, Ports K, Neo P, Ramalingam MB, Lim AT, Tan B, Hart NH, Chan RJ, Loh K. Barriers and facilitators to exercise among adult cancer survivors in Singapore. *Support Care Cancer* 2022 Feb 14. doi: 10.1007/s00520-022-06893-y
- 224 **Chan A**, Chan D, Lee H, Ng CC, Yeo AHL. Reporting adherence, validity and physical activity measures of wearable activity trackers in medical research: A systematic review. *Int J Med Inform* 2022; 160:104696.
- 223 Chazan G, Jupp J, Bauters T, Duncan N, Weddle KJ, Nomura H, O'Connor S, **Chan A**, Alkhudair N, Alshamrani M, Buie LW, Chambers P, Chieh TW, DeRemer DL, Duvivier F, Katabalo D, McFarlane T, Mckavanagh D, Mensah K, Martinez EM, Rowan G, Sae-Teaw M, Tadesse TA, Weru I, Alexander M. Impact of coronaovirus of 2019 on the delivery of pharmacy services to patients with cancer: An international survey of oncology pharmacy practitioners. *J Oncol Pharm Pract* 2021; doi: 10.1177/10781552211048892.
- 222 Gooch M, Mehta A, John T, Lomeli N, Naeem E, Mucci G, Toh YL, **Chan A**, Bota DA, Torno L. Feasibility of Cognitive Training to Promote Recovery in Cancer-Related Cognitive Impairment in Adolescent and Young Adult Patients. *J Adolesc Young Adult Oncol* 2021; doi: 10.1089/jayao.2021.0055.
- 221 Tan YW, Suppiah SD, **Chan A**, Koh GCH, Tang WE, Tay SSC, Malhotra R. *Exploratory Research in Clinical and Social Pharmacy* 2021; 4: 100087.
- 220 Cheung YT, **Chan A**, Charalambous A, Darling HS, Eng L, Grech L, van den Hurk CJG, Kirk D, Mitchell SA, Poprawski D, Rammant E, Ramsey I, Fitch MI, Chan RJ; Multinational Association for Supportive Care in Cancer Survivorship Study Group. The use of patient-reported outcomes in routine cancer care: preliminary insights from a multinational scoping survey of oncology practitioners. *Support Care Cancer* 2021 Sep 15;1-13.
- 219 Chan RJ, Crichton M, Crawford-Williams F, Agbejule OA, Yu K, Hart NH, de Abreu Alves F, Ashbury FD, Eng L, Fitch M, Jain H, Jefford M, Klemanski D, Koczwara B, Loh K, Prasad M, Rugo H, Soto-Perez-de-Celis E, van den Hurk C, **Chan A**; Multinational Association of Supportive Care in Cancer (MASCC) Survivorship Study Group. The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews. *Ann Oncol* 2021 Sep 9;S0923-7534(21)04464-1.
- 218 Chan RJ, Cooper B, Koczwara B, **Chan A**, Tan CJ, Gordon L, Paul SM, Dunn LB, Conley YP, Kober KM, Abrams G, Levine JD, Miaskowski C. Characteristics associated with inter-individual variability in financial distress in patients with breast cancer prior to and for 12 months following surgery. *Support Care Cancer* 2021 Sep 3 doi: 10.1007/s00520-021-06524-y.
- 217 Yap NY, David SP, Zheng HF, Tan QM, Quek LYP, Tan TK, Ho HK, **Chan A**. Evaluation of in vitro cytochrome P450 Inhibition and hepatotoxicity potential of a herbal formula (Xiang Bei Yang Rong Tang) for treatment of cancer-related fatigue; *Pharmacogn Mag* 2021; 17:603-5.

- 216 **Chan A**, Joe MD, Hirsch JD. Supporting COVID-19 Vaccine Rollout Before Charter Class Arrives: The University of California, Irvine Experience. *Pharmacy* 2021; 9(4): 164.
- 215 Tan CJ, Yip SYC, Chan RJ, Chew L, **Chan A**. Investigating how cancer-related symptoms influence work outcomes among cancer survivors: a systematic review. *J Cancer Surviv* 2021; doi: 10.1007/s11764-021-01097-5.
- 214 Malhotra R, Suppiah S, Tan YW, Tay SSC, Tan VSY, Tang WE, Tan NC, Wong RYH, **Chan A**, Koh GC, Vaillancourt R; PROMISE Study Group. Validation of Pharmaceutical Picograms among older adults with limited English proficiency. *Patient Educ Couns* 2021 Jul 10:S0738-3991(21)00474-2. doi: 10.1016/j.pec.2021.07.015.
- 213 Oppegaard K, Harris CS, Shin J, Paul SM, Cooper BA, **Chan A**, Anguera JA, Levine J, Conley Y, Hammer M, Miaskowski CA, Chan RJ, Kober KM. Cancer-related cognitive impairment is associated with perturbations in inflammatory pathways. *Cytokine* 2021;148:155653. doi: 10.1016/j.cyto.2021.155653.
- 212 Adesta F, Mahendra C, Junusmin KI, Rajah AMS, Goh S, Sani L, **Chan A**, Irwanto A. Pharmacogenomics Implementation Training Improves Self-Efficacy and Competency to Drive Adoption in Clinical Practice. *Front Pharmacol* 2021;12:684907. doi: 10.3389/fphar.2021.684907.
- 211 Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, McGlown SM, **Chan A**, Grech LB, Loprinzi CL, Ruddy KJ, Lustberg M. Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). *Cancer Treat Rev* 2021;99:102241. doi: 10.1016/j.ctrv.2021.102241.
- 210 Koh YQ, Ng DQ, Ng CC, Boey A, Wei M, Sze SK, Ho HK, Acharya M, Limoli CL, **Chan A**. Extracellular Vesicle Proteome of Breast Cancer Patients with and Without Cognitive Impairment Following Anthracycline-based Chemotherapy: An Exploratory Study. *Biomark Insights* 2021;16:11772719211018204. doi: 10.1177/11772719211018204.
- 209 Holle LM, Bilse T, Alabelewe RM, Kintzel PE, Kandemir EA, Tan CJ, Weru I, Chambers CR, Dobish R, Handel E, Tewthanom K, Saeteaw M, Dewi LKM, Schwartz R, Bernhardt B, Garg M, Chatterjee A, Manyau P, **Chan A**, Bayraktar-Ekincioglu A, Aras-Atik E, Harvey RD, Goldspiel BR. International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care. *J Oncol Pharm Pract* 2021;27(4):785-801. doi: 10.1177/10781552211017199.
- 208 Yap NY, Toh YL, Tan CJ, Acharya MM, **Chan A**. Relationship between cytokines and brain-derived neurotrophic factor (BDNF) in trajectories of cancer-related cognitive impairment. *Cytokine* 2021; 144:155556. doi: 10.1016/j.cyto.2021.155556.
- 207 Tan CJ, Kumar R, Koomanan N, Loo WS, Farid M, Tao M, Somasundaram N, Poon E, Chan JY, Yang VS, Chang E, Lim ST, Chow WC, **Chan A**, Tang T. Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab. *Pharmacotherapy* 2021; doi: 10.1002/phar.2508
- 206 Ng DQ, Tan CJ, Soh BC, Tan MML, Loh SY, Tan YE, Ong HH, Teng PPC, Chan JJ, Chay WY, Lee J, Lai G, Beh SY, Tan TJY, Yap YS, Lee GE, Wong M, Dent R, Lo YL, **Chan A**, Loh KW. Impact of Cryotherapy on Sensory, Motor, and Autonomic Neuropathy in Breast Cancer Patients Receiving Paclitaxel: A Randomized, Controlled Trial. *Front Neurol* 2020 Dec 18;11:604688. doi: 10.3389/fneur.2020.604688.
- 205 Oh HS, **Chan A**, Seo HJ. Prescribing patterns in breast cancer survivors: A Korean National Health Insurance Service cohort study. *Int J Clin Pharmacol Ther* 2021; doi: 10.5414/CP203816

- 204 Mayo SJ, Lustberg M, M Dhillon H, Nakamura ZM, Allen DH, Von Ah D, C Janelins M, **Chan A**, Olson K, Tan CJ, Toh YL, Oh J, Grech L, Cheung YT, Subbiah IM, Petranovic D, D'Olimpio J, Gobbo M, Koeppen S, Loprinzi CL, Pang L, Shinde S, Ntukidem O, Peters KB. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. *Support Care Cancer* 2020; doi: 10.1007/s00520-020-05860-9.
- 203 Yap NY, Loo WS, Zheng HF, Tan QM, Tan TK, Quek LYP, Tan CJ, Toh YL, Ng CC, Ang SK, Tan VKM, Ho HK, Chew L, Loh KW, Tan TJY, **Chan A**. A study protocol for HEalth-Related quality of life-intervention in survivors of Breast and other cancers experiencing cancer-related fatigue using TraditionAL Chinese Medicine: the HERBAL trial. *Trials* 2020;21(1):909. doi: 10.1186/s13063-020-04810-4.
- 202 Chan R, Cooper B, Paul S, Conley Y, Kober K, Koczwara B, **Chan A**, Tan CJ, Gordon L, Thomy L, Levine J, Miaskowski C. Distinct financial distress profiles in patients with breast cancer prior to and for 12 months following surgery. *BMJ Support Palliat Care* 2020; doi: 10.1136/bmjspcare-2020-002461.
- 201 Fok RW, Low LL, Quah HMJ, Vasanwala F, Low SG, Soh LL, Mohamad F, Loh KW, Soong YL, Ke Y, **Chan A**, Tan NC. Roles and recommendations from primary care physicians towards managing low-risk breast cancer survivors in a shared-care model with specialists in Singapore-a qualitative study. *Fam Pract* 2020; Sep 5;37(4):547-553. doi: 10.1093/fampra/cmaa009.
- 200 Toh YL, Wong E, Chae JW, Yap NY, Yeo AHL, Shwe M, **Chan A**. Association of mitochondrial DNA content and displacement loop region sequence variations with cancer-related fatigue in breast cancer survivors receiving chemotherapy. *Mitochondrion* 2020; S1567-7249(20)30166-5.
- 199 Cheng HL, Lopez V, Lam SC, Leung AKT, Li YC, Wong KH, Au JSK, Sundar R, Chan A, De Ng TR, Suen LKP, Chan CW, Yorke J, Molassiotis A. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. *Health Qual Life Outcomes* 2020;18(1):246.
- 198 Yap NY, Tan NYT, Tan CJ, Loh KW, Ng RCH, Ho HK, **Chan A**. Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer. *Breast Cancer Res Treat* 2020; doi: 10.1007/s10549-020-05807-y.
- 197 Tan CJ, Mah JJJ, Goh WL, Poon E, Farid M, **Chan A**. Self-reported cognitive outcomes among adolescent and young adult patients with non-central nervous system cancers. *Psychooncology* 2020; doi: 10.1002/pon.5456.
- 196 **Chan A**, Ashbury F, Fitch MI, Koczwara B, Chan RJ; MASCC Survivorship Study Group. Cancer Survivorship Care During COVID-19-perspectives and Recommendations From the MASCC Survivorship Study Group. *Support Care Cancer* 2020;28(8):3485-3488.
- 195 Alexander M, Jupp J, Chazan G, O'Connor S, **Chan A**. Global Oncology Pharmacy Response to COVID-19 Pandemic: Medication Access and Safety. *J Oncol Pharm Pract* 2020; doi: 10.1177/1078155220927450
- 194 Chan RJ, Howell D, Lustberg MB, Mustian K, Koczwara B, Ng CC, Kim Y, Nápoles AM, Dixit N, Klemanski D, Ke Y, Toh YL, Fitch MI, Crichton M, Agarawal S, **Chan A**. Advances and Future Directions in the Use of Mobile Health in Supportive Cancer Care:

- Proceedings of the 2019 MASCC Annual Meeting Symposium. *Support Care Cancer* 2020; doi: 10.1007/s00520-020-05513-x
- 193 Toh YL, Pang YY, Shwe M, Kanesvaran R, Toh CK, Chan A, Ho HK. HPLC-MS/MS coupled with equilibrium dialysis method for quantification of free drug concentration of pazopanib in plasma. *Heliyon* 2020; 6: e03813.
- 192 Koh YQ, Tan CJ, Toh YL, Sze SK, Ho HK, Limoli CL, **Chan A**. Role of exosomes in cancer-related cognitive impairment. *Int J Mol Sci* 2020; 21(8). pii: E2755. doi: 10.3390/ijms21082755.
- 191 Tan CJ, Ke Y, Ng T, Tan IMJ, Goh WL, Poon E, Farid M, Neo PSH, Srilatha B, **Chan A**. Work- and insurance-related issues among Asian adolescent and young-adult cancer survivors: a qualitative study. *Support Care Cancer* 2020; doi: 10.1007/s00520-020-05430-z.
- 190 Tan CJ, Ke Y, **Chan A**. Proceedings of the biosimilars workshop at the International Symposium on Oncology Pharmacy Practice 2019. *J Oncol Pharm Pract* 2020 Apr;26(3_suppl):33-39.
- 189 Foreman E, Patel H, Siderov J, Harchowal J, Bubalo J, Chan A. A survey of global biosimilar implementation practice conducted by the International Society of Oncology Pharmacy Practitioners. *J Oncol Pharm Pract* 2020 Apr;26(3_suppl):22-32.
- 188 **Chan A**, Patel H, Siderov J, Bubalo J, Foreman E. Assessing biosimilar education needs among oncology pharmacy practitioners worldwide: An ISOPP membership survey. *J Oncol Pharm Pract* 2020 Apr;26(3_suppl):11-21.
- 187 Frazer MB, Bubalo J, Patel H, Siderov J, Cubilla M, De Lemos M, Dhillon H, Harchowal J, Kuchonthara N, Livinalli A, Macedo R, Mwangi W, Nomura H, O'Connor S, Patterson M, Seadi Torriani M, Yim B, Chan A, Foreman E. International Society of Oncology Pharmacy Practitioners global position on the use of biosimilars in cancer treatment and supportive care. *J Oncol Pharm Pract* 2020 Apr;26(3_suppl):3-10.
- 186 Foreman E, **Chan A**. Preface - *Biosimilars Implementation in Clinical Practice: An ISOPP Collection for Oncology Pharmacists*. *J Oncol Pharm Pract* 2020 Apr;26(3_suppl):2.
- 185 **Chan A**, Lee JY, Han Z. Perception of electronic peer review of SOAP notes among pharmacy students enrolling in their first pharmacotherapeutics course. *Curr Pharm Teach Learn* 2019;11(12):1259-1264.
- 184 Chan RJ, Cooper B, Koczwara B, Chan A, Tan CJ, Paul SM, Dunn LB, Conley YP, Kober KM, Levine JD, Miaskowski C. A longitudinal analysis of phenotypic and symptom characteristics associated with inter-individual variability in employment interference in patients with breast cancer. *Support Care Cancer* 2020 Jan 18. doi: 10.1007/s00520-020-05312-4.
- 183 Han Z, Chan A. Pharmacy students' perceptions toward peer assessment and its use in teaching patient presentation skills. *Curr Pharm Teach Learn* 2020;12(2):228-236.
- 182 Toh YL, Wang C, Ho HK, **Chan A**. Distinct cytokine profiles across trajectories of self-perceived cognitive impairment among early-stage breast cancer survivors. *J Neuroimmunol* 2020;342:577196.
- 181 Ke Y, Tan CJ, Ng T, Tan IMJ, Goh WL, Poon E, Farid M, Neo PSH, Srilatha B, **Chan A**. Optimizing Survivorship Care Services for Asian Adolescent and Young Adult Cancer

- Survivors: A Qualitative Study. *J Adolesc Young Adult Oncol* 2020; doi: 10.1089/jayao.2019.0145
- 180 **Chan A**, Yeo A, Shwe M, Tan CJ, Foo KM, Chu P, Khor CC, Ho HK. An Evaluation of DNA Methyltransferase 1 (DNMT1) Single Nucleotide Polymorphisms and Chemotherapy-Associated Cognitive Impairment: A Prospective, Longitudinal Study. *Sci Rep* 2019; 9(1):14570. doi: 10.1038/s41598-019-51203-y.
- 179 Liang JB, Lao CK, Tian L, Yang YY, Wu HM, Tong HH, Chan A. Impact of a pharmacist-led education and follow-up service on anticoagulation control and safety outcomes at a tertiary hospital in China: a randomized controlled trial. *Int J Pharm Pract* 2019; doi: 10.1111/ijpp.12584.
- 178 Chan A, Hertz D, Morales M, Adams EJ, Gordon S, Tan CJ, Staff NP, Kamath J, Oh J, Shinde S, Pon D, Dixit N, D'Olimpio J, Dumitrescu C, Gobbo M, Kober K, Mayo S, Pang L, Subbiah I, Beutle AS, Peters KB, Loprinzi C, Lustberg M. Biological Predictors of Chemotherapy Induced Peripheral Neuropathy (CIPN): MASCC Neurological Complications Working Group Overview. *Support Care Cancer* 2019; 27(10): 3729-37.
- 177 Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, Sundar R, Chan A, Ng TR, Suen LKP, Chan CW, Yorke J, Lopez V. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. *Brain Behav* 2019; 9(6): e01312.
- 176 Toh YL, Tan CJ, Yeo A, Shwe M, Ho K, Gan YX, Chu P, Olson K, **Chan A**. Association of plasma leptin, pro-inflammatory adipokines and cancer-related fatigue in early-stage breast cancer patients: a prospective cohort study. *Journal of Cellular and Molecular Medicine* 2019; 23(6):4281-4289.
- 175 Yeo F, Ng CC, Loh KW, Molassiotis A, Cheng E, Au JSK, Leung KT, Li C, Wong KH, Suen L, Chan CW, Yorke J, Farrell C, Bandla A, Ang E, Lopez V, Sundar R, **Chan A**. Minimal Clinically Important Difference of the EORTC QLQ-CIPN20 for Worsening Peripheral Neuropathy in Patients Receiving Neurotoxic Chemotherapy. *Support Care Cancer* 2019; 27(12):4753-4762.
- 174 Toh YL, Shariq Mujtaba J, Bansal S, Yeo A, Shwe M, Lau AJ, **Chan A**. Prechemotherapy Levels of Plasma Dehydroepiandrosterone and Its Sulfated Form as Predictors of Cancer-Related Cognitive Impairment in Patients with Breast Cancer Receiving Chemotherapy. *Pharmacotherapy* 2019;39(5):553-563.
- 173 Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, Leung KT, Li YC, Wong KH, Suen LKP, Chan CW, Yorke J, Farrell C, Sundar R. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. *BMC Cancer* 2019;19(1):132.
- 172 Olin JL, Kilbanov O, Chan A, Spooner L. Managing Pharmacotherapy in People Living with HIV (PLWH) and Concomitant Malignancy. *Ann Pharmacother* 2018; 53(8): 812-32.
- 171 Chan RJ, Gordon LG, Tan CJ, Chan A, Bradford NK, Yates P, Agbejule OA, Miaskowski C. Relationships between Financial Toxicity and Symptom Burden in Cancer Survivors: A Systematic Review. *J Pain Symptom Manage* 2019;57(3):646-660.e1.
- 170 Tan CJ, Lim SWT, Toh YL, Ng T, Yeo A, Shwe S, Foo KM, Chu P, Jain A, Koo SL, Dent RA, Ng RCH, Yap YS, Lim EH, Loh KWJ, Chay WY, Lee GE, Tan TJY, Beh SY, Wong M, Chan JJ, Khor CC, Ho HK, **Chan A**. Replication and meta-analysis of the association

- between *BDNF* Val66Met polymorphism and cognitive impairment in patients receiving chemotherapy. *Molecular Neurobiology* 2018; 56(7): 4741-50.
- 169 Chanthawong S, Lim HY, Subongkot S, Chan A, Andalusia R, Bustamam RSA, Chaiyakunapruk N. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. *Support Care Cancer* 2019; 27(3):1109-1119.
- 168 Chan SL, Ng HY, Sung C, Chan A, Winther M, Brunham L, Wee HL. Economic Burden of Adverse Drug Reactions and Potential for Pharmacogenomic Testing in Singaporean Adults. *Pharmacogenomics Journal* 2018; 19(4): 401-10.
- 167 Chae JW, Ng R, **Chan A**. Chemotherapy drug concentrations in hair follicles: a potential biomarker to monitor the effectiveness of scalp cooling for chemotherapy-induced alopecia. *Support Care Cancer* 2018;26(11):3669-3670.
- 166 Kim HJ, Barsevick AM, Chan A, Chae JW. Chemotherapy-associated cognitive impairments in Korean cancer patients: Risk factors and functional outcome. *Psychooncology* 2018;27(8):1995-2001.
- 165 Yeo D, Hossain I, Lim ST, Farid M, Tao M, Quek R, Tang T, **Chan A**. A response to the letter to the editor on "Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study". *J Oncol Pharm Pract*. 2018;24(6):478-479.
- 164 Toh YL, Ng T, Tan M, Tan A, **Chan A**. Impact of brain-derived neurotrophic factor genetic polymorphism on cognition: A systematic review. *Brain Behav* 2018 Jul;8(7):e01009.
- 163 Ke Y, Ng T, **Chan A**. Survivorship care models for breast cancer, colorectal cancer, and adolescent and young adult (AYA) cancer survivors: a systematic review. *Support Care Cancer* 2018 Jul;26(7):2125-214
- 162 Ng T, Phey XY, Yeo HL, Shwe M, Gan YX, Ng R, Ho HK, Chan A. Impact of Adjuvant Anthracycline-Based and Taxane-Based Chemotherapy on Plasma VEGF Levels and Cognitive Function in Breast Cancer Patients: A Longitudinal Study. *Clin Breast Cancer* 2018;18(5):e927-e937.
- 161 **Chan A**, Poon E, Goh WL, Gan Y, Tan CJ, Yeo K, Chua A, Chee M, Law YC, Somasundaram N, Kanesvaran R, Ng QS, Tham CK, Toh CK, Lim ST, Tao M, Tang T, Quek R, Farid M. Assessment of psychological distress among Asian adolescents and young adults (AYA) cancer patients using the distress thermometer: a prospective, longitudinal study. *Support Care Cancer* 2018;26(9):3257-3266.
- 160 Gan YX, Lao CK, **Chan A**. Breast cancer screening behavior, attitude, barriers among middle-aged Chinese women in Macao, China. *Journal of Public Health* 2018;40(4):e560-e570.
- 159 Yeo D, Hossain I, Lim ST, Farid M, Tao M, Quek R, Tang T, **Chan A**. Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study. *J Oncol Pharm Pract* 2018; doi: 10.1177/1078155218763039.
- 158 Chong MF, **Chan A**. Thalidomide for Delayed Chemotherapy-Induced Nausea and Vomiting: Where Is Its Place in Therapy? *J Clin Oncol* 2018; 36(8):827-828.

- 157 Loh KW, Ng T, Choo SP, Saw HM, Mahendran R, Tan C, Chang GCY, Ong YJ, Yee ACP, **Chan A**, Soo KC. Cancer Supportive and Survivorship Care in Singapore: Current Challenges and Future Outlook. *J Glob Oncol* 2018;(4):1-8.
- 156 **Chan A**, Lew C, Wang XJ, Ng T, Chae JW, Yeo HL, Shwe M, Gan YX. Psychometric properties and measurement equivalence of the Multidimensional Fatigue Syndrome Inventory- Short Form (MFSI-SF) amongst breast cancer and lymphoma patients in Singapore. *Health Qual Life Outcomes* 2018; 16(1):20. doi: 10.1186/s12955-018-0846-6.
- 155 Chae JW, Chua PS, Ng T, Yeo AHL, Shwe M, Gan YX, Dorajoo S, Foo KM, Loh KW, Koo SL, Chay WY, Tan TJY, Beh SY, Lim EH, Lee GE, Dent R, Yap YS, Ng R, Ho HK, **Chan A**. Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study. *Breast Cancer Res Treat* 2018; 168(3):713-721.
- 154 Ng T, Dorajoo SR, Cheung YT, Lam YC, Yeo HL, Shwe M, Gan YX, Foo KM, Loh WK, Koo SL, Jain A, Lee GE, Dent R, Yap YS, Ng R, **Chan A**. Distinct and Heterogeneous Trajectories of Self-perceived Cognitive Impairment among Asian Breast Cancer Survivors. *Psychooncology* 2018;27(4):1185-1192.
- 153 Ng T, Lee YY, Chae JW, Yeo AHL, Shwe M, Gan YX, Ng RCH, Chu PPY, Khor CC, Ho HK, **Chan A**. Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study. *BMC Cancer* 2017;17(1):867.
- 152 **Chan A**, Ngai GH, Chung WL, Yeo A, Ng T, Loh KW, Farid M, Lim SY, Fok R. Practitioners' perspectives on community-based breast cancer survivorship care in Singapore: A focus group study. *Health Soc Care Community* 2018;26(3):404-411.
- 151 **Chan A**, Yo T, Wang XJ, Ng T, Chae JW, Shwe M, Yeo HL, Shwe M, Gan YX. Minimal Clinically Important Difference of the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) for Fatigue Worsening in Asian Breast Cancer Patients. *Journal of Pain and Symptom Management* 2018; 55(3):992-997.e2.
- 150 Tan SH, Keng KK, Lim SM, Chan A, Loh J, Lee J. Long-term Clinical and Cost Outcomes of a Pharmacist-managed Risk Factor Management Clinic (RFMP) in Singapore: An Observational Study. *Clinical Therapeutics* 2017; 39(12):2355-2365.
- 149 Dorajoo SR, **Chan A**. Implementing clinical prediction models: pushing the needle towards precision pharmacotherapy. *Clinical Pharmacology & Therapeutics* 2018;103(2):180-183
- 148 Wang XJ, Tan TT, Lim ST, Farid M, Tao M, Quek R, **Chan A**, Tang T. Role of Procalcitonin in Differentiating between Infectious and Noninfectious Fevers among Patients with Lymphoma. *Pharmacotherapy* 2017;37(8):908-915.
- 147 Wang XJ, Tong WX, **Chan A**. Therapeutic Use of Filgrastim for Established Febrile Neutropenia is Cost Effective Among Patients with Solid Tumors and Lymphomas. *Clinical Therapeutics* 2017;39(6):1161-1170.
- 146 Wang XJ, Goh DYT, Dorajoo SR, **Chan A**. The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas. *Supportive Care in Cancer* 2017;25(9):2815-2822.

- 145 Dorajoo SR, Ng JSL, Goh JHF, Lim SC, Yap CW, Chan A, Lee JYC. HbA1c variability in type 2 diabetes is associated with the occurrence of new-onset albuminuria within three years. *Diabetes Research and Clinical Practice* 2017;128:32-39.
- 144 Wang XJ, **Chan A**. Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions. *Curr Oncol Rep* 2017;19(3):20.
- 143 Dorajoo SR, See V, Chan CT, Tan JZ, Tan DSY, Razak SM, Ong TT, Koomanan N, Yap CW, **Chan A**. Identifying potentially avoidable readmissions: A medication-based 15-day readmission risk stratification algorithm. *Pharmacotherapy* 2017;37(3):268-277.
- 142 Chan RJ, Chan A, Yates P, Molassiotis A. A step forward in addressing cancer survivorship in the Asia-Pacific region. *BMC Med* 2017;15(1):17.
- 141 **Chan A**, Gan YX, Oh SK, Ng T, Shwe M, Chan R, Ng R, Goh B, Tan YP, Fan G. A Culturally Adapted Survivorship Program for Asian Early-Stage Breast Cancer Patients in Singapore: A Randomized, Controlled Trial. *Psychooncology* 2017;26(10):1654-1659.
- 140 **Chan A**, Abudllah MM, Ishak WZBW, Ong-Cornel, AB, Villalon AH, Kanesvaran R. Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement. *J Glob Oncol* 2017;3(6):801-813.
- 139 Ke Y, Ng T, Yeo HL, Shwe M, Gan YX, **Chan A**. Psychometric Properties and Measurement Equivalence of the English and Chinese Versions of the Beck Anxiety Inventory in Patients with Breast Cancer. *Support Care Cancer* 2017; 25(2): 633-43.
- 138 Chae JW, Ng T, Yeo HL, Shwe M, Gan YX, Ho HK, **Chan A**. Impact of TNF- α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients. *PLoS One*. 2016 Oct 4;11(10):e0164204.
- 137 Chan SL, Ang X, Sani LL, Ng HY, Winther MD, Liu JJ, Brunham LR, **Chan A**. Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. *Br J Clin Pharmacol* 2016; 82(6): 1636-46.
- 136 Yeang SH, Chan A, Tan CW, Lim ST, Ng HJ. Incidence and Management of Toxicity Associated with LAsparaginase in the Treatment of ALL and NK/TCCell Lymphoma: an Observational Study. *Asian Pac J Cancer Prev* 2016; 17(7): 3155-60.
- 135 Herrstedt, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, Chan A, Aapro MS. MASCC/ESMO Consensus recommendations for the prevention of nausea and vomiting following high emetic risk chemotherapy. *Support Care Cancer* 2017; 25(1): 277-88.
- 134 Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Warr D, Hesketh PJ. MASCC/ESMO Consensus Recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. *Support Care Cancer* 2017; 25(1): 271-5.
- 133 Chae JW, Teo YL, Ho HK, Lee J, Back HM, Y HY, Karlsson MO, Kwon KI, **Chan A**. BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. *Cancer Chemotherapy and Pharmacology* 2016; 78(3): 623-32.
- 132 Wang XJ, Wong CM, **Chan A**. Psychometric Properties of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N) in Asian Cancer Patients with

- Chemotherapy-Induced Neutropenia. *Journal of Pain and Symptom Management* 2016; 52(3); 428-36.
- 131 **Chan A**, Lum ZK, Ng T, Eyob T, Wang XJ, Chae JW, Raaj S, Shwe M, Gan YX, Fok R, Loh K, Tan YP, Fan G. Perceptions and Barriers of Survivorship Care in Asia: Perceptions from Asian Breast Cancer Survivors. *Journal of Global Oncology* 2016; DOI: 10.1200/JGO.2016.004929
- 130 **Chan A**, Ng T, Chan RJ, Poon E, Farid M. Are Adolescent and Young Adult (AYA) Cancer Patients affected by 'Chemobrain'? A Call for Evidence. *Expert Opinion of Quality of Life in Cancer* 2016; 1(3): 187-88.
- 129 American College of Clinical Pharmacy, Sorensen TD, Shapiro NL, Benedict N, Edwards KL, Chan A, Covey D, Daniels C, Hagemann T, Hemstreet B, Miller W, Musselman ME. Recommendations for Aligning PGY2 Pharmacy Residency Training and Pharmacy Specialist Board Certification. *Pharmacotherapy* 2016;36(5):e34-9
- 128 Eyob T, Ng T, Chan R, **Chan A**. Impact of chemotherapy on cancer-related fatigue in 1312 patients: a systematic review of quantitative studies. *Curr Opin Support Palliat Care* 2016;10(2):165-79.
- 127 Wang XJ, Tang T, Farid M, Quek R, Tao M, Lim ST, Wee HL, **Chan A**. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy. *PLoS One* 2016; 11(2): e0148901.
- 126 Holle LM, Harris CS, Chan A, Fahrenbruch RJ, Labdi BA, Mohs JE, Norris LB, Perkins J, Vela CM. Pharmacists' roles in oncology pharmacy services: Results of a global survey. *J Oncol Pharm Pract* 2016; doi: 1078155216629827.
- 125 Hu Z, Liang W, Yang Y, Keefe D, Ma Y, Zhao Y, Xue C, Huang Y, Zhao H, Chen L, Chan A, Zhang L. Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy. *Medicine* (Baltimore) 2016; 95(2): e2476.
- 124 Lee JJX, Chan A, Tang T. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma. *Acta Oncologica* 2016 ;55(4):519-20.
- 123 Chan A, Saeteaw M, Chui WK, Lee JYC. Perceptions of pharmacy students and pharmacists on SOAP note education and utility in pharmacy practice. *Currents in Pharmacy Teaching and Learning* 2016; 8: 77-82.
- 122 Teleni L, Chan RJ, Chan A, Isenring EA, Vela I, Inder W, McCarthy AL. Exercise improves quality of life in ADT-treated prostate cancer: systematic review of RCTs. *Endocr Relat Cancer* 2016;23(2):101-12
- 121 Suzuki S, Chan A, Nomura H, Johnson PE, Endo K, Saito S. Chemotherapy regimen checks performed by pharmacists contribute to safe administration of chemotherapy. *J Oncol Pharm Pract* 2015; doi: 10.1177/1078155215614998.
- 120 Marx W, McKavanagh D, McCarthy AL, Bird R, Ried K, Chan A, Isenring L. The effect of ginger (*Zingiber officinale*) on platelet aggregation: a systematic literature review. *PLOS ONE* 2015; 21;10(10):e0141119.
- 119 Loh KY, Ng T, Lee CP, Ng R, **Chan A**. Medication Use by Early-Stage Breast Cancer Survivors: A 1-Year Longitudinal Study. *Support Care Cancer* 2016;24(4):1639-47.

- 118 Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, Foo KM, Cham MT, Lee JA, Tan YP, Fan G, Yong WS, Preetha M, Loh WK, Koo SL, Jain A, Lee GE, Wong M, Dent R, Yap YS, Ng R, Khor CC, Ho HK, **Chan A**. Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. *Neuro Oncol* 2016;18(2):244-51.
- 117 Lao CK, Chan YM, Tong HHY, Chan A. Under-diagnosis of depression in an economically deprived population in Macao, China. *Asia Pac Psychiatry* 2015; doi: 10.1111/appy.12208
- 116 Chan A, Song M, Langit MR, Lim TA, Fong W, Tay K, Lim ST, Tang T. Carotid artery inflammation associated with gemcitabine-based therapy: a special report. *Future Oncology* 2015;11(14):2049-58.
- 115 Chan RJ, **Chan A**. Survivorship care provision for patients with hematologic malignancies: The quest for quality evidence. *Cancer Nursing* 2015;38(5):414-5.
- 114 Cheung YT, Ong YY, Ng T, Tan YP, Fan G, Chan CW, Molassiotis A, **Chan A**. Assessment of mental health literacy in patients with breast cancer. *J Onc Pharm Pract* 2016;22(3):437-47.
- 113 Langbecker D, Ekberg S, Yates P, Chan A, Chan RJ. What are the barriers of quality survivorship care for haematology cancer patients? Qualitative insights from cancer nurses. *J Cancer Surviv* 2016;10(1):122-30.
- 112 Lao CK, Chan YM, Tong HHY, Chan A. Prevalence, Awareness and Control of Cardiovascular Risk Factors in a Low-Income Population in Macao, China. *Public Health Research* 2015; 5(2):50-57.
- 111 Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, Lee JA, Fan G, Tan YP, Yong WS, Madhukumar P, Loo SK, Ang SF, Wong M, Chay WY, Ooi WS, Dent RA, Yap YS, Ng R, **Chan A**. Association of pro-inflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: A multi-centered, prospective, cohort study. *Ann Oncol* 2015;26(7):1446-51.
- 110 Ng T, Toh MR, Cheung YT, **Chan A**. Follow-up care practices and barriers to breast cancer survivorship: Perspectives from Asian Oncology Practitioners. *Support Care Cancer* 2015;23(11):3193-200.
- 109 Teo YL, Wee HL, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, **Chan A**. Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. *Pharmacogenomics Journal* 2016;16(1):47-53
- 108 Chan A, Cameron MC, Garden B, Boers-Doets CB, Schindler K, Epstein JB, Choi J, Beamer L, Roeland E, Russi EG, Bensadoun RJ, Teo YL, Chan RJ, Shih V, Bryce J, Raber-Durlacher J, Gerber PA, Freytes CO, Rapoport B, LeBoeuf N, Sibaud V, Lacouture ME. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therpaies. *Support Care Cancer* 2015; DOI: 10.1007/s00520-014-2564-x.
- 107 Goldspiel B, Sewell G, Chan A. Happy 20th Birthday to JOPP. *J Onc Pharm Pract* 2015; 21(2): 83-84.

- 106 Chan RJ, McCarthy AL, Devenish J, Sullivan KA, **Chan A**. Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. *European Journal of Cancer* 2015; 51(4):437-450
- 105 Wang XJ, Lopez SE, **Chan A**. Economic Burden of Chemotherapy-Induced Febrile Neutropenia in Patients with Lymphoma: A Systematic Review. *Crit Rev Heme Onc* 2015;94(2):201-12.
- 104 Teo YL, Wee HL, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, **Chan A**. Association of drug exposure with toxicity and clinical response in metastatic renal-cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. *Target Oncol* 2015;10(3):429-37
- 103 **Chan A**, Lim E, Ng T, Shih V, Quek R, Cheung YT. Symptom burden and Medication use in Adult Sarcoma Patients. *Support Care Cancer* 2014;23(6):1709-17.
- 102 Tan HS, Li H, Hong YW, Toh CK, Wong A, Lopes G, Tay MH, Chan A, Yao X, Tang T, Ng QS, Kanesvaran R, Chau NM, Tan MH. Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results from a Prospective Registry in Singapore. *Clin Gen Cancer* 2014; DOI:10.1016/j.clgc.2014.11.004.
- 101 Teo YL, Ho HK, **Chan A**. Formation of reactive metabolites and management of tyrosine kinase inhibitor induced hepatotoxicity: a literature review. *Expert Opin Drug Metab Toxicol* 2014; 15: 1-12.
- 100 Ng T, Khor CC, Ho HK, **Chan A**. The Genetic Variants Underlying Breast Cancer Treatment-Induced Chronic and Late Toxicities: A Systematic Review. *Cancer Treatment Reviews* 2014; 40(10):1199-1214.
- 99 Wang XJ, Wong M, Hsu LY, **Chan A**. Cost associated with febrile neutropenia in solid tumor and lymphoma patients – an observational study in Singapore. *BMC Health Services Research* 2014; 14: 434.
- 98 Teo YL, Ho HK, **Chan A**. Metabolism-related pharmacokinetic drug-drug interactions in tyrosine kinase inhibitors: current understanding, challenges and recommendations. *Br J Clin Pharmacol* 2015;79(2):241-5
- 97 Keefe DM, Chan A, Kim HK, Hsieh RK, Yu S, Wang Y, Nicholls RJ, Burke TA. Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study. *Support Care Cancer* 2014;23(1):253-61.
- 96 Kim HK, Hsieh RK, Chan A, Yu S, Han B, Gao Y, Baños A, Ying X, Burke T, Keefe D. Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. *Support Care Cancer* 2014;23(1):293-300.
- 95 Hsieh RK, Chan A, Kim HK, Yu S, Kim JG, Lee MA, Dalén J, Jung H, Liu YP, Burke T, Keefe D. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. *Support Care Cancer* 2014;23(1):263-72
- 94 Yu S, Burke T, Chan A, Kim HK, Hsieh RK, Hu X, Liang JT, Baños A, Spiteri C, Keefe D. Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy—a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. *Support Care Cancer* 2014; 23(1):273-82.

- 93 Chan A, Kim HK, Hsieh RK, Yu S, Lopez G, Su WC, Baños A, Bhatia S, Burke T, Keefe D. Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice - a longitudinal analysis. *Support Care Cancer* 2014; 23(1):283-91.
- 92 Pachman DR, Watson JC, Lustberg MB, Wagner-Johnston ND, Chan A, Broadfield L, Cheung YT, Steer C, Storey DJ, Chandwani KD, Paice J, Jean-Pierre P, Oh J, Kamath J, Fallon M, Strik H, Koeppen S, Loprinzi CL. Management options for established chemotherapy-induced peripheral neuropathy. *Support Care Cancer* 2014; 22(8):2281-95.
- 91 **Chan A**, Shwe M, Gan YX, Yap K, Chew L, Lim WT. Trajectory and Risk Factors for Chemotherapy-induced Nausea and Vomiting in Asian Head and Neck Cancer Patients. *Head Neck* 2014; DOI 10.1002/hed.23753
- 90 Teo YL, Chue XP, Chau NM, Tan MH, Wee HL, Ho HK, Kanesvaran R, **Chan A**. Toxicities and patient reported outcomes in elderly Asian patients receiving an attenuated dosing of sunitinib for metastatic renal cell carcinoma. *J Geriatr Oncol* 2014; 5 S1:S19
- 89 Yap K, Chia Y, Low XH, **Chan A**. Technological preferences of aging cancer patients for delivery services and devices to solve drug-related problems in oncology. *Support Care Cancer* 2014; 22(10):2733-40.
- 88 Chan A, Lees J, Keefe D. The Changing Paradigm for Supportive Care in Cancer Patients. *Support Care Cancer* 2014;22(6):1441-5.
- 87 Ko Y, Gwee YS, Huang YC, Chiang J, Chan A. Costs and Length of Stay of Drug-Related Hospital Admissions in Cancer Patients. *Clin Ther* 2014; 36(4): 588-92.
- 86 See M, Shih V, Ho HK, Tang T, Farid M, Quek R, Tao M, Lim ST, **Chan A**. A Pilot Study to Evaluate the Role of Therapeutic Drug Monitoring of Pegfilgrastim in Lymphoma Patients Receiving Chemotherapy. *Proceedings of Singapore Healthcare* 2014; 23(1): 13-20.
- 85 **Chan A**, Soh D, Ko Y, Huang YC, Chiang J. Characteristics of Unplanned Hospital Admissions due to Drug Related Problems in Cancer Patients. *Support Care Care* 2014; 22(7): 1875-81.
- 84 Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS, Preetha M, Ooi WS, Chay WY, Dent R, Ang SF, Lo SK, Yap YS, Ng R, **Chan A**. Evaluated Minimal Clinically Important Difference in Perceived Cognitive Disturbances among Patients with Breast Cancer. *J Clin Epidemiology* 2014; 67(7):811-20.
- 83 **Chan A**, Wong QX, Karah Ali M, Wong M, Hsu LY. Clinical Efficacy of Adjunctive G-CSF on Solid Tumor and Lymphoma Patients with Established Febrile Neutropenia. *Support Care Cancer* 2014; 22(4):1105–1112.
- 82 Teo YL, Chong XJ, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, **Chan A**. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo and outcomes investigation. *Cancer Clin Pharmacology* 2014; 73(2): 381-8.
- 81 Cheung YT, Lim SR, Ho HK, **Chan A**. Cytokines as Mediators of Chemotherapy-associated Cognitive Changes: Current Evidence, Limitations and Directions for Future Research. *PLOS ONE* 8(12): e81234. doi:10.1371/journal.pone.0081234
- 80 Engle JP, Erstad BL, Anderson DC, Bucklin MH, Chan A, Donaldson AR, Hagemann TM, O'Connor MB, Rodgers PT, Tennant S, Thomas Z. Minimum Qualifications for Clinical Pharmacy Practice Faculty. *Pharmacotherapy* 2014;34(5):e38–e44.

- 79 Poon KSH, Un MK, Low XH, Cheung YT, Yap KYL, **Chan A**. Impact of cancer-related fatigue on chemotherapy-induced nausea and vomiting in Asian cancer patients. *Pharmacoepidemiol Drug Saf* 2013;22(12):1345-51.
- 78 **Chan A**, Chiang YY, Low XH, Yap K, Ng R. Affordability of Cancer Treatment For Aging Cancer Patients in Singapore: An Analysis of Health, Lifestyle, and Financial Burden. *Support Care Cancer* 2013;21(12):3509-17.
- 77 Ng T, Cheung YT, Ng QS, Ho HK, **Chan A**. Vascular endothelial growth factor inhibitors and cognitive impairment: evidence and controversies. *Expert Opin Drug Saf* 2014; 13(1): 83-92.
- 76 Cheung YT, Lim SR, Chui WK, Tan YP, **Chan A**. Psychometric properties and measurement equivalence of the English and Chinese versions of the functional assessment of cancer therapy-cognitive in Asian breast cancer patients. *Value in Health* 2013;16(6):1001-13.
- 75 Wong RK, Bensadoun RJ, Boers-Doets CB, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Lacouture ME. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. *Support Care Cancer* 2013;21(10):2933-48.
- 74 Lao CK, Ho SC, Chan KK, Tou CF, Tong HHY, Chan A. Potentially inappropriate prescribing and drug-drug interactions among elderly Chinese nursing home residents in Macao. *Int J Clin Pharm* 2013; 35(5):805-12
- 73 Yap KY, Low XH, Koh KS, Un M, Shih V, Chan A. Feasibility and Acceptance of a Pharmacist-Run Tele-oncology Service for Chemotherapy-Induced Nausea and Vomiting in Ambulatory Cancer Patients. *Telemed J E Health* 2013;19(5):387-95.
- 72 **Chan A**, Lee CP, Chiang J, Ng R. Breakthrough Febrile Neutropenia and Associated Complications Among Elderly Cancer Patients Receiving Myelosuppressive Chemotherapy for Solid Tumors and Lymphomas. *Support Care Cancer* 2013; 21(8): 2137-43.
- 71 Cheung YT, Lee H, **Chan A**. Exploring clinical determinants and anxiety symptom domains among Asian breast cancer patients. *Support Care Cancer* 2013; 21(8):2185-94.
- 70 Cheung YT, Shwe M, Tan E, Chui WK, Ng R, **Chan A**. Acknowledging the Relevance of Cognitive Changes in Cancer Patients: Perspectives of Oncology Practitioners in Asia. *J Cancer Surviv.* 2013;7(1):146-54.
- 69 **Chan A**, Ho HK, Cheung YT, Teo YL. Supportive Care in Cancer Patients: Current Challenges and Opportunities. *Adv Pharmacoepidem Drug Safety* 2012; vol 1:e111. doi:10.4172/2167-1052.1000e111.
- 68 Koomanan N, Ko Y, Yong WP, Ng R, Wong YP, Lim SW, Salim A, **Chan A**. Clinical Impact of Drug-Drug Interaction Between Aspirin and Prednisolone at a Cancer Center. *Clin Ther* 2012;34: 2259–2267.
- 67 Cheung YT, Shwe M, Chui WK, Chay WY, Ang SF, Dent RA, Yap YS, Lo SK, Ng R, **Chan A**. Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients. *Ann Pharmacother* 2012; 46(12):1645-55.

- 66 **Chan A**, Tan SH, Low XH, Yap KY. Antiemetic Effectiveness and Nausea and Vomiting Incidence During Capecitabine and Oxaliplatin Chemotherapy. *Nurs Res* 2012; 61(6):405-412.
- 65 Yap KYL, Low XH, Chan A. Exploring Chemotherapy-Induced Toxicities through Multivariate Projection of Risk Factors: Prediction of Nausea and Vomiting. *Toxicol Res* 2012; 28(2): 81-91.
- 64 Cheung YT, **Chan A**. Linguistic validation of Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog): Methodological concerns. *Support Care Cancer* 2012; 21(3):655-6.
- 63 Teo YL, Ho HK, **Chan A**. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. *Cancer Treatment Review* 2013; 39(2):199-206.
- 62 Chen C, Chan A, Yap K. Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy. *J Oncol Pharm Pract* 2013; 19(2):111-20.
- 61 Ko Y, Tan SL, Chan A, Wong YP, Yong WP, Ng RC, Lim SW, Salim A. Prevalence of the Coprescription of Clinically Important Interacting Drug Combinations Involving Oral Anticancer Agents in Singapore: A Retrospective Database Study. *Clin Ther* 2012; 34(8):1696-704.
- 60 Seah J, Lin K, Tai D, Lim ST, **Chan A**. Conservative Management of L-asparaginase-induced Hypertriglyceridemia in an Adult Patient: A Case Report and Review of Literature. *Onkologie* 2012; 35(10):596-8.
- 59 **Chan A**, Shih V, Chiang J, Chew L, Tay K, Quek R, Tao M, Lim ST. Clinical pharmacy services and research for lymphoma patients at a cancer center. *J Onc Pharm Pract* 2013; 19(1): 24-30.
- 58 Shih V, Chan A, Xie F, Yu K. Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore. *Value in Health Regional Issue* 2012; 1: 46-53.
- 57 Shih V, Chan A, Xie F, Yu K. Health State Utility Assessment for Breast cancer. *Value in Health Regional Issue* 2012; 1: 93-97.
- 56 Lopes G, Burke T, Pellissier J, Zhang XH, Dedhiya S, **Chan A**. Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore. *Value in Health Regional Issue* 2012; 1: 66-74.
- 55 Cheung YT, Shwe M, Tan YP, Fan G, Ng R, **Chan A**. Cognitive changes in multiethnic Asian breast cancer patients: a focus group study. *Ann Oncol* 2012; 23(10):2547-52.
- 54 Chan A, Low XH, Yap KYL. Assessment of the Relationship between Adherence with Antiemetic Drug Therapy and Control of Nausea and Vomiting in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy. *J Manag Care Pharm* 2012; 18(5):385-94.
- 53 Cheung YT, Tan EH, **Chan A**. An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. *Support Care Cancer* 2012;20(7):1361-75.
- 52 **Chan A**, Chen C, Chiang J, Tan SH, Ng R. Incidence of Febrile Neutropenia among Early Stage Breast Cancer Patients Receiving Anthracycline-based Chemotherapy. *Support Care Cancer* 2012; 20(7): 1525-32.

- 51 Teo YL, Saetaew M, Chanthawong S, Yap YS, Chan EC, Ho HK, **Chan A**. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. *Breast Cancer Res Treat* 2012; 133(2): 703-11.
- 50 Yap K, Leong C, Chan A. Controlling Chemotherapy-Induced Nausea and Vomiting with Neurokinin-1 Receptor Antagonists in Patients on AC-Based Chemotherapy—Are We There Yet? *Journal of Cancer Therapy* 2012; 3(1): 90-102.
- 49 **Chan A**, Tang T, Ng T, Shih V, Tay K, Quek R, Tao M, Lim ST. To SMILE or not: Supportive Care Matters. *J Clin Oncol* 2012; 30 (9): 1015-6.
- 48 **Chan A**, Ng T, Yap KYL. Clinically-relevant anticancer-antidepressant drug interactions. *Expert Opin Drug Metab Toxicol* 2011; 18(2): 165-74.
- 47 Chiang J, **Chan A**, Lian T, Tay K, Quek R, Tao M, Lim ST. Management of Tumor Lysis Syndrome with a Single Fixed Dose of Rasburicase in Asian Lymphoma Patients: A Case Series and Review of Literature. *Asia Pac J Clin Oncol* 2011; 7: 351–356.
- 46 Yap YK, Low XH, Chui WK, **Chan A**. Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting. *J Clin Psychopharmacol* 2012;32(2):207-217.
- 45 **Chan A**, Lin TH, Shih V, Ching TH, Chiang J. Clinical Outcomes Among Singaporean Cancer Patients Receiving Chemotherapy With Complementary and Alternative Medicine: A Cohort Study. *Altern Ther Health Med* 2012;18(1):12-7.
- 44 Yap KYL, See CS, Kuo EY, Chui WK, **Chan A**. Utilizing mobile networks for the detection of clinically-relevant interactions between chemotherapy regimens and complementary and alternative medicines. *J Altern Complement Med* 2011; 18(2):165-74.
- 43 Cheung YT, Chui WK, **Chan A**. Neuro-cognitive impairment in breast cancer patients: Pharmacological considerations. *Crit Rev Oncol Hematol* 2012; 83(1):99-111.
- 42 Yap KY, Chui WK, **Chan A**. Development of a chemotherapy regimen interaction database for the mobile internet: detecting interactions with psychotropics through OncoRx-MI. *Inform Health Soc Care* 2011;36(3):132-46.
- 41 Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. *Support Care Cancer* 2011;19(8):1079-95.
- 40 **Chan A**, Yap KYL, Koh D, Low XH, Cheung YT. Electronic Database to Predict Drug-Drug Interactions Between Antidepressants and Oral Anticancer Drugs from a Cancer Centre in Singapore: Implications to Clinicians. *Pharmacoepidemiol Drug Saf* 2011; 20(9):939-47
- 39 Lee J, Chan A. Polypharmacy in the elderly cancer patient: clinical implications and management. *Lancet Oncology* 2011;12(13):1249-5
- 38 **Chan A**, Chiang J, Lew KY, Chay WY. Preventing Oxaliplatin-Induced Sensory Neurotoxicity: A Methodology Perspective. *J Clin Oncol* 2011; 29(16):e48.
- 37 Ng TRD, **Chan A**. Dosing recommendations of targeted cancer therapies in patients with special needs: Evidence and Controversies. *Crit Rev Oncol Hematol* 2012; 81: 58-74.

- 36 **Chan A**, Leng XZ, Chiang JYL, Tao M, Quek R, Tay K, Lim ST. A comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients. *Asia Pac J Clin Oncol* 2011;7(1):75-81.
- 35 Ng JH, Ang XY, Tan SH, Tao M, Lim ST, **Chan A**. Breakthrough febrile neutropenia and associated complications in Non-Hodgkin's Lymphoma patients receiving pegfilgrastim. *Acta Haem* 2011;125:107-114.
- 34 **Chan A**, Tan EH. How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? *Support Care Cancer* 2011;19(10):1667-74.
- 33 Chan QR, **Chan A**. Impact of Erythropoiesis-Simulating Agent prescribing at an Asian cancer centre, after release of safety advisories. *J Onc Pharm Pract* 2010; 17(4): 350-9.
- 32 Cheung YT, Yap KYL, Chui WK, **Chan A**. Drug-Drug Interactions between Oral Antiepileptics and Oral Anticancer Drugs: Implications to Clinicians. *European Neurology* 2010; 64:88-94.
- 31 Yap KYL, Yak XR, Shih V, Chui WK, **Chan A**. Application of unsupervised learning in clinical oncology practice – exploring anxiety characteristics in chemotherapy-induced nausea and vomiting through principal variables. *Journal of Computing* 2010; 2(7): 163-171.
- 30 Yap KY, Ho YX, Chui WK, **Chan A**. Harnessing the internet cloud for managing drug interactions with chemotherapy regimens in patients with cancer suffering from depression. *Acta Oncol* 2010. DOI: 10.3109/02841861003801130.
- 29 Chiang J, **Chan A**, Shih V, Hee SW, Tao M, Lim ST. A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center. *Int J Hematol* 2010; 91(5):826-30
- 28 **Chan A**, Fu WH, Shih V, Chua JC, Tan SH, Ng R. Impact of colony stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. *Support Care Cancer* 2011; 19:497–504.
- 27 Yap KYL, Raaj S, **Chan A**. OncoRx-IQ: A tool for quality assessment of online anticancer drug interactions. *Int J Qual Health Care* 2010; 22:93-106.
- 26 Yap KYL, See CS, **Chan A**. Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer. *Recent Patents on Food, Nutrition and Agriculture* 2010; 2(1):12-55.
- 25 Yap KYL, **Chan A**, Chui WK. Opinions on drug interaction sources in anticancer treatments and parameters for an oncology specific database by pharmacy practitioners in Asia. *Health Services Insights* 2010;3: 1-12.
- 24 Yap KYL, **Chan A**, Chui WK, Chen YZ. Cancer informatics for the clinician: An interaction database for chemotherapy regimens and antiepileptic drugs. *Seizure* 2010;19: 59-67.
- 23 **Chan A**, Yap KYL. Detection and management of oncology drug interactions: Can we do better? *Maturitas* 2010; 65(3):181-2.
- 22 **Chan A**, Tan SH, Wong CM, Yap KY, Yu K. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. *Clin Ther* 2009; 31: 2979-86.

- 21 Yap KYL, Kuo EY, Lee JJ, Chui WK, **Chan A**. An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project. *Support Care Cancer* 2010;18(7):883-91.
- 20 Lam CK, Chiang J, Shih V, **Chan A**. The prevalence of complementary and alternative medicine (CAM) usage in Singaporean Breast Cancer patients. *Asia Pacific Journal of Oncology and Hematology* 2009; 1(3): 1-6.
- 19 Tan EH, **Chan A**. Evidence based treatment options for the management of skin toxicities associated with EGFR inhibitors. *Ann Pharmacother* 2009; 43:1658-66.
- 18 Yap KYL, **Chan A**, Chui WK. Improving pharmaceutical care in oncology through pharmacoinformatics: the evolving role of informatics and the internet for drug therapy. *Lancet Oncology* 2009; 10:1011-19.
- 17 Yap KYL, Chui WK, Tan WL, **Chan A**. Clinically relevant drug interactions between anticancer drugs and psychotropic agents. *Eur J Cancer Care* 2011;20(1):6-32
- 16 Lai GG, Lim ST, Tao M, Chan A, Li H, Quek R. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. *Am J Hematol* 2009; 84(7):414-7.
- 15 Yap KYL, Chen YZ, Chui WK, **Chan A**. Oncoinformatics for the healthcare professional: oncology databases and blogs. *Internet Journal of Oncology* 2009;6(1):1-22. Available at:
http://www.ispub.com/journal/the_internet_journal_of_oncology/volume_6_number_1_36/article/oncoinformatics_for_the_healthcare_professional_oncology_databases_and_blogs.html.
- 14 **Chan A**, Lim LL, Tao M. Utilisation Review of epoetin alfa in cancer patients at a cancer centre in Singapore. *Singapore Med J* 2009; 50(4): 365-70.
- 13 Lee JYC, Tan F, **Chan A**. Evaluation of thiazolidinediones on cardiovascular outcomes in patients with type 2 diabetes mellitus: A systematic review. *The Journal of Nursing Practitioner* 2009; 5(3): 176-184.
- 12 Shih V, Hee SW, **Chan A**. Clinical Predictors of Chemotherapy Induced Nausea and Vomiting (CINV) in Breast Cancer Patients Receiving Adjuvant Doxorubicin and Cyclophosphamide (AC) Chemotherapy. *Ann Pharmacother* 2009; 43:444-452.
- 11 **Chan A**, Leow YC, Sim MH. Patients' Perspectives and Safe Handling of Oral Anti-Cancer Drugs at an Asian Cancer Centre. *J Oncol Pharm Pract* 2009; 15:161-165.
- 10 Shih V, Chiang JYL, **Chan A**. Complementary and alternative medicine (CAM) usage in Singaporean adult cancer patients. *Ann Oncol* 2009; 20: 752-757.
- 9 Wong CM, Ko Y, **Chan A**. Clinically Significant Drug-Drug Interactions between Oral Anticancer Agents and Non-Anticancer Agents: Drug-Drug Interaction Profiling and Comparison of Two Drug Compendia. *Ann Pharmacother* 2008; 42:1737-1748.
- 8 Yap KYL, Chui WK, **Chan A**. Drug interactions between chemotherapy regimens and antiepileptics. *Clin Ther* 2008; 8: 1387-407.
- 7 **Chan A**, Shih V, Chew L. Evolving roles of oncology pharmacists in Singapore: A survey on prescribing patterns of antiemetics for Chemotherapy Induced Nausea and Vomiting (CINV) at a Cancer Centre. *J Oncol Pharm Pract* 2008; 14: 23-29.

- 6 **Chan A**, Shih V, Tham CK. Liposomal doxorubicin associated acute hypersensitivity despite appropriate preventive measures. *J Oncol Pharm Pract* 2007; 13(2):105-7.
- 5 **Chan A**, Iannucci A, Dager WE. Systemic Anticoagulant Prophylaxis for Central Catheter-Associated Venous Thrombosis in Cancer Patients. *Ann Pharmacother* 2007;41: 635-41.
- 4 Elg C, **Chan A**, Hernandez L. The war on cancer: Now in a convenient tablet form. *California Journal of Health Systems Pharmacists* 2007; 19(2): 5-13.
- 3 **Chan A**, Ignoffo RJ. Survey of Topical Oral Solutions for the treatment of Chemo-Induced Oral Mucositis. *J Oncol Pharm Pract* 2005;11(4):139-43.
- 2 Olin J, Chan A. Experience with nesiritide at a community hospital. *Am J Health-Syst Pharm* 2004; 61: 1337-8.
- 1 Olin J, Chan A, Lazarus E. Pulmonary Edema and Possible Pneumonitis Associated with Celecoxib. *Ann Pharmacother* 2004; 38: 1086.

C. BOOK CHAPTERS AUTHORED (PEER REVIEWED)

10. **Chan A**, Tan CJ, Griffin S. Lymphomas. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. *Pharmacotherapy: A Pathophysiologic Approach*. 12th ed. New York, NY: McGraw-Hill. Chapter 155, 2022.
9. Mayo S, Toh YL, Oh J, **Chan A**. Pharmacological Treatment of Established Chemotherapy-Induced Peripheral Neuropathy. In: *Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Peripheral Neuropathy*. Chapter 7, 2021.
8. **Chan A**, Nguyen L. Supportive Care. In: Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Lee KC, Bookstaver PB. *Pharmacotherapy Principles and Practice*. 6th ed. New York, NY: McGraw-Hill. Chapter 99, 2022.
7. **Chan A**, Tan CJ, Sessions J. Lymphomas. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. *Pharmacotherapy: A Pathophysiologic Approach*. 11th ed. New York, NY: McGraw-Hill. Chapter 149, 2020.
6. **Chan A**. Breast Cancer. In: *Pharmacotherapy Self-Assessment Program (PSAP): Hematology/Immunology/Oncology Book 2*; American College of Clinical Pharmacy; 132-152, 2018.
5. **Chan A**, Lee JYC. Cancer Survivorship. In: *Ambulatory Care Self-Assessment Program (ACSAP) Book 1*; American College of Clinical Pharmacy; 109-137, 2017.
4. **Chan A**, Sessions J. Lymphomas. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. *Pharmacotherapy: A Pathophysiologic Approach*. 10th ed. New York, NY: McGraw-Hill; Chapter 132; 2181-208; 2016.
3. **Chan A**, Yee GC. Lymphomas. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. *Pharmacotherapy: A Pathophysiologic Approach*. 9th ed. New York, NY: McGraw-Hill; Chapter 109; 2009-36, 2014.
2. **Chan A**, Yee GC. Lymphomas. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. *Pharmacotherapy: A Pathophysiologic Approach*. 8th ed. New York, NY: McGraw-Hill; Chapter 140; 2333-59, 2011.

1. Iannucci A, **Chan A**. Management and Treatment of Hematologic Toxicities. In: Oncology Nursing-Pharmacy Handbook. Ignoffo RJ, Viele C, Ngo Z, eds. 1st ed. Elsevier-Mosby, 2007.

D. WEB PUBLICATIONS

1. Chan, Alexandre. Antimicrobial Agents in Neutropenic Cancer Patients. Medscape Drugs & Diseases. Updated June 2, 2022. Available at: <http://emedicine.medscape.com/article/2500036-overview>
2. Chan, Alexandre. Chemotherapy-induced Peripheral Neuropathy Guidelines. Medscape Drugs & Diseases. Updated June 2, 2022. Available at: <http://emedicine.medscape.com/article/2500023-overview>.
3. American College of Clinical Pharmacy (ACCP) Member Spotlight - The Member Spotlight serves to highlight and provide visibility to important ACCP members with regards to their career path, contributions, and experience with ACCP. Available at: <http://www.accp.com/report/index.aspx?iss=0715&art=13>

E. LIMITED CIRCULATIONS

1. **Chan A**, Lee JYC. Incorporating Physical Assessment Into Undergraduate Pharmacy Education. *CDTLink* January/February 2010. Vol. 14(1).
2. **Guest writer** for Tomorrow Newsletters – publication at National Cancer Centre
 - i. Managing Chemotherapy Side Effects from Treatment of Lymphoma (2008)
 - ii. The Pharmacist's Role in Clinical Trials (2008)
 - iii. Brown Bag @ NCC in 2007 (2007)
3. **Chan A**. Complementary and Alternative Medicine (CAM) Usage in Singaporean Adult Cancer Patients. Faculty of Science Research Newsletter. December 2008. Page 1-3.
4. Understanding Pediatric Pain. *Limited Circulation*: Jersey Shore University Medical Center, January 2004.
5. **Chan A**. Foot Care for People With Diabetes. Published in *American's Pharmacist (The Bottom Line)*, published by the National Community Pharmacists Association (NCPA), November 2003.
6. Antibiotic Susceptibility Report 2002. *Limited Circulation*: JFK Medical Center Infection Control Department, June 2003.

F. ABSTRACTS OF INTERNATIONAL CONFERENCE PRESENTATIONS (SELECTED)

International

- 116 **Chan A**, Usmani M, Krattli R, Khatib S, Le A, Smith S, Baulch J, Ng DQ, Acharya M. Brain-derived neurotrophic factor augmentation with riluzole reverses doxorubicin-induced cognitive impairment. Accepted as a poster presentation at the 2022 Global Conference on Clinical Pharmacy.
- 115 Agapito I, Ng DQ, **Chan A**, Milam J, Anton-Culver, Ziogas A. Prevalence of Neuropsychiatric Conditions in Long-Term Adolescent and Young Adults Cancer Survivors: An All-of-Us Study. Accepted as a poster presentation at the 2022 Global Conference on Clinical Pharmacy.

- 114 Ozaki A, Cadiz CL, Hurley-Kim K, Wisseh C, Knox ED, Lee J, Patel S, Wang A, Mey S, Cordone C, Sung J, **Chan A**. Global pharmacist interventions for medication adherence in rural settings: a systematic review. Accepted as a poster presentation at the 2022 Global Conference on Clinical Pharmacy.
- 113 Ke Y, Fok RWY, Chung WL, Low A, Chong A, Tan NC, **Chan A**. Engaging community pharmacists in a breast cancer survivorship shared care model in Singapore: a mixed-method report. Accepted as a poster presentation at the 2022 Global Conference on Clinical Pharmacy.
- 112 Ng DQ, Tan CJ, Wang C, Cheng I, Toh YL, Koh YQ, Ke Y, **Chan A**. Brain-derived neurotrophic factor and self-perceived cognitive function in adolescent and young adult cancer and non-cancer populations. Accepted as a poster presentation at the 2022 Global Conference on Clinical Pharmacy.
- 111 Chan D, Agrawal P, Ng DQ, **Chan A**. Association of brain-derived neurotrophic factors with cancer-related cognitive impairment: a systematic review of human studies. Accepted as an oral proffered paper at the 2022 MASCC/ISOO Annual Meeting.
- 110 **Chan A**, Ng DQ, Nasr R, Hsu S, Ports K, Milam J, Torno L. Priorities, Barriers, and Facilitators for Conducting Adolescent and Young Adults (AYA) Cancer Survivorship Research in Southern California. Accepted as a poster presentation at the 2022 MASCC/ISOO Annual Meeting.
- 109 Elsayed A, Ng DQ, Ruddy KJ, Loprinzi C, Lustberg M, **Chan A**. A Global Survey of the Utilization of Cryotherapy and Compression Therapy For the Prevention of Chemotherapy-Induced Peripheral Neuropathy. Accepted as a poster presentation at the 2022 MASCC/ISOO Annual Meeting.
- 108 Ke Y, Cheng I, Tan SHG, Fok RWY, **Chan A**. Developing and pilot testing a decision aid for breast cancer survivors considering follow-up care model. Accepted as a poster presentation at the 2022 MASCC/ISOO Annual Meeting.
- 107 Ke Y, Neo PSH, Yang GM, Ho S, Tan YP, Ramalingam MB, Loh KWJ, Quah DSC, Chew L, Mok NKM, Si PEH, Tan YY, Tay BC, Chan RJ, **Chan A**. Effectiveness of a multidisciplinary cancer survivorship care model in Singapore: 6-months results from a cluster randomized controlled trial. Accepted as an oral presentation at the 2022 MASCC/ISOO Annual Meeting.
- 106 Ng DQ, Milam J, Ritt-Olson A, Miller KA, Thomas SM, **Chan A**. Associations between depression, cognitive toxicity and substance use in childhood cancer survivors: a mediation analysis. Accepted as an oral proffered paper for MASCC/ISOO 2022 Annual Meeting in Toronto, Canada.
- 105 Ke Y, Lim SY, Neo PSH, Yang GM, Tan YY, **Chan A**. Symptom profiles of breast and gynaecological cancer patients reporting high and low distress. Accepted as a poster presentation at the 17th World Congress Of The European Association For Palliative Care 2021.
- 104 Ke Y, Tan TXE, Chan R, **Chan A**. Range, effectiveness, and implementation of decision aids supporting cancer survivors' decisions over health services participation in the post-treatment phase: A systematic review. *Journal of Clinical Oncology*. 2021;39(28_suppl):203-. Accepted as a poster presentation at the 2021 ASCO Quality Care Symposium.
- 103 Ke Y, Neo PSH, Yang GM, Ho S, Tan YP, Ramalingam MB, et al. Baseline characteristics of breast and gynecological cancer patients enrolled in the trial of a multidisciplinary survivorship care model in an Asian national ambulatory cancer center. *Journal of Clinical Oncology*. 2021;39(28_suppl):37-. Accepted as a poster presentation at the 2021 ASCO Quality Care Symposium.
- 102 Ng DQ, Milam J, Ritt-Olson A, Miller KA, Thomas SM, **Chan A**. Adverse lifestyle behaviors among childhood cancer survivors with cognitive impairment: The Project Forward Cohort. Accepted as poster presentation for 2021 ASCO Quality Care Symposium (virtual).
- 101 Goyal J, Ng DQ, Maddhuri J, Kumar AS, Jia S, He L, Wisseh C, Nguyen M, Lee J, McBane S, Zheng K, Hurley-Kim K, Nguyen L, **Chan A**, Cadiz CL. Predicting adverse drug events using the All

- of Us cohort data: A feasibility study. Accepted as poster presentation for 2021 American College of Clinical Pharmacy Annual Meeting (virtual).
- 100 Ng DQ, Jia S, Cadiz CL, Wisseh C, Nguyen MH, Lee J, McBane S, Nguyen L, **Chan A**, Hurley-Kim K. An analysis of the National Institutes of Health All of Us research database: sociodemographic disparities among patients who received vaccinations. Accepted as poster presentation for IDWeek 2021 (virtual).
- 99 Ng DQ, Tan CJ, Soh BC, Tan MML, Loh SY, Tan YE, Ong HH, Teng PPC, Chan JJ, Chay WY, Lee J, Lai G, Beh SY, Tan TJY, Yap YS, Lee GE, Wong M, Dent R, Lo YL, **Chan A**, Loh KW Preventing Chemotherapy-Induced Peripheral Neuropathy using Cryotherapy in Breast Cancer Patients receiving Paclitaxel: A Randomized, Controlled Trial. Accepted as poster presentation for 2020 American College of Clinical Pharmacy Annual Meeting (virtual).
- 98 Tan CJ, Ng KYJ, Goh WL, Poon E, Chew L, Farid M, **Chan A** (2020) Cost burden and work outcomes among Singaporean adolescent and young adult cancer survivors. [Abstract], ISPOR 2020 (Virtual).
- 97 Toh YL, Lau AJ, Chew L and **Chan A** (2020) Discriminative capacity of plasma estradiol levels for predicting self-perceived cognitive impairment in early-stage breast cancer patients (Poster presentation) Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting, Seville, Spain.
- 96 Koh YQ, Ng CC, Tan CJ, Toh YL, Sze SK, Ho HK and **Chan A** (2020) Comparison of circulating exosome profiles of breast cancer survivors with and without cognitive impairment (Abstract) MASCC Annual Meeting.
- 95 Loo WS, Mah JJJ, Toh YL, Tan CJ, Ng YH, Nuraishah Z, Tan YY, Lo TH, Goh WL, Farid M, Poon E and **Chan A** (2020) Characterization of health-related quality of life in recently diagnosed adolescent and young adult cancer patients (Abstract) MASCC Annual Meeting.
- 94 Loo WS, Mah JJJ, Toh YL, Tan CJ, Ng YH, Nuraishah Z, Tan YY, Lo TH, Goh WL, Farid M, Poon E and **Chan A** (2020) Impact of a multi-disciplinary psychosocial info-educational intervention programme on adolescent and young adult cancer patients (Abstract) MASCC Annual Meeting.
- 93 Yap NY, Tan NYT, Tan CJ, Loh KWJ, Ho HK, **Chan A** (2020) Evaluation of brain-derived neurotrophic factor (BDNF) in survivors of breast cancer with long-term cancer-related cognitive impairment. [Abstract], MASCC Annual Meeting.
- 92 Rapoport BL, **Chan A**, Tan CJ, Chasen M, Bhargava R, Bosnjak S, Zilic A, Smit T, Jabber A, Zhang Y, Heymans L, de Necker M, Mhazo T (2020) Evaluation of the emetogenicity of carboplatin-based chemotherapy: A MASCC Antiemetics Study Group prospective, observational, real world study. [Abstract], MASCC Annual Meeting 2020.
- 91 Boers-Doets C, Tan CJ, **Chan A**, Epstein J (2020) Patients on EGFRi who used dexpanthenol cream experienced less dry skin & burning sensation than patients who used cetomacrogol. [Abstract], MASCC Annual Meeting.
- 90 Toh YL, Shwe M and Chan A (2019) Evaluating mitochondrial biomarkers between fatigue subclasses identified using latent class analysis in early-stage breast cancer patients (Poster presentation) ESMO Asia, Singapore (<https://doi.org/10.1093/annonc/mdz434.019>)
- 89 Yap NY, Ho HK, Zheng HF, Tan CJ, Toh YL, Ng C and **Chan A** (2019) An in vitro evaluation of CYP2D6 enzymatic inhibition activities of a Chinese herbal medicine formulation (Xiang Bei Yang Rong Tang) for the management of cancer-related fatigue (Abstract). ESMO Asia, Singapore.
- 88 Toh YL, Shwe M, Lau AJ and **Chan A** (2019) Association of plasma dehydroepiandrosterone, its sulfated form [DHEA(S)] and chemotherapy-associated cognitive impairment in early-stage breast cancer patients: a prospective longitudinal study (Abstract) American College of Clinical Pharmacy (ACCP) Global Conference, New York, USA.
- 87 Toh YL, Shariq Mujtaba J, Bansal S, Yeo A, Shwe M, Lau AJ and **Chan A** (2019) Impact of chemotherapy regimen type on plasma DHEA(S) and cognitive function in early-stage breast cancer patients (Encore Poster Presentation) American association of Pharmaceutical Scientists (AAPS-NUS-UNM 14th Pharmacy and Biomedical Symposium, Kuala Lumpur, Malaysia.

- 86 Toh YL, Shariq Mujtaba J, Bansal S, Yeo A, Shwe M, Lau AJ and **Chan A** (2019) Impact of chemotherapy regimen type on plasma DHEA(S) and cognitive function in early-stage breast cancer patients (Poster presentation) XVIII International Symposium on Oncology Pharmacy Practice, London, United Kingdom.
- 85 Toh YL, Shariq Mujtaba J, Bansal S, Yeo A, Shwe M, Lau AJ and **Chan A** (2019) Pre-chemotherapy plasma dehydroepiandrosterone levels and its sulfated form-DHEA(S) as predictor for cancer-related cognitive impairment in breast cancer patients receiving chemotherapy (E-poster presentation) MASCC Annual Meeting, San Francisco, USA.
- 84 Tan CJ, Tan LC, Loh KWJ, Neo PSH, Finkelstein E, **Chan A** (2019) Work-related outcomes among cancer survivors in Singapore. [Abstract], ESMO Asia 2019, Singapore.
- 83 Tan CJ, Mah JJJ, Goh WL, Poon E, Harunal Rashid MF, **Chan A** (2019) Antineoplastic treatment and cognitive impairment among adolescent and young adult cancer patients. [Abstract] (Encore), UNM-Biomed/AAPS-NUS PharmSci@Asia Symposium 2019, Kuala Lumpur, Malaysia.
- 82 Tan CJ, Mah JJJ, Goh WL, Poon E, Harunal Rashid MF, **Chan A** (2019) Antineoplastic treatment and cognitive impairment among adolescent and young adult cancer patients. [Abstract] (Platform presentation), XVIII International Symposium on Oncology Pharmacy Practice, London, United Kingdom.
- 81 Tan CJ, Ke Y, Ng T, Tan IMJ, Goh WL, Poon E, Harunal Rashid MF, Balasubramanian S, **Chan A** (2019) Employment and financial challenges faced by adolescent and young adult (AYA) cancer survivors: A qualitative study. [Abstract] (Platform presentation), MASCC Annual Meeting, San Francisco, USA.
- 80 Yap NY, Ho HK, Zheng HF, Tan CJ, Toh YL, Ng CC, **Chan A** (2019) An in vitro evaluation of CYP2D6 enzymatic inhibition activities of a Chinese herbal medicine formulation (Xiang Bei Yang Rong Tang) for the management of cancer-related fatigue. [Abstract], ESMO Asia 2019, Singapore
- 79 Ke Y, Yeo RSC, Tan CJ, Yeo A, **Chan A** (2019) Utilization of chronic disease medications in early-stage breast cancer survivors: An observational study. [Abstract], XVIII International Symposium on Oncology Pharmacy Practice, London, United Kingdom.
- 78 Ke Y, Tan CJ, Ng T, Tan IMJ, Goh WL, Poon E, Harunal Rashid MF, Balasubramanian S, **Chan A** (2019) Optimizing survivorship care services for adolescents and young adult cancer survivors: A qualitative study. [Abstract], MASCC Annual Meeting, San Francisco, USA.
- 77 Tan CJ, Toh YL, Yeo HL, Shwe M, Gan YX, Dent R, Ng RCH, Yap YS, Loh KWJ, Lee GE, Beh SY, Tan TJY, Wong M, Khor CC, Ho HK, **Chan A** (2018) Protective effect of brain-derived neurotrophic factor (BDNF) genetic polymorphism (rs6265) against chemotherapy-related cognitive decline in early-stage breast cancer patients: A validation study. [Abstract] (Platform presentation), MASCC Annual Meeting, Vienna, Austria.
- 76 Tan CJ, Tio JX, Ng T, Loh KWJ, **Chan A** (2018) Indirect cost of cancer burden among breast cancer survivors after treatment completion in Singapore. [Abstract] (Platform presentation), XVII International Symposium on Oncology Pharmacy Practice, Shanghai, China.
- 75 **Chan A** and Toh YL (2018). Determination of clinical factors associated with symptom burden in early-stage breast cancer patients: A latent class-analysis (LCA) (Abstract) ACCP Global Conference, Washington, USA.
- 74 Toh YL, Tan CJ, Yeo AHL, Shwe M, Ho HK, Gan YX, Foo KM, Chu P, Olson K and **Chan A** (2018) Leptin as a predictive biomarker for the onset of Cancer-Related Fatigue (CRF): A Prospective Cohort [Poster (Clinical Research Junior) and shortlisted for Oral presentation (Allied Health Category)] 5th SingHealth Duke-NUS Scientific Congress, Singapore.
- 73 Toh YL, Tan CJ, Yeo AHL, Shwe M, Ho HK, Gan YX, Foo KM, Chu P, Olson K and **Chan A** (2018) Leptin as a predictive biomarker for the onset of Cancer-Related Fatigue (CRF): A Prospective Cohort (Oral presentation) MASCC Annual Meeting, Vienna, Austria.

- 72 Tan CJ, Toh YL, Yeo HL, Shwe M, Gan YX, Dent R, Ng RCH, Yap YS, Loh KWJ, Lee GE, Beh SY, Tan TJY, Won M, Khor CC, Ho HK and **Chan A** (2018) Protective effect of brain-derived neurotrophic factor (BDNF) genetic polymorphism (rs6265) against chemotherapy-related cognitive decline in early-stage breast cancer patients: a validation study (Abstract). MASCC Annual Meeting, Vienna, Austria.
- 71 Toh YL, Wong E, Lim N, Yeo A, YX Gan, M Shwe and **Chan A** (2018) Characterizing the Incidence, Trajectory and Severity of Cancer-Related Fatigue (CRF) in Asian Breast Cancer Patients (Plenary presentation) XVII International Symposium on Oncology Pharmacy Practice, Shanghai, China.
- 70 Toh YL, Pang YY, Shwe M, Kanesvaran R, Toh CK, **Chan A** and Ho HK (2016) Determining the effect of albumin concentration on plasma free drug concentration of pazopanib (Poster presentation) 4th SingHealth Duke-NUS Scientific Congress, Singapore.
- 69 **Chan A**, Gan YX, Goh WL, Poon EYL, Fan G, Neo P, Quek R, Farid M. Prevalence and types of distress among adult and young adolescent (AYA) newly diagnosed with cancer in Singapore: Preliminary Findings. Presented at the European Society of Medical Oncology Asia Meeting 2016.
- 68 **Chan A**, Ng, T, Oh SK, Eyob T, Shwe M, Gan YX, Chan R, Dent RA, Ng R, Tan M, Goh B, Tan YP, Fan G. A Culturally Adapted, Multidisciplinary Psychoeducation Program For Early-Stage Breast Cancer Survivors in Asia: A Randomized, Controlled Trial. Presented at the American Society of Clinical Oncology Annual Meeting 2016.
- 67 Ng T, Chia MT, Yeo HL, Shwe M, Gan YX, Loh WJ, Koo SL, Jain A, Lee GE, Dent R, Yap YS, Ng R, Cham MT, Lee JA, Chu PY, Khor CC, Ho HK, **Chan A**. DNA Methyltransferase 1 (DNMT1) Polymorphism and Chemotherapy-Associated Cognitive Impairment in Early-Stage Breast Cancer Patients: A Prospective, Longitudinal Study. Presented at the American Society of Clinical Oncology Annual Meeting 2016.
- 66 Lam YCJ, Ng T, Shwe M, Gan YX, Cheung YT, Fan G, Tan YP, Yong WS, Madhukumar P, Loh WJK, Jain A, Lee GE, Koo SL, Wong M, Dent RA, Yap YS, Ng RCH, Chan A. Trajectory of self-perceived cognitive impairment: A 15-month prospective, longitudinal study in Asian early-stage breast cancer (ESBC) patients. Presented at the European Cancer Congress 2015.
- 65 Chia L, Lim PCE, Lim SL, Goh XN, **Chan A**, Cheong HH, Lin XHL, Lim YKT, Yam KLP, John WKJ, Soh LT, Foo KM. Front-line dose-dense weekly paclitaxel with 3-weekly carboplatin for advanced epithelial ovarian cancer (EOC) - A Single Asian Institution's Experience. Presented at the European Society of Gynaecological Oncology Annual Meeting 2015.
- 64 Ng T, Yeo AHL, Shwe M, Gan YX, Cheung YT, Tan YP, Yong WS, Madhukumar P, Loh KWJ, Koo SL, Jain A, Lee GE, Wong M, Dent RA, Yap YS, Ng RCH, Khor CC, Ho HK, **Chan A**. Estrogen Receptor Alpha (ESR1) Genetic Polymorphisms And The Risk Of Chemotherapy-Associated Cognitive Impairment In Early-Stage Breast Cancer Patients (ESBC). Presented at Multinational Association of Supportive Care in Cancer Annual Meeting 2015.
- 63 Ng T, Teo JSM, Yeo AHL, Shwe M, Gan YX, Cheung YT, Tan YP, Yong WS, Madhukumar P, Loh KWJ, Koo SL, Jain A, Lee GE, Wong M, Dent RA, Yap YS, Ng RCH, Khor CC, Ho HK, **Chan A**. Evaluation of brain-derived neurotrophic factor (BDNF) genetic polymorphism (rs6265) on chemotherapy-associated cognitive impairment in early-stage breast cancer (ESBC) patients. J Clin Oncol 33, 2015 (suppl; abstr 9616)
- 62 Ng T, Yap SY, Shwe M, Gan YX, Cheung YT, Fan G, Yong WS, Madhukumar P, Loh KWJ, Koo SL, Jain A, Lee GE, Wong M, Dent RA, Yap YS, Ng RCH, Ho HK, **Chan A**. Evaluation of pro-inflammatory cytokines and anxiety symptoms in early-stage breast cancer (ESBC) patients: A prospective, longitudinal study. J Clin Oncol 33, 2015 (suppl; abstr e20742)
- 61 Shih V, Kwok LL, **Chan A**, Tan G, Lim SW, Yap YS, Dent R. Pharmacist-led Symptom Management Program of Cancer Patients at an Ambulatory Cancer Centre. Presented at the HOPA 10th Annual Meeting. J Onc Pharm Pract 2015 (suppl)

- 60 Ng T, Tan SY, Cheung YT et al. Reversibility of cognitive impairment among Asian early-stage breast cancer patients receiving chemotherapy: a one year longitudinal study. *Support Care Cancer* 22, 2014 (suppl 1: abstr 0139)
- 59 Ng T, Cheung YT, Shwe M et al. The prevalence, severity and trajectory of fatigue with pro-inflammatory biomarkers in Asian breast cancer patients: A prospective cohort study. *Support Care Cancer* 22, 2014 (suppl 1: abstr 0194)
- 58 Ng T, Toh MR, Cheung YT et al. Follow-up care and survivorship issues faced by breast cancer survivors: perspectives from Asian oncology practitioners. *Support Care Cancer* 22, 2014 (suppl 1: abstr 0140)
- 57 Kanesvaran R, Teo YL, Chue XP, Chau NM, Tan MH, Wee HL, Ho HK, **Chan A**. Association between clinical response and toxicities with drug exposure in an alternative dosing regimen of sunitinib. *J Clin Oncol* 32, 2014 (suppl 4; abstr 439).
- 56 Cheung YT, Shwe M, Kee YC, Chui WK, Tan YP, Yong WS, Preetha M, Ng R, Yap YS, Lo SK, Chay WY, Ang SF, Dent RA, Ooi WS, **Chan A**. Post-Chemotherapy Cognitive Changes in Asian Breast Cancer Patients: A Prospective Cohort Study. *Supportive Care in Cancer*. 2013;21:S209. [Abstract] Accepted as poster presentation at the Multinational Association of Supportive Care in Cancer (MASCC) Meeting 2013, Berlin.
- 55 Cheung YT, Shwe M, Kee YC, Chui WK, Tan YP, Yong WS, Preetha M, Ng R, Yap YS, Lo SK, Chay WY, Ang SF, Dent RA, Ooi WS, **Chan A**. Fatigue and Anxiety-related Dimensions in Early-Stage Breast Cancer Patients: A Prospective Cohort Study. *Supportive Care in Cancer*. 2013;21:S209. [Abstract] Accepted as poster presentation at the Multinational Association of Supportive Care in Cancer (MASCC) Meeting 2013, Berlin.
- 54 Cheung YT, Lim SR, Chui WK, Tan YP, **Chan A**. Validity, Reliability, Responsiveness and Measurement Equivalence of the English and Chinese Versions of the Functional Assessment of Cancer Therapy-Cognitive in Breast Cancer Patients. *Supportive Care in Cancer*. 2013;21:S206. [Abstract] Accepted as poster presentation at the Multinational Association of Supportive Care in Cancer (MASCC) Meeting 2013, Berlin.
- 53 Ng T, Cheung YT, Ng QS, **Chan A**. Vascular endothelial growth factor inhibitors (VEGFIs) and cognitive impairment: evidence and controversies. *Supportive Care in Cancer*. 2013;21:S152. [Abstract] Accepted as poster presentation at the Multinational Association of Supportive Care in Cancer (MASCC) Meeting 2013, Berlin.
- 52 Cheung YT, Shwe M, Kee YC, Ho HK, Chui WK, Fan G, Yong WS, Madhukumar P, Ooi WS, Chay WS, Dent RA, Ang SF, Lo SK, Yap YS, Ng R, **Chan A**. The Association between Pro-inflammatory Biomarkers and Post-chemotherapy cognitive changes in Asian Breast Cancer Patients: A Prospective Cohort Study. [Abstract] ASCO Annual Meeting, USA. *J Clin Oncol* 30, 2012.
- 50 Cheung YT, Shwe M, Chui WK, Dent RA, Yap YS, Lo SK, Ng R, **Chan A**. Effect of chemotherapy and psychosocial distress parameters on perceived cognitive disturbances in Asian breast cancer patients. *J Clin Oncol* 30, 2012 (suppl; abstr 9041). [Abstract] ASCO Annual Meeting, USA.
- 49 Teo YL, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A. Association of drug exposure with clinical response and toxicities in metastatic renal cell carcinoma patients (mRCC) receiving an alternative dosing (AD) regimen of sunitinib. *J Clin Oncol* 31, 2013 (suppl; abstr e13582).
- 48 Tan WM, Tan SY, Ng TM, Pan S, Quek R, Tao M, Tai WM, Koh YL, Tan TT, Tan DCL, Ha TC, **Chan A**, Tay K, Lim ST. AIDS-related lymphoma (ARL) in Asians in the era of HAART and rituximab. *J Clin Oncol* 30, 2012 (suppl; abstr e18546). [Abstract] ASCO Annual Meeting, USA.
- 47 Teo YL, Saetaew M, Chanthawong S, Yap YS, Chan EC, Ho HK, **Chan A**. Liver enzymes elevation due to concurrent dexamethasone and lapatinib: Clinical and in vitro evidence. *J Clin Oncol* 30, 2012 (suppl; abstr e13023). [Abstract] ASCO Annual Meeting, USA.
- 46 Shih V, **Chan A**, Sim MH, Teo C, Chen JJ, Wong ZW. Cardiotoxicity risks of adjuvant trastuzumab in Asian breast cancer patients. *CTCR-AACR San Antonio Breast Cancer Symposium* 2011.
- 45 Ko Yu, Shih V, **Chan A**. Health state utility assessment for breast cancer. *International Society for Pharmacoeconomics and Outcomes Research 14th Annual European Congress* 2011.

- 44 **Chan A**, Ko Y, Kurniawan J. Prevalence of the co-prescription of interacting drug combinations in cancer patients in Singapore. ACCP Annual Meeting 2011.
- 43 **Chan A**, Ong R, Low XH, Shih V, Yap KYL. Impact of adherence to antiemetic regimens on outcome of nausea and vomiting control among Asian breast cancer patients receiving anthracycline-based chemotherapy. [Abstract] ESMO Meeting, Sweden.
- 42 **Chan A**. How am I going to take all these medications? Challenges and Consequences of Medication Overload. *Supportive Care in Cancer* 2011;19:S359 [Abstract] MASCC Meeting, Greece
- 41 Chiang J, Chen C, Tan SH, Ng R, **Chan A**. Incidence of Febrile Neutropenia among Early Stage Breast Cancer Patients Receiving Anthracycline-based Chemotherapy. *Supportive Care in Cancer* 2011;19:S326 [Abstract] MASCC Meeting, Greece.
- 40 Yap KYL, Low XH, **Chan A**. Utilizing a Pharmacoinformatics Tool for the Prediction of Chemotherapy-Induced Nausea and Vomiting in Asian Patients of Emetogenic Chemotherapies. *Supportive Care in Cancer* 2011;19:S110 [Abstract] MASCC Meeting, Greece.
- 39 Yap KYL, Low XH, **Chan A**. Integration of Pharmacoinformatics as Part of Onco-culture: Predicting Chemotherapy-Induced Nausea and Vomiting from Patients' Anxiety Symptoms. *Supportive Care in Cancer* 2011;19:S115 [Abstract] MASCC Meeting, Greece.
- 38 Lopes G, Burke T, Pellissier J, Zhang XH, Dedhiya S, **Chan A**. Cost-Effectiveness of Aprepitant Regimen to Prevent Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC) in Singapore. *Supportive Care in Cancer* 2011;19:S201 [Abstract] MASCC Meeting, Greece.
- 37 Ang R, Chau NM, Chew L, **Chan A**. Unmet Supportive Care Needs Among Asian Castrate Resistant Prostate Cancer (CRPC) Patients. *Supportive Care in Cancer* 2011;19:S203 [Abstract] MASCC Meeting, Greece.
- 36 Cheung YT, Chui WK, **Chan A**. Presence of clinical determinants associated with neuro-cognitive dysfunction in breast cancer survivors. *Supportive Care in Cancer* 2011;19:S127 [Abstract] MASCC Meeting, Greece.
- 35 Cheung YT, Chui WK, **Chan A**. Neuro-cognitive impairment in breast cancer patients: Pharmacological considerations. *Supportive Care in Cancer* 2011;19:S171 [Abstract] MASCC Meeting, Greece.
- 34 Cheung YT, Tan EHJ, Chui WK, **Chan A**. An evaluation on the neuropsychological tests used in the assessment of cognitive changes in breast cancer patients. *Supportive Care in Cancer* 2011;19:S172 [Abstract] MASCC Meeting, Greece
- 33 Yap KY, See CS, **Chan A**, Chui WK. Transcending Chemotherapy Regimen Interactions with Complementary and Alternative Medicines Through 3G Networks: OncoRX-MI For the Mobile Internet. [Abstract] 2010. MASCC Meeting, USA.
- 32 Yap KY, **Chan A**, Low XH, Chui WK. Clinical Predictors of Chemotherapy-Induced Nausea and Vomiting Through Identification of Principal Variables In Patients undergoing AC and XELOX regimens. [Abstract] 2010. MASCC Meeting, USA.
- 31 Yap KY, **Chan A**, Low XH, Chui WK. Identification of Anxiety Symptoms in Patients with Chemotherapy-Induced Nausea and Vomiting undergoing moderately emetogenic chemotherapy. [Abstract] 2010. MASCC Meeting, USA.
- 30 **Chan A**, Tan EH. Correlation between the MESTT and CTCAE scales for the classification of dermatologic adverse events associated with oral anticancer agents. [Abstract] 2010. MASCC Meeting, USA.
- 29 **Chan A**, Shih V, Yap KY, Tan S, Low X. Clinical predictors for emesis in breast cancer patients receiving anthracycline-based chemotherapy: Do Asians measure up? [Abstract] 2010. ASCO Annual Meeting, USA.
- 28 **Chan A**, Shih V. A pilot study to evaluate an algorithm to manage EGFR inhibitors (EGFRI) associated cutaneous toxicities [Abstract] 2009. MASCC Meeting, USA.
- 27 Shih V, **Chan A**, Teo C, Chiang J, Zee W. Cardiotoxicity risks of adjuvant trastuzumab in asian breast cancer patients. [Abstract] 2009. ASCO Annual Meeting, USA.
- 26 Tan TS, Tan IB, **Chan A**, Kaneshwaran R, Lim W, Chan ES, Lim ST. Excision repair cross complementing-1 (ERCC1) and personalized chemotherapy regimens in advanced non-small cell

- lung carcinoma (aNSCLC): A systematic review. **[Abstract]** 2008. ASCO Annual Meeting on Molecular Markers in Cancer, USA.
- 25 Yap YLK, Lee JJJ, Kuo EY, Chen YZ, Chui WK, **Chan A.** (2008, June 26) Drug interactions between anticancer drugs and medicinal herbs used as complementary medicines in cancer chemotherapy. **[Abstract]** 2008. 3rdPharmSci@Asia Symposium, Science & Technology Building, Nanjing University, China.
- 24 **Chan A**, XY Ang, Quek R, Tao M, Lim ST. Once-Per-Cycle Pegfilgrastim is effective to prevent breakthrough febrile neutropenia in Asian Cancer Patients. *Ann Oncol* 2008; 19(8): viii283-viii284.
- 23 Yap YLK, Tan SH, Tan PL, Lee JJJ, Kuo EY, Chen YZ, Chui WK, **Chan A.** (2008, July 1-4) Drug interactions between anticancer drugs and traditional Chinese medicinal herbs used in supportive care management. **[Abstract]**. 8th Asian Conference on Clinical Pharmacy (ACCP), Hyatt Regency Surabaya Hotel, Surabaya, Indonesia.
- 22 Yap KYL, **Chan A**, Chen YZ, Chui WK. (2008, November 7-10) Computer-assisted detection of anticancer-psychotropic drug interactions. Paper presented as poster presentation (HSP052) at the 22nd Federation Asian Pharmaceutical Associations Congress, Grand Copthorne Waterfront Hotel, Singapore.
- 21 DSW Tan, Kanessvaran R, BH Tan, ST Lim, **Chan A.** ERCC1 levels as a predictor of response to platinum based chemotherapy and survival in non-small cell lung cancer patients: A systematic review. **[Abstract]** 2008. Singapore General Hospital Annual Science Meeting, 2008, Singapore.
- 20 Lim CLL, **Chan A**, Tao M. Response to erythropoietin growth factors in cancer patients at National Cancer Centre. Singapore General Hospital Annual Science Meeting, 2008, Singapore.
- 19 Yap YLK, Chan A, Chen YZ, Chui WK. (2007, October 19-21). Reducing drug-related problems in chemotherapy through the use of information technology. Paper presented as poster presentation (PPN-28) at the 19th Singapore Pharmacy Congress 2007, Grand Copthorne Waterfront Hotel, Singapore.
- 18 Tay WL, Yap YLK, **Chan A.** Creation of a drug interaction database between anticancer agents and psychotropics. Singapore General Hospital Annual Science Meeting, 2008, Singapore.
- 17 Wong CM, Ko NY, **Chan A.** Clinically significant drug-drug interactions between oral anticancer agents and non-anticancer agents: Drug-drug interaction profiling and comparison of two drug compendia. [Singapore General Hospital Annual Science Meeting, 2008, Singapore.
- 16 Quek R, Lai GGY, Tao M, **Chan A**, Gao F, Yap SP, Loong S, Tan LHC, Sng I, Lim ST. Late-Onset Neutropenia is Infrequent and Self-limiting in Patients with Diffuse Large B-Cell Lymphoma in Complete Remission following Therapy with Rituximab In Combination with Chemotherapy. European Conference of Clinical Oncology, Barcelona, 2007, Spain.
- 15 Yap YL, **Chan A**, Chui WK, Chan YC. OncoRx-DB: an oncoinformatic drug interaction database for chemotherapeutic regimens. **[Abstract]** 2007. Asian Conference of Clinical Pharmacy, 2007, Shanghai, China.
- 14 **Chan A**, Shih V, Chew L. Prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting at a cancer center in Singapore **[Abstract]** 2007. Asian Conference of Clinical Pharmacy, 2007, Shanghai, China.
- 13 **Chan A**, Shih V, Chew L. Prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting at a cancer center in Singapore **[Abstract]** 2007. Hematology Oncology Pharmacy Association Meeting, 2007. USA.
- 12 **Chan A.** Medication Review at National Cancer Centre. Singapore Pharmacy Congress, 2007, Singapore.
- 11 Yap YL, **Chan A**, Chui WK, Chan YC. Reducing drug-related problems in chemotherapy through the use of information technology. Singapore Pharmacy Congress, 2007, Singapore.
- 10 Lai G, Lim ST, Tao M, **Chan A**, Hee SW, Chua LS, Lim LC, Yap SP, Leong S, Tan L, Sng I, Quek R. Late Onset Neutropenia in Patients with Diffuse Large B Cell Lymphoma following Rituximab in combination with chemotherapy. Singapore General Hospital Annual Science Meeting, 2007, Singapore.
- 9 **Chan A**, Shih V, Chew L. Prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting at a cancer center in Singapore. Singapore General Hospital Annual Science Meeting, 2007, Singapore.

- 8 **Chan A**, Iannucci A, Reed J, Welborne J. Evaluation of Induction Therapy for AML in the adult population at UCDMC. **[Abstract]** 2006. Hematology Oncology Pharmacy Association Meeting, USA.
- 7 **Chan A**, Ignoffo RJ. Survey of Topical Oral Solutions for the treatment of Chemo-Induced Oral Mucositis. UCSF Department of Pharmacy 7th Annual Spring Research Seminar, 2005, USA.
- 6 **Chan A**, Ignoffo RJ. Survey of Topical Oral Solutions for the treatment of Chemo-Induced Oral Mucositis **[Abstract]** 2005. American College of Clinical Pharmacy Annual Meeting, 2005, USA.
- 5 **Chan A**, Olin J. Assessment of Nesiritide Utilization over One Year at a Community Hospital. Presented at New Jersey Health Systems Pharmacist Meeting, 2004, USA.
- 4 **Chan A**, Olin J. Assessment of Nesiritide Utilization over One Year at a Community Hospital. **[Abstract]** American Health Systems Pharmacist Midyear Meeting, 2003, USA.
- 3 **Chan A**, Olin J. "Medication Use Evaluation of Meperidine at a Community Hospital" **[Abstract]** American Health Systems Pharmacist Midyear Meeting, 2003, USA.
- 2 **Chan A**, Olin J. Assessment of Nesiritide Utilization over One Year at a Community Hospital. New Jersey Pharmacist's Association Annual Meeting, 2003, USA.
- 1 **Chan A**, Hanna I. "Metabolism of methoxyflavones by rat and human cytochrome P450s" Schering Plough Research Institute Annual Intern Poster Session, 2002, USA.

G. SELECTED PRESENTATIONS/INVITED LECTURES/WORKSHOPS CHAIRED

"Eliminating Health Disparities by Enhancing Patient Experience" Presented to the audience of the Hong Kong Pharmacy Congress 2025. February 22nd 2025, **Hong Kong**.

"Research Opportunities to Improve Cancer Survivorship". Presented to the audience of the University of Macau. January 6th 2025. **Macau**.

"Ten Things I have learned for Interdisciplinary Research" Presented to the audience of the Japanese Society of Health System Pharmacists Meeting. November 2nd, 2024. **Tokyo, Japan**.

"To CAM and Beyond! Role of Complementary and Alternative Medicine in Improving Medical Outcomes". Presented to the audience of the American College of Clinical Pharmacy Annual Meeting. October 15th 2024. **Phoenix, Arizona**.

"Improving Health Equity by Enhancing Patient's Experience". Presented to the audience of the 150th Anniversary Academic Conference of Centro Hospitalar Conde de Sao Januario Macau. June 15th 2024, **Macau**.

"The Great Debate G-CSF Prophylaxis and FN Risk Stratification: Personalizing Treatment Choices and Optimizing Multidisciplinary Care". Presented to members of MASCC. January 31st, 2024. **Virtual**.

"Neuropsychiatric Complications and Genetic Insights Among Adolescents and Young Adult (AYA) Cancer Survivors". Presented to the audience of the All of Us Seminar series. May 8th 2024, **Virtual**.

"Oncology Pharmacist-Driven Symptom Monitoring System Uncovered Health Disparities in Minoritized Patients Receiving Anticancer Therapies." Presented to the audience of the Hematology/Oncology Pharmacy Association Annual Meeting 2024, April 5th 2024, Tampa, Florida, **United States**.

"The Grand Multidisciplinary Debate: Traditional Medicine is 'Fundamentally' Compatible with Evidence-Based Medicine." Presented to the participants of the Best of MASCC 2023, Singapore, **Singapore**.

"Interdisciplinary and Translational Research in Cancer-related Cognitive Impairment." Presented to the participants of the 1st UCI Neurotherapeutics Symposium, Irvine, **United States**.

“Improving AYAC Survivorship Research: Opportunities, Barriers, and Facilitators.” Presented to the participants of the Duke-NUS Singapore Congress 2023. Singapore, **Singapore**

“MASCC Health Disparities Committee: Findings from Our Members Survey.” Presented to the participants of the MASCC Annual Meeting 2023. Nara, **Japan**.

“The Grand Multidisciplinary Debate: Traditional Medicine is ‘Fundamentally’ Compatible with Evidence-Based Medicine (A Pharmacist’s & trialist’s Perspective).” Presented to the participants of the MASCC Annual Meeting 2023. Nara, **Japan**.

“Relationship Between Pre-Chemotherapy Omega-3 and Appetite Changes in Early-Stage Breast Cancer Patients.” Presented to the participants of the MASCC Annual Meeting 2023. Nara, Japan.

“Clinical Trial Bootcamp: Safety, Data Storage, & Reporting.” June 6th 2023. Presented to the participants of the bootcamp at Chao Family Comprehensive Cancer Center. Orange, USA.

“Interdisciplinary and Translational Research in Cancer-related Cognitive Impairment.” May 15th 2023. Presented to the faculty and students at Macau Polytechnic University. **Macau**.

“Research Workshop (Objectives and Proposal Development).” May 10th 2023. Presented to the allied health professionals and pharmacists at National Cancer Centre Singapore. **Singapore, Singapore**.

“Chemotherapy Principles in Gyn Onc and Chemo-Induced Nausea and Vomiting.” April 28th 2023. Presented to the fellows of the UCI Gyn/Onc Fellows program. **Virtual**.

“Side effects management.” February 13th 2023. Presented to the audience of Bioventures of Global Health located in Africa. **Virtual**.

“Introductory to Cancer Chemotherapy.” January 17th 2023. Presented to the audience of Bioventures of Global Health located in Africa. **Virtual**.

“A Rising Star in the Pandemic: UC Irvine School of Pharmacy & Pharmaceutical Sciences”. December 27th 2022. Presented to the faculty and students at Taiwan Medical University. **Taipei, Taiwan**

“Cancer Symptom Management: The Crossroad between Supportive Care and Integrative Oncology.” December 5th 2022. Presented at the UCI-Kyung Hee University Joint Symposium. **Korea**

“Brain Derived Neurotrophic Factor (BDNF) in Cancer-related Cognitive Impairment (CRCI).” November 28th 2022. Presented to the members of the National Cancer Institute CRCI Workgroup. **Virtual**.

“What the ONC? The Biggest Medication-Based Oncology Updates from the Past Year.” November 3rd 2022. Presented to the delegates of the CSHP Annual Meeting. **Anaheim, California, USA**

“Interdisciplinary and Translational Research in Cancer-related Cognitive Impairment.” Presented to the Dana Faber Cancer Institute Health Outcomes Group. October 25th 2022. Presented to members of the group. **Boston, USA**

“The State of the Art on Supportive Care Pharmacotherapy for Oncology Patients. I Congreso Nacional de Farmacia Oncologica.” The first National Pharmacy Congress on Oncology Pharmacy in Mexico. October 28th 2022. Presented to members of the organization. **Virtual**.

“Community Input on ICTS Research Agenda. Interdisciplinary and Translational Research in Cancer-related Cognitive Impairment.” October 4th 2022. Presented to community members of UCI. **Virtual.**

“ISOPP Masterclass: How should we manage cancer patients with complex symptoms.” June 9th, 2022. **Virtual.**

“Cancer Control Presentation: Identifying Priorities, Barriers, and Facilitators for Conducting AYA Cancer Survivorship Research: A Delphi Approach.” Presented to members of cancer center control at Chao Family Comprehensive Cancer Center. June 8th, 2022. **Virtual.**

“UCI Health Webinar: Update on Antiemesis in Cancer Patients.” Presented to members of UCI Health. May 4th, 2022. **Virtual.**

“ISOPP Masterclass: Adolescent and Young Adult Cancer Survivor Health Issues.” Presented to participants residing in the Middle East. February 4th, 2022. **Virtual.**

“ISOPP Masterclass: Oral Anticancer Therapies.” Presented to participants of the SOPA/ISOPP Hybrid Regional Conference. November 18th, 2021. **Virtual.**

“ISOPP Masterclass: Cancer-related cognitive impairment.” Presented to participants residing in the Middle East. September 22nd, 2021. **Virtual.**

“Risk factors for Cancer-related cognitive impairment (CRCI).” Presented to the participants of the Multinational Association of Supportive Care Cancer Workshop on CRCI. September 15^h 2021. **Virtual.**

“COVID-19 Vaccines Boosters.” Presented to community partners of UCI. September 14th 2021. **Virtual.**

“Interdisciplinary Paths for Clinical Investigators with Pharmacy and Pharmaceutical Sciences.” Presented to clinical investigators at UCI School of Medicine. September 14th 2021. **Virtual.**

“Antibody-Drug Conjugates for Cancer Therapy.” Presented to the participants of the Great Debates & Updates. July 22-24th 2021. **Virtual.**

“ISOPP Masterclass: Supportive Care.” Presented to participants residing in the Middle East. June 30th 2021. **Virtual.**

“Genotyping to Avoid ADRs.” Presented to faculty and staff at Macao Polytechnic Institute. June 9th 2021. **Virtual.**

“Current COVID-19 Vaccines: Efficacy and Safety.” Presented to community partners of UCI. February 9th 2021 and March 1st 2021. **Virtual.**

“Supportive Care and Palliative Care Abstracts: Discussant.” Presented as part of the IASLC Conference 2021. January 31st 2021. **Virtual.**

“Management of complex physical symptoms in cancer survivors.” 2nd Oncology Pharmacy Masterclass (Part 2). November 14th 2020. **Virtual.**

“Oncologic Emergencies: An update.” Presented as part of the ESMO Asia Conference 2020. Nov 17th 2020. **Virtual.**

“Predictors for cancer-related cognitive disorders.” 2nd Oncology Pharmacy Masterclass. October 3rd 2020. **Virtual.**

“Clinical Pipeline Updates: Part 1”. Presented as part of the ASHP Summer Sessions 2020.

<http://elearning.ashp.org/products/8233> **Virtual.**

“Cancer survivorship care during and after COVID-19”. Presented to participants of the 3rd Saudi Oncology Hematology Pharmacy Symposium 2020. June 30th 2020. **Virtual.**

“Global Oncology Pharmacy Response to COVID-19: Medication Access and Safety” Presented to participants of the ISOPP Webinar. May 13th 2020. Available on: <https://www.isopp.org/virtual-library/isopp-covid19-webinar> **Virtual.**

“Adverse Drug Reactions in the Cancer Population” Presented to participants of the 8th Annual ABC Medical Center Meeting, March 2020, Mexico City, **Mexico**

“Adverse Drug Reactions in the General Population” Presented to participants of the 8th Annual ABC Medical Center Meeting, March 2020, Mexico City, **Mexico**

“Management of Complex Physical Symptoms in Cancer Survivors” Presented to participants of the Best of MASCC 2019 Meeting, November 2019, Singapore, **Singapore**

“Credentialing of Oncology Pharmacists in Singapore” Presented to participants of the Clinical Oncology Society Australia 2019 Annual Science Meeting, November 2019, Adelaide, **Australia**

“Cancer Survivorship” Presented to participants of the American College of Clinical Pharmacy (ACCP)/American Society of Health-System Pharmacists (ASHP) Oncology Webinar Series. Available on: <https://www.accp.com/bookstore/w Onc2 16r.aspx>

“Biosimilar – Practical Considerations in Pharmacy (Global Perspective)” Presented to participants of the Clinical Oncology Society Australia 2019 Annual Science Meeting, November 2019, Adelaide, **Australia**

“Management of supportive care issues associated with treatment of prostate cancer patients” Presented to participants of the Clinical Oncology Society Australia 2019 Annual Science Meeting, November 2019, Adelaide, **Australia**

“Engaging AYA Cancer Patients - Challenges or Opportunities” Presented to participants of the Clinical Oncology Society Australia 2019 Annual Science Meeting, November 2019, Adelaide, **Australia**

“Pharmacy Practitioners as Researchers: Panel Discussion” Presented to participants of the BOPA/ISOPP International Symposium on Oncology Pharmacy Practice, October 2019, London, **United Kingdom**

“The Role of Microbiome Restoration in Chemotherapy and Immunotherapy” Presented to participants of the 2019 World Conference on Lung Cancer, September 2019, Barcelona, **Spain**

“Emerging Targets and Pathways in Cancer-Related Cognitive Impairment (CRCI)” Presented to participants of the Multinational Association Supportive Care in Cancer Meeting, June 2019, San Francisco, **USA**

“AYA Clinical Trials in Asia: An Update” Presented to participants of the Multinational Association Supportive Care in Cancer Meeting, June 2019, San Francisco, **USA**

“How to initiate research studies in clinical practice” Presented to participants of the Africa Regional Oncology Pharmacy Symposium 2019, May 2019, Nairobi, **Kenya**

“How to set up a clinical practice in oncology pharmacy?” Presented to participants of the Africa Regional Oncology Pharmacy Symposium 2019, May 2019, Nairobi, **Kenya**

“Real Life Data in Immunotherapy: Managing Immune-Related Adverse Effects” Presented to participants of Spanish Society of Hospital Pharmacists (SEFH), November 2018, Palma de Mallorca, **Spain**

“PRO: Managing Breathless with Medications” Presentation to participants at the World Conference of Lung Cancer 2018, September 2018, Toronto, **Canada**

“Cancer Survivorship” Presented to participants at the Asia Pacific Oncology Pharmacy Congress, September 2018, Singapore, **Singapore**

“How to initiate clinical research in a clinical practice?” Presented to participants at the Clinical Oncology Pharmacy Symposium organized by the Asian Pacific Oncology Pharmacy Society (Thailand), August 2018, Bangkok, **Thailand**

“Cancer Survivorship” Presented to participants at the Clinical Oncology Pharmacy Symposium organized by the Asian Pacific Oncology Pharmacy Society (Thailand), August 2018, Bangkok, **Thailand**

“Managing Challenging Issues in Adolescent and Young Adult (AYA) Cancer Survivors: Cognitive Impairment in AYA Cancer Survivors” Presented to participants at the Multinational Association of Supportive Care in Cancer Annual Meeting, June 2018, Vienna, **Austria**

“Immune-Related Adverse Effect Management” Presented to participants at the IX Congresso Brasileiro de Farmacêuticos em Oncologia 2018, May 2018, Rio de Janeiro, **Brazil**

“The Future of Pharmacy Practice In Cancer Supportive Care” Presented to participants at the IX Congresso Brasileiro de Farmacêuticos em Oncologia 2018, May 2018, Rio de Janeiro, **Brazil**

“Shared Experiences of Student Research Projects” Presented to participants at the International Society of Oncology Pharmacy Practitioners, April 2018, Shanghai, **China**

“New Dimensions and Advances in Supportive Care for Asian Cancer Patients” Presented to participants at the 5th National Hospital and Institutional Pharmacists Congress, TUKED, March 2018, Antalya, **Turkey**

“Advances in Cancer Supportive Care and Survivorship” Presented to participants at the School of Pharmacy, International Medical University, Kuala Lumpur, March 2018, **Malaysia**

“Management of immunotherapy-related adverse events” Presented to participants of the European Medical Society of Oncology Asia Meeting, Singapore, November 2017, **Singapore**

“Targeted therapies: Management and Care” Presented to participants of the International Thoracic Oncology Nursing Forum, IASLC 18th World Conference in Lung Cancer, Yokohama, October 2017, **Japan**

“Cancer Survivorship Care: A Clinical Pharmacist’s Role”, Presented to participants of Asian Conference on Clinical Pharmacy, Surabaya, July 2017, **Indonesia**

“Chemotherapy-induced Nausea and Vomiting: An Update” Presented to participants of Asian Conference on Clinical Pharmacy, Surabaya, July 2017, **Indonesia**

“Supportive Care Updates” Organized and chaired workshop at Asian Conference on Clinical Pharmacy, Surabaya, July 2017, **Indonesia**

“Reduction of White Matter in Adolescent and Young Adult Cancer Survivors Receiving Chemotherapy” Presented to participants of the Multinational Association Supportive Care in Cancer Meeting, Washington DC, June 2017, **USA**

“Biomarkers in Cancer Supportive Care: Applications to Clinicians” Presented to participants of the 20th Cancer Nursing Society of Australia Annual Meeting, Adelaide, June 2017, **Australia**

“The Changing Paradigm of Cancer Supportive Care” Presented to participants of the 20th Cancer Nursing Society of Australia Annual Meeting, Adelaide, June 2017, **Australia**

“Management of immune-related adverse events” Presented to participants of the International Society of Oncology Pharmacy Practitioner Annual Meeting, Budapest, April 2017, **Hungary**

“Role of a Board Certified Oncology Pharmacist: The Asian Context” Presented to participants of the Japanese Society of Pharmaceutical Oncology Annual Meeting, Niigata, March 2017, **Japan**

“Pharmacokinetics/Pharmacodynamics of Anticancer Agents in the Elderly” Presented to participants of the European Society of Medical Oncology Asia Meeting 2016, **Singapore**

Discussion of abstracts under the Supportive Care/Palliative Care track. Presented to participants of the European Society of Medical Oncology Asia Meeting 2016, **Singapore**

“Chemobrain: Impact of Asian Patients” Presented to participants of the 5th Asian Psycho-Oncology Summit, November 2016, **Singapore**

“Chemotherapy-Induced Nausea and Vomiting Guidelines and Antiemetic Guideline Adherence” Presented to participants of the International Conference on Cancer Nursing, September 2016, **Hong Kong**

“New Dimensions and Advances in Supportive Care for Asian Cancer Patients” Presented to faculty and students at the University of Sydney Faculty of Pharmacy, May 2016, **Australia**

“International Experiences for the Development of Clinical Pharmacy” Presented to faculty and staff at the Universidad Andres Bello, Santiago, April 2016, **Chile**

“Interacting with Professional Journals: Reviewing and Publishing” Presented to the participants of the International Society of Oncology Pharmacy Practitioners Meeting, Santiago, April 2016, **Chile**

“Cytokine gene polymorphism, plasma concentration and cognitive impairment: intricate relationships in chemotherapy-receiving breast cancer patients” Presented to the participants of the International Society of Oncology Pharmacy Practitioners Meeting, Santiago, April 2016, **Chile**

“Hematological Malignancies Update: Lymphoma” Presented to the participants of the International Society of Oncology Pharmacy Practitioners Meeting, Santiago, April 2016, **Chile**

“Antiemetics Update: All About Olanzapine” Presented to the participants of the International Society of Oncology Pharmacy Practitioners Meeting, Santiago, April 2016, **Chile**

“The Steven Grunberg Memorial Award Lecture: Pharmacogenomics in Cancer Supportive Care” Presented to the participants of the Multinational Association in Supportive Care Cancer Meeting, Copenhagen, June 2015, **Denmark**

“Antiemetic Guidelines: An Update” Presented to the participants of the audience of the Asian Antiemetic Summit, Bangkok, April 2015, **Thailand**

“PrACTICE study: Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy” Presented to the participants of the China Emend Chemotherapy-Induced Nausea and Vomiting (CINV) Key Account Summit, Beijing, March 2015, **China**

“The past, recent and future of pharmacy practice: Cancer Supportive Care” Presented to the faculty and students at Chungnam National University, Daejeon, March 2015, **South Korea**

“Pharmacy & Pharmaceutical Science Education and Training in Singapore” Presented to the faculty and students at Chungnam National University, Daejeon, March 2015, **South Korea**

“Epidermal Growth Factor Receptor Inhibitor-Induced Dermatological Toxicities: Clinical Management” Presented to the participants of the Shanghai Anticancer Association, the Committee of Oncology Pharmacy, December 2014, Shanghai, **China**

“Cognitive Impact of Androgen Deprivation Therapy in Prostate Cancer – Real or Spurious?” Presented to the participants of the 1st Advances in Prostate Cancer Conference (APCC), November 2014, Singapore, **Singapore**

“An Overview of Oral Anticancer Therapies and Its Implications” Presented to the participants of the 5th Asia Pacific Oncology Pharmacy Congress, September 2014, Seoul, **South Korea**

“MASCC/ISOPP 2014 Updates” Presented to the participants of the 5th Asia Pacific Oncology Pharmacy Congress, September 2014, Seoul, **South Korea**

“Febrile Neutropenia: How do prediction models help us to improve our management?” Presented to the participants of the Shanghai Pharmacists Association Meeting, September 2014, Shanghai, **China**

“Drug-drug interactions in Oncology: An Overview” Presented to the participants of the National Conference on Hospital Pharmacy and the Satellite Symposium of the 73rd International Congress of FIP, September 2014, Shenyang, **China**

“Supportive Care in Cancer Patients: Focus on Acute Side Effects” Presented to the participants of the Pharmacist Association of Macao Continual Education Meeting, August 2014, **Macau**.

“Management of metastatic breast cancer – A pharmacist’s perspective” Presented to the participants of the Japanese Society of Medical Oncology Annual Meeting, July 2014, Fukuoka, **Japan**

“Clinical Pharmacy Services and Research for Lymphoma Patients at an Asian Cancer Center” Presented to the participants of the Japanese Society of Medical Oncology Annual Meeting, July 2014, Fukuoka, **Japan**

“Supportive Care and Medicine Matters in the older cancer patients: The Asian Perspective” Presented to the participants of the International Society of Geriatric Oncology 2nd Asia Pacific Conference, July 2014, Singapore, **Singapore**

“Adherence to Antiemetic Therapy in Asian Head and Neck Cancer Patients” Presented to participants of the Multinational Association of Supportive Care in Cancer Annual Meeting, June 2014, Miami, **USA**

“Chemotherapy-associated cognitive impairment” Presented to the nurses, researchers, psychologists, pharmacists and other health professionals at Princess Alexandra Hospital, Royal Brisbane Hospital and Queensland University of Technology (Institute of Health and Biomedical Innovation (IHBI)) June 2014, Brisbane, **Australia**

“Cancer Survivorship: A Focus on Physical Side Effects” Presented to the participants of the 14th International Symposium of Oncology Pharmacy Practitioner Meeting, April 2014, Montreal, **Canada**

“Antiemetics: Formulary and Protocol Development” Presented to the participants of the 14th International Symposium of Oncology Pharmacy Practitioner Meeting, April 2014, Montreal, **Canada**

“Castrate-Resistant Prostate Cancer: New wine and its challenges” Presented to the participants of the 40th Clinical Oncology Society of Australia (COSA) Annual Meeting, November 2013, Adelaide, **Australia**

“Advanced Practice Framework: The Singapore Experience” Presented to the participants of the 40th Clinical Oncology Society of Australia (COSA) Annual Meeting, November 2013, Adelaide, **Australia**

“Medicine matters in the older cancer patients: Drug interactions and toxicities” Presented to the participants of the 40th Clinical Oncology Society of Australia (COSA) Annual Meeting, November 2013, Adelaide, **Australia**

“Neurocognitive Toxicity of Chemotherapy: Cultural Considerations” Presented to the participants of the 40th Clinical Oncology Society of Australia (COSA) Annual Meeting, November 2013, Adelaide, **Australia**

“Clinical Pharmacy Services and Research at a Cancer Center” Presented to the participants of the National Conference on Hospital Pharmacy and the Satellite Symposium of the 73rd International Congress of FIP, October 2013, Suzhou, **China**

“How to Live Instead of Just Survive After a Diagnosis of Cancer: Heme/Onc PRN Focus Session” Presented to participants of the American College of Clinical Pharmacy, October 2013, Albuquerque, **USA**

“Hodgkin Lymphoma” Presented to participant of the Asia Conference of Clinical Pharmacy, September 2013, Haiphong, **Vietnam**

“The Association between Pro-inflammatory Biomarkers and Post-chemotherapy cognitive changes in Asian Breast Cancer Patients: A Prospective Cohort Study” Presented to participant of the Best of ASCO Southeast Asia meeting, August 2013, Singapore, **Singapore**

“Treat, Educate And Manage: Multidisciplinary collaboration to support mRCC Patients on Votrient”. Presented to participants of the Multinational Association of Supportive Care in Cancer Annual Meeting, June 2013, Berlin, **Germany**

“Febrile Neutropenia Management of Cancer Patients in Singapore”. Presented to participants of the Multinational Association of Supportive Care in Cancer Annual Meeting, June 2013, Berlin, **Germany**

“An Overview: The Clinical Impact of Drug-Drug Interactions in Cancer Patients”. Presented to participants of the Multinational Association of Supportive Care in Cancer Annual Meeting, June 2013, Berlin, **Germany**

“Clinical Pharmacy Services and Research at a Cancer Center”. Presented to participants of the 3rd International Conference on Pharmacy and Advanced Pharmaceutical Sciences, June 2013, Yogarkarta, **Indonesia**

“A Pharmacist’s Experience in the Treatment of Advanced Soft Tissue Sarcoma”. Presented to participants of an industrial symposium at the American Society of Clinical Oncology Meeting, May 2013, Chicago, **USA**

“Supportive Care in Early Stage Breast Cancer: Current Challenges” Presented to participants of the 2nd Asian Pacific Breast Cancer Summit, April 2013, Kuala Lumpur, **Malaysia**

“My role as a pharmacist in managing mRCC and aSTS patients on Votrient® (pazopanib)” Presented to participants of European Association of Health System Pharmacists Salletite Symposium, March 2013, Paris, **France**

“Clinical Pharmacy Services and Research to Patients at a Cancer Center” Presented to Pharmacy Faculty and Hospital Preceptors at Ubon Ratchathani University, February 2013, Ubon Ratchathani, **Thailand**

“Various Topics: PHAR 5950 Advanced Certificate in Specialty Training of Oncology Pharmacist – One Week Training” Presented to Hospital Authority Trainees at Chinese University of Hong Kong, January 2013, Hong Kong, **Hong Kong**

“Supportive Care in Breast Oncology” Presented as a Continual Education Session for Pharmacists, Pharmaceutical Society of Macao, November 2012, Macau, **Macau**

“Clinical Pharmacy Services and Research to Patients at a Cancer Center” Presented at the Drug Safety and Risk Management Conference, November 2012, Macau, **Macau**

“Chemotherapy-Induced Nausea and Vomiting” Presented at the Asia Pacific Oncology Pharmacy Congress, November 2012, Jakarta, **Indonesia**.

“Literature Evaluation in Oncology:Application to Daily Practice” Presented at the Asia Pacific Oncology Pharmacy Congress, November 2012, Jakarta, **Indonesia**.

“An evaluation of the drug-drug interaction between Proton-Pump Inhibitors and EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Patients” Presented at the American College of Clinical Pharmacy Annual Meeting, October 2012, Hollywood, **USA**.

“Toxicity Management Workshop: Votrient in Renal Cell Carcinoma” Presented at the 12th Asian Conference on Clinical Pharmacy, July 2012, Hong Kong, **China**

“Dermatological Toxicities of Targeted Therapies” Presented at the 12th Asian Conference on Clinical Pharmacy, July 2012, Hong Kong, **China**

“Supportive Care in Breast Cancer Patients” Presented at the 12th Asian Conference on Clinical Pharmacy, July 2012, Hong Kong, **China**

“Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy” Presented at MASCC Annual Meeting, June 2012, New York City, **USA**.

“Patients’ Perceptions on E-Health Technologies to Improve Pharmaceutical Care: Aging Cancer Patients as a Case Study” Presented at MASCC Annual Meeting, June 2012, New York City, **USA**.

“Safety Considerations of Antiemetics” Chaired and Presented at a Merck Sharp &Dohme-sponsored symposium at Presented at the International Society of Oncology Pharmacy Practitioners XIII Annual Meeting, May 2012, Melbourne, **Australia**.

“Updates in Lymphoma Treatment” Presented at International Society of Oncology Pharmacy Practitioners XIII Annual Meeting, May 2012, Melbourne, **Australia**.

“Drug Interactions in Oncology” Presented at International Society of Oncology Pharmacy Practitioners XIII Annual Meeting, May 2012, Melbourne, **Australia**

“Toxicity Management Workshop: Votrient in Renal Cell Carcinoma” Presented at European Association of Hospital Pharmacists, March 2012, Milan, **Italy**

“Minimizing Toxicity of Adjuvant Therapy” Presented at Asia Pacific Breast Cancer Summit, February 2012, Singapore, **Singapore**

“Impact of adherence to antiemetic regimens on outcome of nausea and vomiting control among Asian breast cancer patients receiving anthracycline-based chemotherapy” Presented at the American College of Clinical Pharmacy Annual Meeting, October 2011, Pittsburgh, **USA**

“How am I going to take all these medications? Challenges and Consequences of Medication Overload” Presented at Multinational Association of Supportive Care in Cancer Annual Meeting, June 2011, Athens, **Greece**.

“Oral Anticancer Agents Toxicities: An Overview” Presented at ISOPP 4th IOM Meeting, May 2011, Salzburg, **Austria**

“Assessing Your Patient’s Risk for Chemotherapy Induced Nausea and Vomiting (CINV): A Team Care Perspective” Presented at the 1st Asia-Pacific Oncology Nurses Speaker Forum, May 2011, Kuala Lumpur, **Malaysia**

“Management of pruritus associated with EGFR Inhibitors” Presented at MASCC Dermatological Toxicities Management Workshop, Nov 2010, Chicago, **USA**

“Asia Pacific Emesis Registry Advisory Panel – Singapore Perspectives” Presented at Asia Pacific Emesis Registry Advisory Panel Meeting, Nov 2010, Beijing, **China**

“Supportive Care Research in Clinical Oncology” Presented at University of Medicine and Pharmacy, May 2010, Ho Chi Minh City, **Vietnam**

“Management of tyrosine kinase inhibitors” Presented at International Society of Oncology Pharmacy Practitioners 2010, May 2010, Prague, **Czech Republic**

“Safety and Benefits of Erythropoietin Stimulating Agents” Presented at International Society of Oncology Pharmacy Practitioners 2010, May 2010, Prague, **Czech Republic**

“Supportive Care Update” Presented at Asian Oncology Summit 2010, April 2010, Bali, **Indonesia**

“Management of Myelosuppression” Presented at Khon Kaen University, February 2010, Khon Kaen, **Thailand**

“The Significance of Preceptorship” Presented at Bumrungrad International Hospital, February 2010, Bangkok, **Thailand**

“Cancer Supportive Care” Presented to participants of International Seminar on Clinical Pharmacy in Holistic Care of Cancer, January 2009, Yogarata, Ahmad Dahlan University, **Indonesia**

“Clinical Update: Renal Cell Carcinoma” Presented to participants of Asia-Pacific Oncology Pharmacy Congress, September 2008, Bangkok, **Thailand**

“Erythropoietic stimulating agents in cancer anemia patients: Friend or Foe?” Presented to participants of Asian Conference of Clinical Pharmacy Meeting, July 2008, Surabaya, **Indonesia**.

“Updates of Soft Tissue Sarcoma” Presented to participants of Joint HOPA/ISOPP Meeting, June 2008, Anaheim, **USA**

“Chemotherapy Induced Toxicities ”Presented to faculty and students of Prince of Songkla University, March 2008, Hatyai, **Thailand**

“Pharmacist management of EGFR skin toxicities” Presented to pharmacists, International Society of Oncology Pharmacy Practitioners Australasian meeting, September 2007, Brisbane, **Australia**

“Chemotherapy Induced Nausea and Vomiting”, “Parkinson’s Disease”, “Depression” Presented to pharmacy technician students, Macao Polytechnic Institute, School of Health Sciences, May 2007, **Macau**

“Pharmacy and Therapeutics Monograph: Rasburicase” Presented to physicians, July 2006, Sacramento, **USA**

“Hematology/Oncology Fellows Series: Targeted Therapies: Solid Tumors” Presented to physicians, UC Davis Cancer Center, July 2006, Sacramento, **USA**

“Evaluation of Induction Therapy for AML in the adult population at UCDMC” Presented to pharmacists and pharmacy residents, Western States Conference, May 2006, Pacific Grove, **USA**

“Pain Management in Cancer Patients” Presented to physicians, UC Davis Medical Center, December 2005, Sacramento, **USA**

“Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer” Presented to pharmacist, UC Davis Medical Center, December 2005, Sacramento, **USA**

“Use of IVIG in Bone Marrow Transplant” Presented to physicians and medical residents, UC Davis Medical Center, October 2005, Sacramento, **USA**

“Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia”. Presented to pharmacists and students, UC Davis Medical Center, October 2005, Sacramento, **USA**

“New drugs in Oncology” Presented to physicians and pharmacists, UC Davis Medical Center, August 2005, Sacramento, **USA**

“Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies” Presented to faculty and pharmacy students, UCSF Medical Center, June 2005, San Francisco, **USA**

“Survey of Topical Oral Solutions for the treatment of Chemo-Induced Oral Mucositis” Presented to pharmacists and pharmacy residents, Western States Conference, May 2005, Pacific Grove, **USA**

“Pharmacological Cardioversion for Atrial Fibrillation” Presented to faculty and pharmacy students, UCSF Medical Center, March 2005, San Francisco, **USA**

“Continuous Renal Replacement Therapy in Pediatrics Population” Presented to faculty and pharmacy students, UCSF Medical Center, February 2005, San Francisco, **USA**

“Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers” Presented to pharmacists, UCSF Medical Center, December 2004, San Francisco, **USA**

“Docetaxel and Estramustine compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer” Presented to faculty and pharmacy students, UCSF Medical Center, December 2004, San Francisco, **USA**

“Glaucoma: Pathophysiology and Treatment” Presented to faculty and pharmacy students of School of Pharmacy, UCSF Medical Center, July 2004, San Francisco, **USA**

“Oral Ximelagatran for secondary prophylaxis after myocardial infarction: The ESTEEM randomized controlled trial” Presented to physicians, pharmacists and students, Crownpoint Health Facility, February 2004, Crownpoint, **USA**

“Hairy Cell Leukemia: A review and case study” Presented to faculty and pharmacy students, Rutgers University, October 2003, New Brunswick, **USA**

“Tumor Board: Patient case presentations” Presented to physicians, nurses, radiologists and pharmacists, University Medical Center at Princeton, September 2003, Princeton, **USA**

“An Update on Warfarin Dosing Strategies for Deep Vein Thrombosis” Presented to faculty and students of School of Pharmacy, Graduation Seminar, September 2003, New Brunswick, **USA**

“Low-Molecular-Weight Heparin versus a Coumarin for the prevention of recurrent Venous Thromboembolism in patients with cancer” Presented to faculty and pharmacy students, Rutgers University, September 2003, New Brunswick, **USA**

Singapore-based presentations

“Cancer Myths Debunked: Facts from Research: Presented to Senior Alumni of National University of Singapore, July 2018, **Singapore**

“Pre-emptive genotyping to reduce adverse drug reactions” Presented to participants at a workshop conducted at National University of Singapore, February 2018, **Singapore**

“Evaluating biomedical literature” Organized and chaired workshop at Singapore Pharmacy Congress 2017, September 2017, **Singapore**

“Demystifying Post-chemotherapy Cognitive Impairment: The Singapore Journey” Presented to participants at the 5th Singapore Rehabilitation Conference, September 2017, **Singapore**

“Survivorship Program – What it may look like in the local landscape” Presented to participants of a workshop conducted by Singapore Cancer Society, September 2017, **Singapore**

“Updates in Immunotherapies in Non-Small Cell Lung Cancer: Challenges in Patient Therapies” Presented to participants at the Singapore Pharmacy Congress workshop, October 2016, **Singapore**

“Chemotherapy-Induced Nausea and Vomiting: An Update” Presented to nurses at grand rounds at National Cancer Centre Singapore, September 2016, **Singapore**

“A rare complication of malignancy: Hemophagocytic lymphohistiocytosis”, Presented to pharmacists at National Cancer Centre Singapore, November 2015, **Singapore**

“Toxicities of hormonal therapies”, Presented to breast cancer survivors, November 2015, **Singapore**

“The Generation and Interpretation of Clinical Data for the Biomedical Industry”, Presented to industrial pharmacists at Pharmaceutical Society of Singapore, October 2015, **Singapore**

“Management of long-term side effects and medications in breast cancer survivorship”, Presented to breast cancer survivors, September 2015, **Singapore**

“Luck and Cancer”, Presented to pharmacists at National Cancer Centre Singapore, March 2015, **Singapore**

“Cancer Survivorship”, Presented to pharmacists at National Cancer Centre Singapore, August 2014, **Singapore**

“MASCC Update”, Presented to pharmacists at National Cancer Centre Singapore, August 2014, **Singapore**

“Supportive Care in Cancer Patients: A Focus on Symptom Burden & Psychosocial Distress”, Presented to the Chapter of Psychiatrists, Academy of Medicine, Singapore, March 2014, **Singapore**

“Chemotherapy-associated cognitive impairment”, Presented to patients and relatives, NCC Enreach program, March 2014, **Singapore**

“Anticancer drug pharmacology and toxicities”, Presented to medical officers (residents), July 2013, February 2014, **Singapore**

“Late Effect and Long-Term Effects of Chemotherapy” Presented to nurses at the Nursing Grand Round, July 2013, **Singapore**

“Management of toxicities associated with oral Anti-Cancer targeted therapies: Pharmacist’s Role” Presented to participants of 22nd Singapore Pharmacy Congress, September 2012, **Singapore**

“Sunitinib-Induced Systemic Toxicities: An Asian Perspective” Presented at the Healthcare Decision Making in the Age of Personalized Medicines Symposium, May 2012, **Singapore**

“Supportive Care Research in Breast Oncology” Invited speaker at the continuous education session at National University Hospital Singapore, April 2012, **Singapore**

“Biostatistics Refresher (I) and (II)” Presented at Pharmaceutical Society of Singapore Continuous Education, April 2012, August 2014, **Singapore**

“Toxicity Management Workshop: Votrient in Renal Cell Carcinoma” Presented at European Association of Hospital Pharmacists, April 2012, **Singapore**

“Supportive Care Research in Breast Oncology” Presented at Annual Pharmacy Research Symposium 2012, April 2012, **Singapore**

“Local Management of Chemotherapy-Induced Nausea and Vomiting: A Singapore Perspective” Presented to fellow pharmacists and other participants – sponsored by Mundipharma Pharmaceuticals, March 2012, **Singapore**

“Clinical Management of Cancer Patients: Focus on Side Effects” Presented to JC College students, December 2011, **Singapore**

“New Drugs Update in Hematology/Oncology” Presented to participants of Singapore Pharmacy Congress, July 2011, **Singapore**

“Your Future in Pharmacy: Academia & Research” Presented to Pre-registration Pharmacists, July 2011, **Singapore**

“Clinical Paper Appreciation” Presented to Janssen Employees, April 2011, **Singapore**

“Training: Chemotherapy: Principles and Concepts” Presented to Janssen Employees, January 2011, **Singapore**

“Advancing Clinical Pharmacy and Pharmacy Practice through Research” Presented to students, faculty. January 2011, **Singapore**

“Anticancer drug pharmacology and toxicities”, Presented to medical officers (residents), November 2010, **Singapore**

“Supportive Care: Overview and Updates”, Presented to oncology fellows (registrars), July 2010, December 2011, **Singapore**

“Anticancer drug pharmacology and toxicities”, Presented to medical officers (residents), November 2009, **Singapore**

“Expert Sharing Session: Chemotherapy Induced Nausea and Vomiting” Presented at Merck Sharpe and Dohme Meeting, October 2009, **Singapore**

“A review of the recent advances on endocrine treatment for postmenopausal women with early stage breast cancer” Presented to participants of 20th Singapore Pharmacy Congress, July 2009, **Singapore**

“Hypersensitivity Reactions” Presented to participants of Pre-congress Workshop, Aseptic Dispensing Conference, July 2009, **Singapore**

“Anticancer drug pharmacology and toxicities”, Presented to medical officers (residents), May 2009, **Singapore**

“Postgraduate Education and Training for Today’s Pharmacist” Presented to participants of 22nd Federation Asian Pharmaceutical Associations Congress (FAPA), November 2008, **Singapore**.

“Anticancer drug pharmacology and toxicities”, Presented to medical officers (residents), May 2008, **Singapore**

“Optimizing treatment outcomes with pegfilgrastim” Presented to physicians and students, Singapore General Hospital, Department of Hematology, March 2008, **Singapore**.

“Becoming a Pharmacist” Presented to public, Career 2008 & Education 2008, Suntec City, March 2008, **Singapore**

“Managing chemotherapy side effects” Presented to medical officers, National Cancer Centre, December 2007, **Singapore**

“Optimizing treatment outcomes with pegfilgrastim” Presented to physicians, nurses, pharmacists and students, National Cancer Centre, November 2007, **Singapore**.

“Anticancer drugs pharmacology” Presented to research associates, Novartis Pharmaceuticals, October 2007, **Singapore**

“Oncology Update 2007” Presented to pharmacists, Singapore Pharmacy Congress, October 2007, **Singapore**

“Cancer Pain Management” Presented to nurses, National Cancer Centre, June 2007, September 2007, April 2008, **Singapore**

“Chemotherapy on the ground: The Theory” Presented to physicians, National Cancer Centre, May 2007, **Singapore**

“Advanced Pain Management Course: Medications use in pain management” Presented to international nurses, Singapore General Hospital, May 2007, **Singapore**

“Chemotherapy in pregnancy” Presented to physicians, National Cancer Centre, May 2007, August 2007, **Singapore**

“Prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting at a cancer center in Singapore” Presented to physicians; short-listed for Young Investigator Award (Allied Health), Singapore General Hospital, April 2007, **Singapore**

“What is Clinical Pharmacy?” Presented to prospective students, National University Singapore Open House, March 2007, **Singapore**

“Cytotoxic Pharmacology and Supportive Care” Presented to community physicians, National Cancer Centre, January 2007, **Singapore**

“Cytotoxic Pharmacology” Presented to physicians and research associates, National Cancer Centre, December 2006, November 2007, **Singapore**

“Chemotherapy on the ground: The Theory” Presented to physicians, National Cancer Centre, November 2006, **Singapore**

IN PERSON WORKSHOPS AND CONFERENCE ORGANIZER (AS LEADER, MAIN CHAIR OR SCIENTIFIC CHAIR)

- | | |
|------|---|
| 2010 | The 10 th Asian Conference on Clinical Pharmacy (~1100 pax, Singapore) |
| 2012 | Asian Conference on Clinical Pharmacy – Oncology Update (30 pax, Hong Kong) |
| 2013 | Asian Conference on Clinical Pharmacy – Oncology Update (30 pax, Hanoi, Vietnam) |
| 2014 | American College of Clinical Pharmacy – Clinical Practice and Preceptorship (34 pax, Singapore) |
| 2014 | International Society of Oncology Pharmacy Symposium (~700 pax, Montreal, Canada) |
| 2015 | American College of Clinical Pharmacy – Clinical Practice and Preceptorship (33 pax, Singapore) |
| 2016 | American College of Clinical Pharmacy – Clinical Practice and Preceptorship (33 pax, Singapore) |
| 2014 | International Society of Oncology Pharmacy Symposium (300 pax, Santiago, Chile) |
| 2017 | Asian Conference on Clinical Pharmacy – Cancer Supportive Care Update (25 pax, Indonesia) |
| 2017 | Pharmaceutical Society of Singapore – Advanced Evaluation of Biomedical literature (16 pax, Singapore) |
| 2018 | Clinical Implementation of Pharmacogenomics and Pharmacists’ Roles (30 pax, Singapore) |
| 2018 | International Society of Oncology Pharmacy Practitioners Masterclass in Cancer Supportive Care (15 pax, Turkey) |
| 2018 | International Society of Oncology Pharmacy Practitioners Masterclass in Cancer Supportive Care (30 pax, Rio de Janeiro, Brazil) |
| 2019 | Africa Regional Oncology Pharmacy Symposium 2019 (106 pax, Nairobi, Kenya) |
| 2019 | Best of MASCC in Singapore (200 pax, Singapore, Singapore) |

- | | |
|------|---|
| 2023 | Research Workshop at National Cancer Centre Singapore (20 pax, Singapore, Singapore) |
| 2023 | Oncology Pharmacy Training at University of Ilorin Teaching Hospital, Nigeria (30 pax, Ilorin, Nigeria) |
| 2024 | Oncology Pharmacy Training at Kenyatta National Hospital, Nairobi, Kenya (50 pax, Nairobi, Kenya) |

H. SELECTED MEDIA HIGHLIGHTS

Research Themes

Highlights within the media

Chemobrain/ Cancer-related Fatigue

- UCI Study Finds Possible Link Between Protein Expression and Cognitive Impairment After Chemotherapy in Cancer Patients. UCI SPPS, July 2021
- Fighting cancer and the 'fog' it brings – *The Straits Times*, May 2019
- New biomarkers associated with 'chemobrain' found – *NUS News, Channel 8* (Mediacorp), May 2019
- Mitochondria dysfunction underlying cancer-related fatigue – *Lianhe Zaobao*, May 2018
- 'Chemobrain' the new enemy in cancer fight – *The Straits Times*, April 2018
- Gene could be linked to forgetfulness after chemo – *The Straits Times*, December 2015
- Protein gene may protect from 'chemobrain' : Study – *Today*, December 2015
- Asian breast cancer patients suffer from cognitive problems: study - *Lianhe Zaobao/Channelnewsasia*, March 2012
- NUS study finds cognitive effects of chemotherapy for breast cancer - *Todayonline*, March 2012

Sarcoma

- Study reveals sarcoma symptom burden- *NUS News*, March 2015
- Programme to help manage and treat sarcoma cancer - *The Straits Times*, February 2015
- Sarcoma patients keeping mum about less severe symptoms - *Today*, February 2015

Breast Cancer Care/Survivorship

- Biomarkers predict for chemotherapy-related gastrointestinal symptoms. *Hem Onc Today* March 2024
- Vaping linked to cancer-related cognitive impairment among young adult cancer survivors. *Hem Onc Today* April 2023.

**Pharmaceutical
Care**

- Further optimizing cryotherapy may improve patient's quality of life. UCI SPPS February 2021.
- Anxiety and depression a major issue for cancer survivors – *ESMO Asia 2016 Press Release*, December 2016
- Cancer survivorship programme proves beneficial for patients – *Tomorrow's Medicine*, June 2016
- Structured support for cancer survivors 'reduces side effects' – *The Straits Times*, June 2016
- Impact of cancer fatigue in local breast cancer patients- *NUS News*, December 2014
- Some breast cancer survivors dogged by anxiety - *The Straits Times*, June 2013
- Need to address anxiety issues faced by breast cancer patients: Study - *Today*, June 2013
- NUS study shows that 20% of local breast cancer patients suffer from anxiety - *Lianhe Zhaobao*, June 2013
- Experts Worry Trump's hydroxychloroquine claims could have major consequences. *HuffPost*, May 2020
- Web tool spots patients at risk of being readmitted to hospital – *The Straits Times*, *Tamil Murasu*, *Berita Harian*, *Lianhe Zaobao*, March 2017
- Avoiding adverse reaction to medication – *A*STAR Research*, November 2016
- Alternative medicine may help cancer patients - *The Straits Times*, June 2012
- Local research shows organic fruits and vegetables and ginseng, cordyceps and birds nest may benefit cancer patients - *Lianhe Wanbao*, June 2012
- Pharmacists to play a bigger role in patient care - *The Straits Times*, May 2012
- Polypharmacy an 'Escalating Issue' in Older Cancer Patients - *Medscape Medical News*, July 2011
- Cancer drug database may protect patients - *The Straits Times*, August 2011
- Taking a variety of medicines? Here's what you need to know - *Prime Magazine*, April 2011
- During its Five-Month Run, the Bren Events Center Vaccine Clinic Served More than 44,500 People. UCI SPPS News, June 2021

**Oncology
Pharmacy**

- UCI Webinar Creates Venue to Discuss Healthcare Disparities in Pharmacy. UCI SPPS News, June 2021
- UCI pharmacists on the front lines. UCI SPPS News, June 2021
- UCI Team Develops Recommended Practices for Study of Adverse Drug Events Using Electronic Health Records, October 2021
- Oncology Pharmacy Thrives When it Goes Global. *Pharmacy Practice News*, October 2019
- Global oncology pharmacists face restricted access to essential PPE items, UCI study finds, *UCI News, Drug Topics, Pharmacist.com*, June 2020
- Mitigating Costs of Cancer Treatment: The Role of Pharmacists, *Drug Topics*, <https://www.drugtopics.com/view/mitigating-costs-of-cancer-treatment-the-role-of-pharmacists>, September 2022

**Trackable
Devices Related**

- Researchers standardize collection, reporting of wearable activity trackers' data. *Medical Xpress*, February 2022
- Team aims to make activity tracker data more consistent. *Futurity*, February 2022
- Why UCI Researchers Created a Framework for Analyzing Wearables Data, *Health IT Analytics*, March 2022

INSTRUCTIONAL ACTIVITIES**A. DIDACTIC TEACHING AT VARIOUS INSTITUTIONS*****Contributions at University of California, Irvine (2020 - present)***Undergraduate Didactics

Public Health Practicum 195W

Winter 2020

Freshmen Seminar: Uni Stu 3 Sem A: Life After Cancer (10 seminars, 1 hour each)

Winter 2021

Spring 2022

Spring 2023

Introduction

Trajectory of Cancer Treatment, from Diagnosis to Survivorship (I) and (II)

Geriatric Cancer Survivors

Pediatrics and AYA Cancer Survivors

Technology of Survivorship

Complications and Toxicities (I), (II) and (III)

Epilogue

Doctor of Pharmacy Didactics

PHMD204B Information Analytics and Numeracy II (2022 – present)

Case Control and Cohort Studies

Cross Sectional Studies, Case Reports and Case Series

PHMD204C Information Analytics and Numeracy III (2022 – present)

Regression

PHMD201B Pharmacy Practice II (2022 – present)

OSCE Session

PHMD 203C Therapeutics	Disorder of Calcium and Phosphorous OA/RA/Gout
PHMD 203G Heme/Onc Therapeutics	Chemotherapy-Induced Nausea and Vomiting Lung Cancer and Case Discussion Breast Cancer and Case Discussion
PHMD IPPE Readiness Assessment	OSCE Session

School of Medicine Didactics

Underrepresented in medicine (URIM) Medical Students Cancer Summer Internship program	Cancer Pharmacology (I) and (II)
---	----------------------------------

Contributions at National Cancer Centre Singapore, Singapore (2006 - 2019)

Medical Officers (Residents) Teaching	Cancer Pharmacology Supportive Care (Basic, 2 lectures)
Registrars (Fellows) Teaching	Supportive Care (Advanced, 2 lectures) Pharmacology (Advanced, 2 lectures)

Contributions at National University of Singapore, Singapore (2006 - 2019)

Undergraduate Didactics

PR 2133 Pharmacotherapeutics I (2015-present)	Introduction to Pharmaceutical Care Interpretation of Clinical Laboratory Tests Peptic Ulcer Disease
PR 4101 Pharmacotherapy II (2006-2011)	Gout Osteoarthritis Rheumatoid Arthritis
PR 4102 Pharmacotherapy III (2006-2017) PR 3136 Pharmacotherapeutics IV (2017-present)	Chemotherapy-induced nausea and vomiting Pharmacology of Anticancer Agents Cancer Supportive Care Depression (up to 2011)
PR 4103 Research Methodology (2011-present)	Biostatistics Refresher (I) and (II) Intro to Pharmacoepidemiology Diagnostic/Screening Research Systematic Review and Meta-Analysis Tutorial
PR 3107 Pharmacy Practice II (2007- 2012)	Constipation Diarrhea
PR 3137 Pharmacy Skills IV (2018 – present)	Physical Assessment Effective Case Presentations
PR 4104 Pharmacy Practice III (2006 – 2017)	SOAP Case Analysis (up to 2012) Medication Management and Counseling (up to 2013) Physical Assessment Dispensing Practical (up to 2012)

Doctor of Pharmacy Didactics

PR 5115 Clinical Pharmacokinetics (2009 – present)

Pharmacokinetics of Methotrexate

PR 5131 Advanced Pharmacotherapy II (2009 – 2015)

Invasive Fungal Infections (up to 2014)
Viral Infections
Viral Hepatitis

PR 5132 Advanced Pharmacotherapy III (2009 – present)

Principles of Anti-Cancer Therapies
Cancer Supportive Care
Anticancer Pharmacology
Bleeding Disorders
Leukemias
Lymphomas
Biologics in Rheumatologic Diseases

PR 5135 Advanced Pharmacy Practice (2014, 2016)

Biostatistics Refresher (I), (II) and (III)
Hands-on Session using SPSS
Diagnostic/Screening Research
Pharmacoepidemiology
Systematic Review and Meta-Analysis
Survival Analysis

PR 5136 Pharm.D. Seminar

Panelist

Doctor of Philosophy Didactics

PR 5110 Ph.D. Seminar (2018 – present)

Updates on Clinical and Health
Services Research
Writing clinical research proposals
Panelist for seminars***Contributions at Health Authority Hong Kong, Hong Kong, China [Guest Speaker] (2013, 2014, 2018, 2022, 2024)***

PHAR 5950 Advanced Certificate in Specialty Training of Oncology Pharmacist (1 week workshop)

Chemotherapy Pharmacology
Supportive Care
Oncologic Emergency
Genitourinary
(Kidney/Bladder/Testicular) Cancers
Prostate Cancer
Leukemias and Lymphomas
Special Monitoring Issues in Cancer
Biostatistics and Diagnostic Science
Oncology Literature Appreciation
Sarcomas***Contributions at School of Pharmacy, Hong Kong University, Hong Kong, China [Guest Speaker] (2015, 2017, 2019)***MCPH7101 Professional Practice –Oncology
2Introduction to Pharmacoeconomics and
Outcomes Research
Oncologic Emergencies
Leukemia
Lymphoma
Hematopoietic Stem Cell Transplantation

Contributions at Hospital Conde S. Janurio, Macau, China [Workshop Speaker] (2015)

Workshop: Development Clinical Pharmacy
Services in Oncology Clinics

Clinical Oncology Pharmacy Services
Introduction to Pharmaceutical Care
Advances in Supportive Care and
Survivorship

Contributions at University of Ilorin Teaching Hospital, Ilorin, Nigeria [Workshop Trainer] (2023)

Workshop: Oncology Pharmacist Training
Program

Anticancer Agents Pharmacology
Supportive Care
Clinical Pharmacy Services
Safe Handling Training

Contributions at Kenyatta National Hospital, Nairobi, Kenya [Workshop Trainer] (2024)

Workshop: Oncology Pharmacist Training
Program

Anticancer Agents Pharmacology
Supportive Care
Clinical Pharmacy Services
Pharmacy Education Discussion

B. ONCOLOGY RESIDENT/FELLOW SUPERVISION

- Suthan Chanthawong, BCOP – Khon Kaen University (2009)
- Manit Saetaew, BCOP – Khon Kaen University (2010)
- Ricky Ang, BScPharm(Hon), BCOP - National University of Singapore (2010-2011)
- Mohamed Houmem Karah Ali, Pharm.D., BCOP - National University of Singapore (2012)
 - Awarded during supervision: 2nd Runner Up for Best Poster Award, Pharmaceutical Society of Singapore (2012)
- Foo Koon Mian, BScPharm(Hon), BCOP – National University Singapore (2012)
- Jung-woo Chae, PhD – National University Singapore (2015 – 2017)
 - Awarded during supervision: MASCC Young Investigator Award (2017), ASCO Conquer Cancer Foundation Merit Award (2017)
- Chiu Chin Ng, PhD – National University Singapore (2018 – 2020)
- Christina Yap Ning Ni, PhD - National University Singapore (2018 – 2021)
- Koh Yongqin, PhD - National University Singapore (2019 – Present)
- Amna Elsayed, PharmD (2021-2022): *A Global Survey on the Utilization of Cryotherapy and Compression Therapy for the Prevention of Chemotherapy-Induced Peripheral Neuropathy*
- Kaleem Anwar, PharmD (2022-2023): *Real-Time Digital Analytics Assists Pharmacist-Led Symptom Management in Cancer Patients Receiving Treatment: A Prospective Single-Arm Trial*

C. RESEARCH THESIS SUPERVISION

Various Final Year and Undergraduate Research Students (>100 students, between 2007- 2019) - National University of Singapore

Various PharmSci199 Undergraduate Research Students (2021 – onwards) – University of California, Irvine

Doctor of Philosophy (Ph.D.) Candidates

1. Kevin Yap Yi-Lwern, BScPharm(Hon), Ph.D. (2007-2011): *The Application of Pharmacoinformatics in Enhancing Pharmaceutical Care of Patients with Cancer*
 - Awarded during candidature: MASCC Young Investigator Award (2011), NUS Wang Gungwu Medal and Prize - Best PhD Thesis in the National Sciences (2011), MASCC Fatigue Study Group Award (2014)
2. Yin Ting Cheung, BScPharm(Hon), PhD (2010-2014): *Chemotherapy-associated cognitive changes in Asian Breast Cancer Patients*
 - Awarded during candidature: ASCO Conquer Cancer Foundation Merit Award (2013), MASCC Young Investigator Award (2013), NUS Department of Pharmacy Annual Research Symposium Postgraduate Poster Award – 1st Prize
3. Yi Ling Teo, BScPharm(Hon), PhD (2011-2015): *Exploring the role of pharmacokinetic variation in tyrosine kinase inhibitors associated toxicities and possible management strategies*
 - Awarded during candidature: MASCC Young Investigator Award (2013)
4. Terence Ng, BScPharm(Hon) (2013-2017): *Biochemical and Genetic Insights into Chemotherapy-associated Cognitive Impairment among Asian Breast Cancer Patients*
 - Awarded during candidature: MASCC Fatigue Study Group Award (2014), ASCO Conquer Cancer Foundation Merit Award (2015), (2016), (2017), MASCC Outstanding Young Investigator Award (2015), NUS Department of Pharmacy Annual Research Symposium Postgraduate Poster Award – 1st Prize
5. Wang Xiaojun, BSc (2013-2017): *Optimizing Febrile Neutropenia Management among Asian Cancer Patients in Singapore*
 - Awarded during candidature: ACCP Global Clinical Pharmacy Conference Student Poster 2nd Runner-up (2015)
6. Sreemanee Raaj S/O Dorajoo, BscPharm(Hon) (2014-2018): *Propelling precision in clinical practice through clinical prediction models*
 - Awarded during candidature: ISPOR Asia Best Podium Award (2016)
7. Chia Jie Tan, BsPharm(Hon), BCOP (2017-2021) : *Work-related outcomes in Cancer Survivors*
 - Awarded during candidature: MASCC Outstanding Young Investigator Award (2018), ISOPP Best Platform Presentation Award (2019)
8. Yi Long Toh, BScPharm(Hon) (2017-2021): *Biomarkers in Cancer Supportive Care*
 - Awarded during candidature: MASCC Young Investigator Award (2018), MASCC Best Trainee Abstract in Neurological Complications (2019), ISOPP Best Research Poster Award (2019)
9. Ke Yu, BScPharm(Hon) (2018-2023): *Development, Implementation, And Evaluation of Survivorship Care Models Among Breast Cancer Survivors in Singapore*
 - Awarded during candidature: MASCC Young Investigator Award (2023), ASCO Merit Award (2020)
10. Ding Quan Ng, BScPharm(Hon) (2020-2025) : *Acupuncture and Integrative Oncology for Neuropsychiatric Symptoms in Cancer: Balancing Evidence, Science, and Value*
 - Awarded during candidature: PhRMA Foundation Pre-Doctoral Fellowship (2023)
11. Julia Ellen Trudeau, BSc (2023-2028) : *Thesis title TBC*

- Awarded during candidature: ICCTF 2025 Best Poster Award (2025)

Doctor of Pharmacy Research Candidates

1. Vivianne Shih, PharmD, BCOP, BCPS (2009-2011): *Economic Evaluation of Anastrozole versus Tamoxifen for Early-Stage Breast Cancer*
2. Deepika Mallya, PharmD (2010-2012): *Relationship between Cyclosporine C₂ concentrations and clinical outcomes in kidney transplant patients one-year post-transplant: A retrospective cohort analysis*
3. Michelle See, PharmD, BCPS (2011-2013): *Therapeutic Drug Monitoring of Pegfilgrastim Levels in Lymphoma patients receiving chemotherapy*
4. Adeline Wee, BScPharm(Hon), PharmD, BCPS (2012-2014): *Neuromuscular Blockade Protocol in the intensive care unit: A retrospective and prospective approach*
5. Shu Hui Yeang, BScPharm(Hon), PharmD (2012-2014): *L-asparaginase utilization and associated toxicities*
6. Lim Yi Jing, PharmD, BCPS (2013-2015): *Evaluation of a Sedation Protocol in Mechanically Ventilated Patients in a Medical Intensive Care Unit*
7. Hong Yu Wen, PharmD, BCPS (2014-2016): *Genetic polymorphism associated with cancer-related fatigue in early stage breast cancer patients*
8. Tong Wei Xiang, PharmD, BCPS (2014-2016): *Evaluation of cost effectiveness of therapeutic management of febrile neutropenia with G-CSF*
9. Goh Xuena, BScPharm(Hon), BCOP (2016- 2018): *Evaluation of symptom burden in pediatric hematology/oncology patients*
10. Jennifer Ng, BScPharm(Hon), BCOP (2016- 2018): *Cost of illness in adolescent and young adult cancer patients: A cohort study*
11. Fiona Yeo Hui Ing, BScPharm (Hon) (2016- 2018): *Regional cryotherapy to prevent chemotherapy-induced peripheral neuropathy: A pilot study*
12. Narendran S/O Koomanan, BScPharm (Hon) (2019-2021): *Economic evaluation of a prospective monitoring algorithm in Hepatitis B Core Antibody positive patients receiving rituximab for B-cell lymphoma*
13. Ivan Agapito, BSc (2022- 2024): *TBC*
14. Ryan Baniel, BSc (2022-) : *TBC*
15. Sara Sapas, BSc (2023-) : *TBC*

D. PRECEPTOR FOR DOCTOR OF PHARMACY CLERKSHIPS

1. University of California Irvine (Ambulatory Care APPE) 2024–
2. University of California San Francisco (CP 148E, USA), 2010 – 2013
3. National University of Singapore (PR 5199 Acute Care Rotation, Singapore), 2010 – 2019

4. St Louis College of Pharmacy (USA), 2012
5. University of North Carolina – Chapel Hill (USA), 2012 – 2014
6. Western University (USA), 2012
7. University of Pacific (USA), 2014 - 2019

PROFESSIONAL SERVICES

A. EDITORIAL SERVICES FOR SCIENTIFIC PUBLICATIONS

2022-Present	Assistant Editor, <i>Pharmacotherapy: A Pathophysiologic Approach</i> . 13 th ed onwards. DiPiro et al.
2023-Present 2020-2023	Associate Editor-In-Chief, <i>Supportive Care in Cancer</i> Associate Editor, <i>Supportive Care in Cancer</i>
2010-Present	Associate Editor, <i>Journal of Oncology Pharmacy Practice</i>
Present	Editorial Board Member, <i>Pharmacotherapy</i> Editorial Board Member, <i>Advances in Pharmacoepidemiology and Drug Safety</i> Editorial Board Member, <i>Expert Review of Quality of Life in Cancer</i> Editorial Board Member, <i>Open Journal of Blood Diseases</i>
2010	Invited Book Proposal Reviewer: <i>Drugs in Oncology</i> , Oxford Press
2014	Invited Book Proposal Reviewer: <i>Drug Therapy and Interactions in Pediatric Oncology</i> , Springer
2010-2015	Invited Reviewer, American Society of Health Systems Pharmacists <i>Oncology Pharmacy Preparatory Review Course for Home Study</i>
2009	Invited Chapter Reviewer: Malignant Lymphoma, <i>Pharmacotherapy Principles & Practice, Second Edition</i>
2006-Present	Invited Journal Reviewer: Reviewer, <i>Annals of Pharmacotherapy</i> Reviewer, <i>Annals of Oncology</i> Reviewer, <i>Asian Journal of Hematology-Oncology</i> Reviewer, <i>BMC Complementary and Alternative Medicine</i> Reviewer, <i>BMC Cancer</i> Reviewer, <i>Behavioural Brain Research</i> Reviewer, <i>Cancer Chemotherapy and Pharmacology</i> Reviewer, <i>Epilepsia</i> Reviewer, <i>European Journal of Oncology Nursing</i> Reviewer, <i>European Journal of Hospital Pharmacy</i> Reviewer, <i>Expert Opinion On Drug Metabolism and Toxicology</i> Reviewer, <i>Drugs</i> Reviewer, <i>Journal of Cancer</i> Reviewer, <i>Journal of Global Oncology</i> Reviewer, <i>Lancet Oncology</i> Reviewer, <i>Lancet Hematology</i> Reviewer, <i>Malaysian Journal of Pharmaceutical Sciences</i> Reviewer, <i>Nature Reviews Clinical Oncology</i>

Reviewer, *Molecular Neurobiology*
Reviewer, *Neuroinflammation*
Reviewer, *Pediatrics*
Reviewer, *Pharmacotherapy*
Reviewer, *PLOS ONE*
Reviewer, *Supportive Care in Cancer*
Reviewer, *Critical Review in Food Science and Nutrition*

B. REVIEWER FOR RESEARCH PROTOCOLS AND GRANTS

2023	National Institute of Health - SEP-9: NCI Clinical and Translational Research Review Meeting
2020	Imperial College London and Imperial College Healthcare NHS Trust
2017	National Medical Research Council (NMRC) Singapore – Health Services Research Grants
2016	Ministry of Education Tier 2 (Biomedical Engineering and Life Sciences) Grants
2014	Princess Alexandra Hospital Research Support Scheme
2014 -2019	National University Hospital Systems Seed Fund for Basic Science Research Grant Call (FY2014, 2015)
2015, 2017	National Science Centre Poland Grant Call
2018	Institut National Du Cancer (Programme for Hospital Clinical Research in Cancer)

C. REVIEWER FOR DOCTORATE THESIS

2023	Faculty of Medicine, Universiti Malaya
2022	Monash University, School of Pharmacy (Advancement Committee)
2021	University of Sydney, School of Pharmacy
2019	Queensland University of Technology, School of Public Health and Social Work
2017	Monash University, School of Pharmacy
2006-2019	National University of Singapore, Department of Pharmacy

D. MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS

1. American College of Clinical Pharmacy – Elected
2. American Society of Clinical Oncology– Elected
3. Hematology Oncology Pharmacy Association – Open
4. Multinational Association of Supportive Care in Cancer – Open
5. International Society of Oncology Pharmacy Practitioners – Open

6. International Association for the Study of Lung Cancer - Open
7. Pharmaceutical Society of Singapore – Open
8. Phi Delta Chi (Pharmacy Fraternity)
9. Phi Lambda Sigma (Pharmacy Leadership Society)
10. Rho Chi (Pharmacy Honors Society)

E. EXTERNAL REVIEW OF PHARMACY PROGRAMS

2020 - 2023	Bachelor of Sciences in Biomedical Technology (Pharmacy Technology), Macao Polytechnic Institute, Macau, China SAR
2016 - 2017	Bachelor of Pharmacy Program, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia

F. LEADERSHIP AND SERVICES TO PROFESSIONAL ORGANIZATIONS

1. International Society of Oncology Pharmacy Practitioners (ISOPP)

- a. Organizing committee member and ISOPP liaison for Oral Cancer Therapies Masterclass, 2021
- b. Past President, 2020 - 2021
- c. President, 2018-2020
- d. President-Elect, 2016-2018
- e. Coordinator and presenter for Cancer Supportive Care Masterclass, 2018 – onwards
- f. Faculty, Oncology Pharmacotherapy in Biosimilars Program – Supportive Care
- g. Chair, Nomination Committee, 2016-2018
- h. Biosimilar Task Force, Secretariat Liaison and Member, 2018-2021
- i. Immunotherapy Task Force, Member, 2021-onwards
- j. Member, Finance Committee, 2016-2018, 2018- onwards
- k. Secretariat Liaison and Member, Biosimilar Taskforce, 2018-onwards
- l. Member, Specialization Task Force, 2018-onwards
- m. Chairman, Education Committee: International Society of Oncology Pharmacists (ISOPP), 2010-2012, 2012-2014
- n. Scientific Co-Chair, ISOPP 14 Meeting, Montreal, Canada, 2014
- o. Scientific Co-Chair, ISOPP 15 Meeting, Santiago, Chile, 2016
- p. Scientific Chair, Saudi Arabia Oncology Pharmacist Meeting 2021

2. Multinational Association of Supportive Care in Cancer (MASCC)

- a. President-Elect, 2024-2026
- b. Chair, MASCC Fellows Program, 2022-
- c. Co-Chair, Health Disparities Task Force, 2022-
- d. Member, Antiemesis Guidelines, 2022-2023
- e. Co-chair, Cognitive Impairment Interest Group under Neurotoxicity Study Group 2022-
- f. Board of Director, 2012-2014, 2014-2016, 2016-2018, 2018-2020, 2022-2024
- g. Member, Executive Committee, 2016-2018, 2021-
- h. Elected Annual Meeting Chair, 2022, 2024
- i. Treasurer, 2016-2018
- j. Co-Chair, Membership Committee, 2012-2014
- k. Chair, Membership Committee, 2014-2016
- l. Member, Membership Committee, 2018-present
- m. Vice-Chair, Neurotoxicity Study Group, 2014-2020
- n. Member, Awards Committee, 2013-Present

- o. Panel Member, Clinical management guideline for EGFR Dermatological Toxicities, 2010
- p. Panel Member, Clinical practice guideline for the prevention and treatment of acute and late radiation reactions, 2011-2012
- q. Session Chair, Annual Meeting 2012, 2013, 2014
- r. Member, Organizing Committee for Annual Meeting, 2015, 2016

3. American College of Clinical Pharmacy (ACCP)

- a. Foundation Grants Reviewer, 2021
- b. Committee Member, Awards Committee, 2019-2020; 2021-2002; 2022-2023
- c. Panel Member, American College of Clinical Pharmacy (ACCP) Publications Committee – Update of the Pharmacotherapy Didactic Toolkit, 2018-2019
- d. Panel Member, Fellows of American College of Clinical Pharmacy (FCCP) Credential Committee, 2016-2017, 2017-2018
- e. Panel Member, American College of Clinical Pharmacy (ACCP) Clinical Practice Affairs, 2014-2015
- f. Vice Chair, American College of Clinical Pharmacy (ACCP) Certification Task Force, 2013-2014
- g. Panel Member, American College of Clinical Pharmacy (ACCP) Education Affairs Committee, Minimum Qualifications for Clinical Pharmacy Faculty, 2012-2013
- h. Panel Member, American College of Clinical Pharmacy (ACCP) Task Force on Residencies, 2010-2012
- i. Reviewer, ACCP Online Curriculum Vitae Review Service, 2012- Present
- j. Poster Reviewer, ACCP Virtual Poster Symposium, May 2013
- k. Member, ACCP Hematology/Oncology PRN, 2006- Present

4. American Society of Clinical Oncology (ASCO)

- a. Panel Member, ASCO/ONS Standards Update, 2023-2024
- b. Committee Member, QOPI Certification Steering Group Meeting, 2022-Present
- c. Panel Member; Prevention of Pediatrics Mucositis Endorsement Panel, 2015
- d. Member, 2009-Present

5. Asia-Pacific Oncology Pharmacy Congress (APOPC)

- a. Scientific Committee Member, 2008, 2010, 2012, 2014
- b. Session Chair, 2012, 2014

6. Asian Conference on Clinical Pharmacy (ACCP)

- a. Chair of overall meeting, Asian Conference on Clinical Pharmacy (Singapore), 2010
- b. Workshop Chair (Cancer Updates), Asian Conference on Clinical Pharmacy (Hong Kong), 2012, 2013
- c. Workshop Chair (Supportive Care Updates), Asian Conference on Clinical Pharmacy (Indonesia), 2017

7. Best of ASCO in Asia

- a. Chair, Nausea and Vomiting Breakfast Symposium, 2015

8. Board of Pharmacy Specialties (BPS)

- a. Vice-Chair, Board of Pharmacy Specialties Councils, 2024-2025
- b. Specialty Council Member, Board of Pharmacy Specialties Councils, 2023-2025
- c. Item Writing Member, Oncology Specialty Exam Item Writing Workshop, 2008
- d. Panel Judge, Clinical Reasoning Series Recertification Material, 2013

9. European Society of Medical Oncology (ESMO)

- a. Committee Member, ESMO Asia 2016 Planning Committee – Supportive Care Subgroup
- b. Co-Chair, ESMO Asia 2017 Planning Committee – Supportive Care Subgroup

- c. Committee Member, ESMO Asia 2018 Planning Committee – Supportive Care Subgroup
- d. Co-Chair, ESMO Asia 2020 Planning Committee – Supportive Care Subgroup

10. International Society of Geriatrics Oncology (SIOG)

- a. Committee Member, Supportive Care Track Planning Committee, 2016

11. International Association for the Study of Lung Cancer (IASLC)

- a. Committee Member, Nursing and Allied Health Professionals, 2018-2020
- b. Panel Member, Program Committee, 2019-2020

12. Pharmaceutical Society of Singapore (PSS)

- a. Chair, Oncology Supportive Care Workshop, 2011
- b. Chair, Clinical Oncology Workshop, 2012
- c. Chair, Evaluation of biomedical literature workshop, 2017
- d. Member of Scientific Program, Singapore Pharmacy Congress, 2007, 2009, 2011
- e. Honorary Secretary, Pharmaceutical Society of Singapore, 2008-2009
- f. Assistant Honorary Secretary, Pharmaceutical Society of Singapore, 2007-2008

13. Ministry of Health, Singapore

- a. Member, National Advisory Committee on Cancer: Subcommittee (Supportive Care and Palliative Care), 2019-Present
- b. Academic Advisor, Residency Policy and Oversight Committee (RPOC), 2015-Present
- c. Residency Program Director, National Pharmacy Residency Program in Oncology (PY2), 2015 - Present
- d. Senior Project Administrator, Chief Pharmacist Office, 2011- 2015
- e. Chair, Pharmacy Specialist Training Committee (PSTC), 2013-2015
- f. Member, Pharmacy Specialist Accreditation Committee (Oncology), Pharmacy Specialists Accreditation Board, 2012 - Present
- g. Member, Ministry of Health (MOH) Singapore: Supplementary Prescribing Rights Workgroup, 2008

14. Singapore Pharmacy Council (SPC)

- a. External Examiner to Board of Examiners (Competency), 2013 - 2015

G. SERVICES TO PHARMACEUTICAL INDUSTRY**1. Consultancy**

- a. GlaxoSmithKline, 2011 - 2014
- b. Merck Sharp & Dohme, 2010 – 2017
- c. The McGraw-Hill Companies, 2012 – 2016
- d. Lexicomp, 2013 – 2017
- e. Mundipharma, 2014 – 2016
- f. Nalagenetics, 2018 – Present
- g. Blueprint Medicine, 2021
- h. Eli Lilly, 2021 - Present
- i. HengRui USA, 2022 - Present

2. Speaker bureau member

- a. Eisai, 2014
- b. GlaxoSmithKline, 2011 - 2014
- c. Merck Sharp & Dohme, 2011 - 2017

- d. Kirin Pharmaceuticals, 2007-2008, 2015

E. LEADERSHIP AND SERVICES TO UNIVERSITY AND DEPARTMENT COMMITTEES

University of California, Irvine

Campus wide committees:

1. Search Committee: UCI Dean of Nursing – Member, 2021
2. ICTS Internal Advisory Committee – Member, 2021- Present
3. Academic Senate Council on Faculty Welfare, Diversity, and Academic Freedom (CFW) – Member, 2022-2025

College wide committees:

1. Affiliated Health Committee – Chair, 2021 - Present
2. Affiliated Health Committee – Vice Chair, 2021
3. Affiliated Health Committee – Member, 2020
4. Committee Member, Samueli Scholar Award, 2021

School wide committees:

1. School Leadership Cabinet – Member, 2020 – Present
2. UCI SPPS Strategic Planning – Member, 2021
3. UCI SPPS Space Committee – Member, 2022
4. Strategic Planning with UCI Medical Center - Co-Chair, 2021 - Present

Department wide committees:

1. Mentorship Program – Member, 2020 – Present
2. Wellness Committee – Member, 2021 – Present
3. Doctor of Pharmacy Implementation Committee – Member, 2020 – Present
4. Search Committees (Full Time and Part Time) – Chair, 2020 – Present

National University of Singapore, Department of Pharmacy

1. Master of Pharmacy Committee – Chair, 2017 – 2019
2. Pre-Employment Clinical Training Coordination Committee – Member, 2016 – 2019
3. Search Committee for the Department of Pharmacy – Member, April 2015- June 2017
4. Department Executive Committee – Member, 2013 – 2019
5. Doctor of Pharmacy Curriculum Committee – Member, 2006- 2019
6. Doctor of Pharmacy Admission Committee – Member, 2010- 2019
7. Oncology Pharmacy Residency Committee – Co-Director and member, 2009 – 2019
8. Thematic Research (Oncology) – Chair, 2013 – 2014
9. Department Search Committee – Member, 2009, 2012
10. Department Search Committee – Chair, 2014, 2018
11. Department Promotional and Tenure Committee – 2013 – 2019
12. Midterm Assessment Committee (for candidates) – Chair, 2013 – 2019
13. Department Graduate Committee –Member, 2015 - 2019

Last Update: May 2025